
<html lang="en"     class="pb-page"  data-request-id="f343e38b-b985-487e-ac1c-6a01853a30ae"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-6;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.8b01750"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria" /></meta><meta name="dc.Creator" content="Chenghui  Shi" /></meta><meta name="dc.Creator" content="Yinyong  Zhang" /></meta><meta name="dc.Creator" content="Ting  Wang" /></meta><meta name="dc.Creator" content="Wenchao  Lu" /></meta><meta name="dc.Creator" content="Shuhua  Zhang" /></meta><meta name="dc.Creator" content="Bin  Guo" /></meta><meta name="dc.Creator" content="Qian  Chen" /></meta><meta name="dc.Creator" content="Cheng  Luo" /></meta><meta name="dc.Creator" content="Xianli  Zhou" /></meta><meta name="dc.Creator" content="Yushe  Yang" /></meta><meta name="dc.Description" content="Spiropyrimidinetriones are a novel class of antibacterial agents that target the bacterial type II topoisomerase via a new mode of action. Compound ETX0914 is thus far the only drug from this class..." /></meta><meta name="Description" content="Spiropyrimidinetriones are a novel class of antibacterial agents that target the bacterial type II topoisomerase via a new mode of action. Compound ETX0914 is thus far the only drug from this class..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="January 30, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.8b01750" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01750" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.8b01750" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.8b01750" /></link>
        
    
    

<title>Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.8b01750" /></meta><meta property="og:title" content="Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0021.jpeg" /></meta><meta property="og:description" content="Spiropyrimidinetriones are a novel class of antibacterial agents that target the bacterial type II topoisomerase via a new mode of action. Compound ETX0914 is thus far the only drug from this class that is being evaluated in clinical trials. To improve the antibacterial activity and pharmacokinetic properties of ETX0914, we carried out systematic structural modification of this compound, and a number of compounds with increased potency were obtained. The most promising compound 33e, with incorporation of a spirocyclopropane at the oxazolidinone 5 position reduced metabolism, exhibited excellent antibacterial activity against Gram-positive pathogens and a good pharmacokinetic profile combined with high aqueous solubility. In addition, compound 33e exhibited good selectivity for Staphylococcus aureus gyrase over human Topo IIα. In a murine model of systemic methicillin-resistant S. aureus infection, 33e exhibited superior in vivo efficacy (ED50 = 3.87 mg/kg) compared to ETX0914 (ED50 = 11.51 mg/kg)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.8b01750"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.8b01750">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.8b01750&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.8b01750&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.8b01750&amp;href=/doi/10.1021/acs.jmedchem.8b01750" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 6</span><span class="cit-fg-pageRange">, 2950-2973</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/6" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.8b01583" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.8b01759" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Chenghui Shi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Chenghui Shi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Chenghui++Shi">Chenghui Shi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Yinyong Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yinyong Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan Province 610031, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yinyong++Zhang">Yinyong Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ting Wang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ting Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology, Sichuan Primed Bio-Tech Group Co., Ltd., Chengdu, Sichuan Province 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ting++Wang">Ting Wang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Wenchao Lu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Wenchao Lu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Wenchao++Lu">Wenchao Lu</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Shuhua Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shuhua Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Microbiology, Sichuan Primed Bio-Tech Group Co., Ltd., Chengdu, Sichuan Province 610041, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shuhua++Zhang">Shuhua Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bin Guo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Guo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Guo">Bin Guo</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Qian Chen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Qian Chen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Qian++Chen">Qian Chen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Cheng Luo</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Cheng Luo</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Cheng++Luo">Cheng Luo</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3864-8382" title="Orcid link">http://orcid.org/0000-0003-3864-8382</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Xianli Zhou</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Xianli Zhou</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Life Science and Engineering, Southwest Jiaotong University, Chengdu, Sichuan Province 610031, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#7d0715120805113d0e0a17090853181908531e13"><span class="__cf_email__" data-cfemail="0a7062657f72664a797d607e7f246f6e7f246964">[email protected]</span></a>. Phone: +86-28-66367232 (X.Z.)</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Xianli++Zhou">Xianli Zhou</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Yushe Yang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Yushe Yang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</div><div class="loa-info-affiliations-info">University of Chinese Academy of Sciences, Beijing 100049, China</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#1b6268627a757c5b767a7277356873787578357a78357875"><span class="__cf_email__" data-cfemail="6d141e140c030a2d000c0401431e050e030e430c0e430e03">[email protected]</span></a>. Phone/fax: +86-21-5080 6786 (Y.Y.).</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Yushe++Yang">Yushe Yang</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1007-2492" title="Orcid link">http://orcid.org/0000-0002-1007-2492</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01750&amp;href=/doi/10.1021%2Facs.jmedchem.8b01750" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 6</span><span class="cit-pageRange">, 2950–2973</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 30, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>11 November 2018</li><li><span class="item_label"><b>Published</b> online</span>30 January 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 March 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.8b01750" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b01750</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D2950%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DChenghui%2BShi%252C%2BYinyong%2BZhang%252C%2BTing%2BWang%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D6%26contentID%3Dacs.jmedchem.8b01750%26title%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BDNA%2BGyrase-Inhibiting%2BSpiropyrimidinetriones%2Bas%2BPotent%2BAntibiotics%2Bfor%2BTreatment%2Bof%2BInfections%2BCaused%2Bby%2BMultidrug-Resistant%2BGram-Positive%2BBacteria%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D2973%26publicationDate%3DMarch%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.8b01750"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2198</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">16</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.8b01750" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design, Synthesis, and Biological Evaluation of Novel DNA Gyrase-Inhibiting Spiropyrimidinetriones as Potent Antibiotics for Treatment of Infections Caused by Multidrug-Resistant Gram-Positive Bacteria&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Chenghui&quot;,&quot;last_name&quot;:&quot;Shi&quot;},{&quot;first_name&quot;:&quot;Yinyong&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Ting&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Wenchao&quot;,&quot;last_name&quot;:&quot;Lu&quot;},{&quot;first_name&quot;:&quot;Shuhua&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Guo&quot;},{&quot;first_name&quot;:&quot;Qian&quot;,&quot;last_name&quot;:&quot;Chen&quot;},{&quot;first_name&quot;:&quot;Cheng&quot;,&quot;last_name&quot;:&quot;Luo&quot;},{&quot;first_name&quot;:&quot;Xianli&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Yushe&quot;,&quot;last_name&quot;:&quot;Yang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;01&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;6&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;2950-2973&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.8b01750&quot;},&quot;abstract&quot;:&quot;Spiropyrimidinetriones are a novel class of antibacterial agents that target the bacterial type II topoisomerase via a new mode of action. Compound ETX0914 is thus far the only drug from this class that is being evaluated in clinical trials. To improve the antibacterial activity and pharmacokinetic properties of ETX0914, we carried out systematic structural modification of this compound, and a number of compounds with increased potency were obtained. The most promising compound 33e, with incorporation of a spirocyclopropane at the oxazolidinone 5 position reduced metabolism, exhibited excellent antibacterial activity against Gram-positive pathogens and a good pharmacokinetic profile combined with high aqueous solubility. In addition, compound 33e exhibited good selectivity for Staphylococcus aureus gyrase over human Topo IIα. In a murine model of systemic methicillin-resistant S. aureus infection, 33e exhibited superior in vivo efficacy (ED50 = 3.87 mg/kg) compared to ETX0914 (ED50 = 11.51 mg/kg).&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01750&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01750" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01750&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01750" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.8b01750&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01750" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.8b01750&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.8b01750&amp;href=/doi/10.1021/acs.jmedchem.8b01750" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.8b01750" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.8b01750" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b01750&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.8b01750%26sid%3Dliteratum%253Aachs%26pmid%3D30698430%26genre%3Darticle%26aulast%3DShi%26date%3D2019%26atitle%3DDesign%252C%2BSynthesis%252C%2Band%2BBiological%2BEvaluation%2Bof%2BNovel%2BDNA%2BGyrase-Inhibiting%2BSpiropyrimidinetriones%2Bas%2BPotent%2BAntibiotics%2Bfor%2BTreatment%2Bof%2BInfections%2BCaused%2Bby%2BMultidrug-Resistant%2BGram-Positive%2BBacteria%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D6%26spage%3D2950%26epage%3D2973%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291074" title="Purification">Purification</a>,</li><li><a href="/action/doSearch?ConceptID=291011" title="High-performance liquid chromatography">High-performance liquid chromatography</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292017" title="Solvents">Solvents</a>,</li><li><a href="/action/doSearch?ConceptID=291676" title="Antibacterial activity">Antibacterial activity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/6" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/jmcmar.2019.62.issue-6/20190328/jmcmar.2019.62.issue-6.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Spiropyrimidinetriones are a novel class of antibacterial agents that target the bacterial type II topoisomerase via a new mode of action. Compound ETX0914 is thus far the only drug from this class that is being evaluated in clinical trials. To improve the antibacterial activity and pharmacokinetic properties of ETX0914, we carried out systematic structural modification of this compound, and a number of compounds with increased potency were obtained. The most promising compound <b>33e</b>, with incorporation of a spirocyclopropane at the oxazolidinone 5 position reduced metabolism, exhibited excellent antibacterial activity against Gram-positive pathogens and a good pharmacokinetic profile combined with high aqueous solubility. In addition, compound <b>33e</b> exhibited good selectivity for <i>Staphylococcus aureus</i> gyrase over human Topo IIα. In a murine model of systemic methicillin-resistant <i>S. aureus</i> infection, <b>33e</b> exhibited superior in vivo efficacy (ED<sub>50</sub> = 3.87 mg/kg) compared to ETX0914 (ED<sub>50</sub> = 11.51 mg/kg).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54481" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54481" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Antibacterial drugs, including β-lactams, glycopeptides, aminoglycosides, macrolides, and fluoroquinolones, have saved innumerable human lives over the past 80 years, but the continuing emergence of drug-resistant bacteria has limited the use of many antibiotic drugs.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1,2)</a> In contrast to the growing antibacterial resistance, few new antibacterial compounds have entered the drug market in the last two decades.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3,4)</a> Recently, the World Health Organization has published the global priority list of antibiotic-resistant bacteria to guide the research, discovery, and development of new antibiotics.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> In addition to some worrisome Gram-negative pathogens, Gram-positive pathogens, including methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), vancomycin-resistant <i>Enterococci</i> and penicillin-resistant <i>Streptococcus pneumoniae</i> (PRSP) are also causes for concern. Among these pathogens, MRSA is one of the main causes of hospital-acquired infections and community-acquired infection.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> One of the most effective ways to address bacterial resistance is to develop antibacterial agents that have new targets or new modes of action to avoid cross-resistance to the drugs currently in clinical use.</div><div class="NLM_p">Bacterial DNA type II topoisomerases, including DNA gyrase and topoisomerase IV, are the traditional targets for both Gram-positive and Gram-negative bacteria.<a onclick="showRef(event, 'ref7 ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref7 ref8 ref9">(7−9)</a> Spiropyrimidinetriones (SPTs) are a new class of antibacterials that inhibit bacterial DNA gyrase and topoisomerase IV and exhibit no cross-resistance with fluoroquinolones because of differences in the modes of action of these compounds.<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10−12)</a> QPT-1 (<b>1</b>) (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) was the first compound of this class, which was discovered via high-throughput screening at Pharmacia & Upjohn and determined to be an inhibitor of DNA gyrase by reverse genomics.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Then, scientists at Pfizer explored the structure–activity relationship (SAR) of <b>1</b>, including via placement of various substituents at different positions on the benzene ring or modification of the spirocyclic pyrimidinetrione pharmacophore and the morpholine ring.<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> Scientists at AstraZeneca synthesized a series of compounds using a benzisoxazole scaffold to replace the benzene ring and identified active compound <b>2</b>. However, compound <b>2</b> did not enter clinical trials due to bone marrow toxicity and genotoxicity.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> After further examination of the SARs, compound <b>3</b> (Zoliflodacin, ETX0914, AZD0914), which has an oxazolidinone substituent on the benzisoxazole ring, was developed; this compound did not exhibit bone marrow toxicity and genotoxicity and had improved antibacterial activity.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Compound <b>3</b> was shown to be effective against bacteria that were resistant to other topoisomerase inhibitors as well as against fastidious Gram-negative bacteria, including <i>Haemophilus influenzae</i> and <i>Neisseria gonorrhoeae</i>. Based on these factors in addition to a clean toxicity profile and efficacy in a murine <i>S. aureus</i> infection model, compound <b>3</b> became the first compound of this class that entered clinical trials for antigonorrhea therapy and one phase II clinical trial has been completed.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0001.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SPTs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">However, the moderate antibacterial activity and suboptimal pharmacokinetic (PK) properties (high plasma protein binding and high clearance (Cl) rate) of <b>3</b> resulted in high doses (2 or 3 g) in clinical trials. High doses usually lead to some problems in humans, including low patient compliance and idiosyncratic drug toxicity.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Hence, identifying a compound with high antibacterial activity and improved PK properties is necessary.</div><div class="NLM_p last">Co-crystal structures of DNA-cleavage complexes for compound <b>1</b> have been reported to reveal the main interactions between spirocyclic pyrimidinetrione pharmacophore and DNA gyrase.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, there is a lack of clear understanding regarding the interactions between other moieties on SPTs and gyrase. Herein, we used traditional medicinal chemistry strategies, such as isostere replacement and structural fine tuning, to design a series of SPTs and tested the antibacterial activities of these compounds by phenotypic screening in different strains. Optimized compounds with superior antibacterial activity were selected for further testing of their PK properties in rodent models. A number of novel compounds with superior antibacterial activities and PK properties have been discovered, including the preclinical candidate <b>33e</b>, which qualifies for further evaluation.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77406" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77406" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The key reaction in the synthesis of this class of compounds was the tertiary amino effect reaction (T-reaction)<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> using aromatic aldehyde with <i>ortho</i>-dialkylamine and barbituric acid, which has been previously described. As shown in <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>, 2,6-dimethylmorpholine with different configurations yielded various mixtures with different diastereomeric ratios, wherein the (2R,4S,4aS) isomer was the active ingredient.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0002.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. T-reaction for the synthesis of SPTs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Considering the high cost of (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, compounds (±)-<b>16a</b>–<b>d</b>, (±)-<b>20</b>, (±)-<b>24</b>, and (±)-<b>33a</b>–<b>e</b> were synthesized as racemates using <i>cis</i>-2,6-dimethylmorpholine. After acquiring active racemic (±)-<b>33e</b>, enantiomer <b>33e</b> was synthesized using (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine and the other final compounds with the active configuration (2R,4S,4aS) were obtained using this method. The absolute configuration of the final compounds was confirmed by a crystal structure of <b>39e</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0003.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single<b>-</b>crystal X-ray structure of <b>39e</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The synthesis of the fluoroquinazoline series (±)-<b>16a</b>–<b>d</b> is shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. 2,3,4-Trifluorobenzoic acid <b>4</b> was treated with lithium diisopropylamide (LDA) followed by the addition of dimethylformamide (DMF) to afford product <b>5</b>, which formed ester <b>6</b> upon reaction with iodomethane. Protection of the aldehyde group on <b>6</b> with ethylene glycol gave compound <b>7</b>. Compound <b>8</b> was prepared by a selective nucleophilic aromatic substitution (S<sub>N</sub>Ar) reaction of the fluorine adjacent to the methyl ester with ammonia. Hydrolysis of the ester by treatment of <b>8</b> with a 2 M NaOH aqueous solution followed by ethylene glycol deprotection using a 2 M HCl aqueous solution gave compound <b>9</b>. <i>cis</i>-2,6-Dimethylmorpholine substituted the fluorine to afford compound <b>10</b>. The aldehyde on <b>10</b> was again protected with <i>O</i>-methylhydroxylamine hydrochloride to afford compound <b>11</b>, which was subsequently converted to fluoroquinazoline <b>12</b> with formamidine acetate. Chlorination of fluoroquinazoline with phosphorus oxychloride afforded the key intermediate <b>13</b>. Compounds <b>14a</b>, <b>14b</b>, and <b>14d</b> were prepared via S<sub>N</sub>Ar reactions or Buchwald–Hartwig cross-coupling of compound <b>13</b> with corresponding nucleophiles. Subsequent <i>O</i>-methylhydroxylamine deprotection using dilute hydrochloric acid gave compounds <b>15a</b>, <b>15b</b>, and <b>15d</b>. Compound <b>15c</b> was prepared by S<sub>N</sub>Ar reaction of <b>13</b> with thiomorpholine, and then, <i>O</i>-methylhydroxylamine was deprotected with dilute hydrochloric acid directly. Finally, compounds <b>15a</b>–<b>d</b> were converted to compounds (±)-<b>16a</b>–<b>d</b>, respectively, via T-reactions with barbituric acid.</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds (±)-<b>16a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LDA, DMF, tetrahydrofuran (THF), −78 °C, 77%; (b) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, room temperature (rt), 59%; (c) ethylene glycol, <i>p</i>-toluenesulfonic acid, toluene, 140 °C, 80%; (d) 7 M NH<sub>3</sub> in MeOH, sealed tube, 90 °C, 42%; (e) 2 M NaOH aqueous solution, EtOH, 40 °C; (f) 2 M HCl aqueous solution, EtOH, rt, 90% (for two steps); (g) <i>cis</i>-2,6-dimethylmorpholine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), CH<sub>3</sub>CN, 90 °C, 85%; (h) methoxyammonium chloride, Et<sub>3</sub>N, MeOH, rt, 87%; (i) formamidine acetate, 1,4-dioxane, MeOH, microwave at 90 °C, 70%; (j) POCl<sub>3</sub>, Et<sub>3</sub>N, toluene, 105 °C, 84%; (k) for <b>14a</b>: CH<sub>3</sub>MgBr, THF, Ar, 0 °C to rt, 64%; for <b>14b</b>: morpholine, THF, rt, 78%; for <b>14c</b>: thiomorpholine, THF, rt; for <b>14d</b>: 3-ketomorpholine, dimethylbisdiphenylphosphinoxanthene, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 45%; (l) 2 M HCl aqueous solution, formaldehyde, CH<sub>3</sub>COOH, acetone, rt, 79% for <b>15a</b>, 80% for <b>15b</b>, 66% for <b>15c</b> (for two steps), 46% for <b>15d</b>; (m) barbituric acid, CH<sub>3</sub>COOH, toluene, 100 °C, 50–87%.</p></p></figure><div class="NLM_p">Originally, we attempted to use this procedure to synthesize compound (±)-<b>20</b>. Unfortunately, 1,2,4-triazole was removed under the conditions used for <i>O</i>-methylhydroxylamine deprotection. Therefore, we deprotected <i>O</i>-methylhydroxylamine before chlorination of intermediate <b>12</b> to obtain compound <b>17</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). Then, chlorination of <b>17</b> afforded compound <b>18</b>. Subsequently, 1,2,4-triazole substituted the chlorine to give compound <b>19</b>, which was then converted to compound (±)-<b>20</b> by T-reaction with barbituric acid.</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound (±)-<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2 M HCl aqueous solution, formaldehyde, CH<sub>3</sub>COOH, acetone, rt, 90%; (b) POCl<sub>3</sub>, Et<sub>3</sub>N, toluene, reflux, 33%; (c) 1,2,4-triazole, THF, 80 °C, 89%; (d) barbituric acid, CH<sub>3</sub>COOH, toluene, 100 °C, 51%.</p></p></figure><div class="NLM_p">Compound (±)<b>-24</b> was prepared from compound <b>13</b>, which reacted with ethanolamine to afford compound <b>21</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). Then, compound <b>21</b> was treated with 1,1′-carbonyldiimidazole (CDI) to give compound <b>22</b>, which was then converted to (±)<b>-24</b> in the same manner as described for compounds (±)-<b>16a</b>–<b>d</b>.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound (±)-<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethanolamine, THF, rt, 93%; (b) CDI, DMF, 105 °C, 66%; (c) HCl aqueous solution, formaldehyde, CH<sub>3</sub>COOH, acetone, rt, 48%; (d) barbituric acid, CH<sub>3</sub>COOH, toluene, 100 °C, 73%.</p></p></figure><div class="NLM_p">The procedures for the synthesis of compounds <b>26a</b>–<b>c</b> were initiated from compound <b>25</b>, as described by Basarab and co-workers,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> by using different isosteres or analogues of barbituric acid in the T-reaction (<a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>).</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>26a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,2,6-thiadiazinane-3,5-dione 1,1-dioxide, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 74%; (b) 2-thioxodihydropyrimidine-4,6(1<i>H</i>,5<i>H</i>)-dione, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 55%; (c) 1,3-dimethylpyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 80%.</p></p></figure><div class="NLM_p">General procedures for the synthesis of compounds <b>33a</b>–<b>h</b> are depicted in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. Compound <b>27</b><a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> was chlorinated with <i>N</i>-chlorosuccinimide (NCS), and then, appropriate amines were added to substitute the chlorine atom, followed by the addition of Cs<sub>2</sub>CO<sub>3</sub> to form the benzisoxazoles <b>28a</b>–<b>h</b>, which were treated with CDI or 1,1′-thiocarbonyldiimidazole to obtain compounds <b>29a</b>–<b>h</b>. Subsequent removal of the ethylene glycol in the acid gave compounds <b>30a</b>–<b>h</b>. Nucleophilic displacement of the fluorine with <i>cis</i>-2,6-dimethylmorpholine or (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine afforded compounds <b>31a</b>–<b>e</b> or compounds <b>32e</b>–<b>h</b>. Finally, the T-reaction of compounds <b>31a</b>–<b>e</b> and <b>32e</b>–<b>h</b> with barbituric acid yielded compounds (±)-<b>33a</b>–<b>e</b> and <b>33e</b>–<b>h</b>, respectively.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>33a–h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCS, DMF, 40 °C; (b) appropriate amines, DMF, 0 °C to rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt to 40 °C, 53–76% (for three steps); (d) for <b>29a</b>–<b>c</b> and <b>29e</b>–<b>h</b>: CDI, 4-dimethylaminopyridine (DMAP), DMF, 100 °C, 63–91%; for <b>29d</b>: 1,1’-thiocarbonyldiimidazole, DMAP, DMF, 100 °C, 40%; (e) for <b>30a</b>–<b>g</b>: 6 M HCl aqueous solution, 1,4-dioxane, rt, 80–99%; for <b>30h</b>: 4 M H<sub>2</sub>SO<sub>4</sub> aqueous solution, 1,4-dioxane, rt, 75%; (f) <i>cis</i>-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 41–69%; (g) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 41–88%; (h) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 43–86%.</p></p></figure><div class="NLM_p">General procedures for the synthesis of compounds <b>39a</b>–<b>o</b> are depicted in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Compounds <b>34a</b>–<b>m</b> were prepared using compound <b>27</b> via similar procedures to those used for compounds <b>28a</b>–<b>h</b>. Compounds <b>35a</b>–<b>o</b> were obtained by the Mitsunobu reaction with thioacetic acid, <b>28c</b>–<b>d</b> and <b>34a</b>–<b>m</b>. Hydrolysis of the thioester in compounds <b>35a</b>–<b>o</b> using NaOH yielded the corresponding thiol anions, which reacted with CDI to afford compounds <b>36a</b>–<b>o</b>. The subsequent steps to obtain <b>39a</b>–<b>o</b> from <b>36a</b>–<b>o</b> were similar to the procedures described for <b>33e</b>.</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>39a–o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCS, DMF, 40 °C; (b) corresponding amine, DMF, 0 °C to rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt to 40 °C, 46–88% (for three steps); (d) PPh<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), thioacetic acid, THF, 0 °C, 49–99%; (e) 2 M NaOH aqueous solution, <span class="smallcaps smallerCapital">dl</span>-1,4-dithiothreitol (DTT), MeOH, rt; (f) CDI, DMAP, DMF, 100 °C, 26–93% (for two steps); (g) 6 M HCl aqueous solution, 1,4-dioxane, rt, 56–100%; (h) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 39–87%; (i) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 59–84%.</p></p></figure><div class="NLM_p">Synthesis of compound <b>50</b> was also performed via the key intermediate <b>27</b> by using the similar procedures to those described for compounds <b>39a</b>–<b>o</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). <i>tert</i>-Butyldimethylsilyl chloride (TBSCl) was used to protect the primary alcohol to afford compound <b>41</b>. The Mitsunobu reaction of compound <b>41</b> with thioacetic acid yielded compound <b>42</b>. Hydrolysis of the thioester and treatment with CDI yielded compound <b>43</b>. Deprotection of ethylene glycol and <i>tert</i>-butyldimethylsilyl (TBS) under acidic conditions yielded compound <b>44</b>. The subsequent procedures were similar to the synthesis of <b>33e</b>. The synthesis of compound <b>51</b> was initiated by methylation of intermediate <b>44</b> with trimethyloxonium tetrafluoroborate to yield compound <b>46</b>, which was reacted with (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine to afford compound <b>47</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). The T-reaction of compound <b>47</b> with barbituric acid yielded compound <b>51</b>. Methyl sulfonylation of intermediate <b>45</b> to compound <b>48</b>, followed by displacement with the azide group afforded compound <b>49</b>, which reacted with barbituric acid to yield compound <b>52</b> (<a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>). Compound <b>69</b> was obtained by reduction of <b>52</b> to <b>68</b>, followed by acetylation of the amine group with acetic anhydride.</div><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>50</b>–<b>52</b> and <b>69</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCS, DMF, 40 °C; (b) (<i>S</i>)-3-aminopropane-1,2-diol, DMF, 0 °C to rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt to 40 °C, 77% (for three steps); (d) TBSCl, imidazole, DMF, rt, 74%; (e) PPh<sub>3</sub>, DIAD, thioacetic acid, THF, 0 °C, 86%; (f) 2 M NaOH, <span class="smallcaps smallerCapital">dl</span>-1,4-dithiothreitol, MeOH, rt; (g) CDI, DMAP, DMF, 100 °C, 73% (for two steps); (h) 6 M HCl aqueous solution, 1,4-dioxane, rt, 74%; (i) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 49–66%; (j) barbituric acid, EtOH, 6 M HCl aqueous solution, 100 °C, 87%; (k) trimethyloxonium tetrafluoroborate, 2,6-bis(1,1-dimethylethyl)pyridine, dichloromethane (DCM), rt, 99%; (l) methanesulfonyl chloride (MsCl), DIPEA, DCM, 0 °C to rt, 87%; (m) NaN<sub>3</sub>, DMF, 70 °C, 90%; (n) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 40–85%; (o) PPh<sub>3</sub>, THF, H<sub>2</sub>O, rt, 62%; (p) acetic anhydride, DIPEA, DCM, EtOAc, rt, 86%.</p></p></figure><div class="NLM_p">Compounds <b>57</b>, <b>61</b>, and <b>67</b> were also prepared via the same intermediate <b>43</b> (<a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>). Removal of TBS from <b>43</b> yielded compound <b>53</b>. Then, fluorination or trifluoromethylation of the hydroxyl group afforded compound <b>54</b> or <b>58</b>, respectively, which was then converted to <b>57</b> or <b>61</b> in the same manner as that described for <b>33e</b>. Methyl sulfonylation of compound <b>53</b> afforded compound <b>62</b>. Sodium thiomethoxide replaced the methanesulfonate to form compound <b>63</b>, which was converted to sulfone <b>64</b> by oxidation of the thioether. The subsequent procedures were the same as those described for the synthesis of <b>33e</b>, yielding compound <b>67</b>.</div><figure id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>57</b>, <b>61</b>, and <b>67</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) tetra-<i>n</i>-butylammonium fluoride, DMF, 0 °C, 72%; (b) diethylaminosulfur trifluoride, THF, 35 °C, 74%; (c) 6 M HCl aqueous solution, 1,4-dioxane, rt, 80–99%; (d) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 59–91%; (e) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 34–65%; (f) AgOTf, Selectfluor, KF, 2-fluoropyridine, (trifluoromethyl)trimethylsilane, EtOAc, rt, 11%; (g) MsCl, DIPEA, DCM, 0 °C, 92%; (h) CH<sub>3</sub>SNa, DIPEA, 0 °C, 43%; (i) H<sub>2</sub>O<sub>2</sub>, Na<sub>2</sub>WO<sub>4</sub>·2H<sub>2</sub>O, MeOH/H<sub>2</sub>O, rt, 41%.</p></p></figure><div class="NLM_p">General procedures for the synthesis of compounds <b>79a</b>–<b>c</b> are depicted in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. 2,6-Difluorobenzonitrile <b>70</b> was treated with LDA, followed by the addition of DMF to yield product <b>71</b>, which was protected with ethylene glycol to yield compound <b>72</b>. Compound <b>73</b> was obtained by introducing an aldehyde group in compound <b>72</b> and was then converted to oxime <b>74</b> using hydroxylamine hydrochloride. Compound <b>74</b> was chlorinated with NCS and then treated with the corresponding amines to yield compounds <b>75a</b>–<b>c</b>. Subsequently, the ethylene glycol was removed with 6 M HCl aqueous solution, and the pH of the mixture was adjusted to 7–8 with NaHCO<sub>3</sub> to construct the benzisoxazole, affording compounds <b>76a</b>–<b>c</b>. (2<i>R</i>,6<i>R</i>)-2,6-Dimethylmorpholine was reacted with <b>76a</b>–<b>c</b> to yield compounds <b>77a</b>–<b>c</b>, respectively. Compounds <b>78a</b>–<b>c</b> were prepared by reaction of <b>77a</b>–<b>c</b> and CDI, and these compounds were reacted with barbituric acid to yield compounds <b>79a</b>–<b>c</b>. Compound <b>82</b> was synthesized using <b>77c</b> as the starting material, which reacted with thioacetic acid via the Mitsunobu reaction to yield <b>80</b>. The thioester of compound <b>80</b> was hydrolyzed under basic conditions and then reacted with CDI to afford compound <b>81</b>. Finally, the SPT architecture was constructed to afford compound <b>82</b> (<a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>).</div><figure id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0014.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compounds <b>79a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LDA, DMF, THF, −78 °C, 48%; (b) ethylene glycol, <i>p</i>-toluenesulfonic acid, toluene, 140 °C, 76%; (c) LDA, DMF, THF, −78 °C, 64%; (d) hydroxylamine hydrochloride, pyridine, MeOH, rt, 96%; (e) NCS, DMF, 40 °C; (f) the corresponding amine, DMF, 0 °C to rt, 27–77% (for two steps); (g) 6 M HCl aqueous solution, 1,4-dioxane, 35 °C; (h) NaHCO<sub>3</sub>, DMAP, DMF, rt, 18–44% (for two steps); (i) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 40 °C, 70–88%; (j) CDI, DMAP, DMF, 100 °C, 50–70%; (k) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 32–54%.</p></p></figure><figure id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0015.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Compound <b>82</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, thioacetic acid, THF, 0 °C, 35%; (b) 2 M NaOH aqueous solution, <span class="smallcaps smallerCapital">dl</span>-1,4-dithiothreitol, MeOH, rt; (c) CDI, DMAP, DMF, 90 °C, 62% (for two steps); (d) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 62%.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_07874" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_07874" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> SARs of the Newly Synthesized SPTs</h3><div class="NLM_p">To improve the antibacterial activity as well as the PK properties of the SPTs, we carried out structural modification of compound <b>3</b> via empirical medicinal chemistry approaches. All of the new compounds were evaluated for in vitro antibacterial activity against a panel of susceptible and resistant Gram-positive strains, including fluoroquinolone-resistant MRSA, and the results are summarized in the form of minimal inhibitory concentrations (MICs).</div><div class="NLM_p">Previously, we described a series of SPTs containing various benzoheterocycle scaffolds, such as benzoxazolinone and benzimidazolone (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>),<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> but all of these compounds showed very weak potency against the tested strains. The newly designed quinazoline compounds (±)-<b>16a</b>–<b>d</b>, (±)-<b>20</b>, and (±)-<b>24</b>, which retain the aromatic nature as well as a hydrogen bond acceptor, also exhibited distinct loss of activity against these strains (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf" class="ext-link">Table S1</a>). Taken together with previous results from our laboratory, these results suggested that the benzisoxazole scaffold may be optimal for antibacterial activity.</div><figure id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0004.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modification of the benzisoxazole scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The barbituric acid moiety on SPT is critical for antibacterial activity because of a hydrogen bond between the central keto oxygen of the barbituric acid moiety and the N–H of Asp437 on gyrase.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> To further explore the SARs of this pharmacophore, compounds <b>26a</b>–<b>c</b>, which retained this important hydrogen bond acceptor, were synthesized via isostere replacement of barbituric acid or its analogues. However, these compounds exhibited no activity against the strains mentioned above (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf" class="ext-link">Table S2</a>). These results again confirmed that spirocyclic pyrimidinetrione is a critical pharmacophore, and even a slight modification can lead to significant loss of activity.</div><div class="NLM_p">It was reported that the substituent at the benzisoxazole 3 position is tolerant to structural modification and that degradation of oxazolidinone is one of the main metabolic pathways of <b>3</b> in mice.<a onclick="showRef(event, 'ref18 ref25'); return false;" href="javascript:void(0);" class="ref ref18 ref25">(18,25)</a> Therefore, we decided to fine-tune the substituent at the benzisoxazole 3 position to improve potency and reduce the metabolism of <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Using 3-ketomorpholine to replace the oxazolidinone led to compound (±)-<b>33a</b>, which exhibited very weak antibacterial activity, indicating that ring expansion was harmful to potency. Compound (±)-<b>33b</b>, with a gem-dimethyl at the oxazolidinone 4 position, lost almost all its potency. Compound (±)-<b>33c</b>, in which the <i>gem</i>-dimethyl was cyclized into a cyclopropane, exhibited higher antibacterial activity than compound (±)-<b>33b</b> but was 2- to 30-fold less potent than compound <b>3</b>. Moving the cyclopropane from position 4 to position 5 yielded compound (±)-<b>33e</b>. Surprisingly, (±)-<b>33e</b> exhibited great improvement in potency, with MIC values ≤0.03 mg/L against most tested strains. An optically pure form of this compound, <b>33e</b>, exhibited improved potency compared to the racemate. Compound (±)-<b>33d</b>, with an oxazolidine-2-thione moiety in place of the oxazolidinone in <b>3</b>, exhibited weaker antibacterial activity. Unexpectedly, compound <b>39a</b>, with a 2-thiazolidinone moiety, exhibited significantly improved antibacterial activity against all strains (MIC ≤ 0.03 mg/L). Both compounds <b>33e</b> and <b>39a</b> are 2- to 32-fold more potent than their prototype compound <b>3</b>, respectively, indicating that subtle structural modification could greatly improve the antibacterial activity of <b>3</b>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Antibacterial Activity of SPTs <b>33a–e</b> and <b>39a</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0022.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0016.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">MSSA, methicillin-sensitive <i>S. aureus</i>, five strains; MRSA, methicillin-resistant <i>S. aureus</i>, five strains; MSSE, methicillin-sensitive <i>Staphylococcus epidermidis</i>, five strains; MRSE, methicillin-resistant <i>S. epidermidis</i>, five strains; PRSP, penicillin-resistant <i>S. pneumoniae</i>, three strains; Spy, <i>Streptococcus pyogenes</i>, three strains.</p></div></div><div></div></div><div class="NLM_p">Given the encouraging outcomes for compound <b>33e</b>, further investigation of spirocyclic compounds at the oxazolidinone 5 position were carried out. Ring expansion of the cyclopropane in compound <b>33e</b> led to compounds <b>33f</b> (cyclobutane) and <b>33g</b> (cyclopentane), which exhibited weaker antibacterial activities than compound <b>33e</b> but were as potent as compound <b>3</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Changing the cyclobutane to an oxetane resulted in compound <b>33h</b>, which maintained the antibacterial activity of <b>33f</b>, indicating that a polar oxygen atom was tolerated at this position. Thus, a spirocyclopropane might be an optimal substituent at position 5 of the oxazolidinone, and compound <b>33e</b> stood out as the most potent compound in this series. Furthermore, nitrile is sometimes considered an isostere of halogens;<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> this group is more polar than halogens and might improve the aqueous solubility of compounds as well as decrease plasma protein binding. Therefore, the fluorine on the benzisoxazole moiety was changed to a nitrile to yield compounds <b>79a</b>–<b>c</b>. However, these compounds exhibited a loss of potency, as shown in <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Antibacterial Activity of SPTs <b>33f</b>–<b>h</b> and <b>79a</b>–<b>c</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0017.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0018.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">MSSA, methicillin-sensitive <i>S. aureus</i>, five strains; MRSA, methicillin-resistant <i>S. aureus</i>, five strains; MSSE, methicillin-sensitive <i>S. epidermidis</i>, five strains; MRSE, methicillin-resistant <i>S. epidermidis</i>, five strains; PRSP, penicillin-resistant <i>S. pneumoniae</i>, three strains; Spy, <i>S. pyogenes</i>, three strains.</p></div></div><div></div></div><div class="NLM_p">The 2-thiazolidinone compound <b>39a</b>, exhibiting excellent antibacterial activity, has not been reported in the literature. Therefore, we performed a detailed analysis of modifications at the 2-thiazolidinone 4 or 5 position (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Methyl-substituted compounds <b>39b</b>–<b>e</b> were synthesized to probe the impact of chirality and positions of substitution on antibacterial activity. The potency of compounds <b>39d</b> and <b>39e</b> was similar to that of <b>39a</b>, whereas <b>39b</b> and <b>39c</b> exhibited a slight loss of potency. These results indicated that 5-methyl is preferred over 4-methyl. Comparison of <b>39d</b> with <b>39e</b> showed that an (S)-configuration is preferred. The similar SAR was observed from the ethyl substitution in compounds <b>39f</b>–<b>i</b>. Aromatic groups such as phenyl (<b>39j</b>) and benzyl (<b>39k</b>) led to decreased activity. The incorporation of a spirocyclopropane at the thiazolidinone 4 position afforded compound <b>39l</b>, which exhibited low potency. An additional polar group, such as a hydroxyl (<b>50</b>), an amide (<b>69</b>), or methylsulfonyl group (<b>67</b>), was also introduced on the methyl group of <b>39e</b> to reduce plasma protein binding and improve aqueous solubility, but various degrees of potency loss were observed for these compounds. Recovery of potency was achieved when the hydroxyl group was methylated to yield ether (<b>51</b>). These results indicated that a nonpolar group at the 2-thiazolidinone 5 position was better than a polar group for antibacterial activity. Several lipophilic groups, such as fluorine (<b>57</b>), trifluoromethoxy (<b>61</b>), and azide (<b>52</b>), were also tested. Compounds <b>52</b> and <b>61</b> exhibited modest potency, while compound <b>57</b> exhibited high potency against the tested strains. Some compounds with a cyclopentane or cyclohexane fused to the 2-thiazolidinone with different configurations were also synthesized. <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> shows that cyclopentane afforded higher potency than cyclohexane (<b>39m</b> vs <b>39n</b>) and the (4S,5R) configuration was better than the (4R,5S) configuration (<b>39m</b> vs <b>39o</b>). Nitrile-substituted compound <b>82</b> was also prepared and exhibited lower potency than the fluorine analogue compound <b>39e</b>, which was consistent with the results for the oxazolidinone series.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Antibacterial Activity of the 2-Thiazolidinone Series<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0019.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0020.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">MSSA, methicillin-sensitive <i>S. aureus</i>, five strains; MRSA, methicillin-resistant <i>S. aureus</i>, five strains; MSSE, methicillin-sensitive <i>S. epidermidis</i>, five strains; MRSE, methicillin-resistant <i>S. epidermidis</i>, five strains; PRSP, penicillin-resistant <i>S. pneumoniae</i>, three strains; Spy, <i>S. pyogenes</i>, three strains.</p></div></div><div></div></div><div class="NLM_p">Compound <b>3</b> is being studied for the treatment of gonorrhea in a clinical trial because of the strong potency of this compound against <i>N. gonorrhoeae</i>. Thus, compounds <b>33e</b>, <b>39a</b>, <b>39d</b>, <b>39e</b>, and <b>51</b> were also tested against 40 strains of <i>N. gonorrhoeae</i> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). Except for compound <b>51</b>, the potency values of all of these compounds were similar to those of <b>3</b>.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activities of <b>33e</b>, <b>39a</b>, <b>39d</b>, <b>39e</b>, and <b>51</b> against 40 Strains of <i>N. gonorrhoeae</i></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">MIC<sub>50</sub> (μg/mL)</th><th class="colsep0 rowsep0" align="center" char=".">MIC<sub>90</sub> (μg/mL)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39a</b></td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39d</b></td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39e</b></td><td class="colsep0 rowsep0" align="char" char=".">0.06</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="char" char=".">0.25</td><td class="colsep0 rowsep0" align="char" char=".">0.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">0.03</td><td class="colsep0 rowsep0" align="char" char=".">0.125</td></tr></tbody></table></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Absorption, Distribution, Metabolism, Excretion, and Toxicity</h3><div class="NLM_p">Based on the results of the in vitro antibacterial activity assay, compounds <b>33e</b>, <b>39a</b>, <b>39d</b>, <b>39e</b>, <b>39h</b>, and <b>51</b> were selected for evaluation of the PK properties in mice (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>). All of the tested compounds exhibited better overall PK profiles than compound <b>3</b> in mice, as indicated by the higher area under the concentrations (AUCs) and <i>C</i><sub>max</sub> values as well as the longer half-lives. Compound <b>3</b> had a low AUC because of the high clearance rate in mice without pretreatment with the P450 inhibitor 1-aminobenzotriazole (ABT),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> for which the decarboxylation of oxazolidinone is a plausible metabolic pathway.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> The incorporation of spirocyclopropane may block this decarboxylation reaction, as indicated by the much higher AUC and long half-life observed for compound <b>33e</b> (AUC<sub>0–<i>t</i></sub> = 24 241 ng h/mL, <i>T</i><sub>1/2</sub> = 6.20 h). Furthermore, the 2-thiazolidinone series exhibited much better PK profiles than compound <b>3</b>, especially compound <b>39e</b> (AUC<sub>0–<i>t</i></sub> = 22 525 ng h/mL, <i>T</i><sub>1/2</sub> = 7.68 h), suggesting that 2-thiazolidinone is more stable than oxazolidinone in mice. Compounds <b>33e</b> and <b>39e</b> were further evaluated in rats. Compound <b>3</b> exhibited a poor dose–exposure relationship in humans at large oral doses.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Thus, two doses, namely, 10 and 100 mg/kg, were selected for determination of the dose–exposure relationship by oral administration. The results showed that compounds <b>33e</b> and <b>39e</b> exhibited excellent dose-dependent exposure, good oral bioavailability, and low clearance rates in rats (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Further tests in dogs showed that compound <b>33e</b> had excellent oral bioavailability (<i>F</i> = 96.6%) (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). Compound <b>33e</b> also exhibited 2-fold higher aqueous solubility (277 μM) than compound <b>3</b> (128 μM) (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>).</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vivo PK Properties of Selected Compounds in Mice<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub><a class="ref internalNav" href="#t5fn2" aria-label="b">b</a> (ng h/mL)</th><th class="colsep0 rowsep0" align="center" char=".">MRT<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub><a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>max</sub><a class="ref internalNav" href="#t5fn5" aria-label="e">e</a> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t5fn6" aria-label="f">f</a> (h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="char" char=".">748</td><td class="colsep0 rowsep0" align="char" char=".">7.06</td><td class="colsep0 rowsep0" align="char" char=".">183</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">3.41</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="char" char=".">24 241</td><td class="colsep0 rowsep0" align="char" char=".">8.94</td><td class="colsep0 rowsep0" align="char" char=".">2576</td><td class="colsep0 rowsep0" align="char" char=".">2.67</td><td class="colsep0 rowsep0" align="char" char=".">6.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39a</b></td><td class="colsep0 rowsep0" align="char" char=".">7334</td><td class="colsep0 rowsep0" align="char" char=".">3.70</td><td class="colsep0 rowsep0" align="char" char=".">1548</td><td class="colsep0 rowsep0" align="char" char=".">1.33</td><td class="colsep0 rowsep0" align="char" char=".">2.90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39d</b></td><td class="colsep0 rowsep0" align="char" char=".">12 034</td><td class="colsep0 rowsep0" align="char" char=".">4.85</td><td class="colsep0 rowsep0" align="char" char=".">2188</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">2.70</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39e</b></td><td class="colsep0 rowsep0" align="char" char=".">22 525</td><td class="colsep0 rowsep0" align="char" char=".">11.40</td><td class="colsep0 rowsep0" align="char" char=".">2079</td><td class="colsep0 rowsep0" align="char" char=".">1.33</td><td class="colsep0 rowsep0" align="char" char=".">7.68</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39h</b></td><td class="colsep0 rowsep0" align="char" char=".">8057</td><td class="colsep0 rowsep0" align="char" char=".">3.45</td><td class="colsep0 rowsep0" align="char" char=".">2376</td><td class="colsep0 rowsep0" align="char" char=".">1.17</td><td class="colsep0 rowsep0" align="char" char=".">1.59</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="char" char=".">8240</td><td class="colsep0 rowsep0" align="char" char=".">3.72</td><td class="colsep0 rowsep0" align="char" char=".">2051</td><td class="colsep0 rowsep0" align="char" char=".">0.58</td><td class="colsep0 rowsep0" align="char" char=".">2.51</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">CD-1 mice (female), po, 10 mg/kg, <i>n</i> = 3.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">AUC<sub>0–<i>t</i></sub>, area under the concentration–time curve up to the last sampling time.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">MRT, mean retention time.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last"><i>C</i><sub>max</sub>, maximum plasma concentration.</p></div><div class="footnote" id="t5fn5"><sup><sup>e</sup></sup><p class="last"><i>T</i><sub>max</sub>, time to reach <i>C</i><sub>max</sub>.</p></div><div class="footnote" id="t5fn6"><sup><sup>f</sup></sup><p class="last"><i>T</i><sub>1/2</sub>, elimination half-life.</p></div></div></div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. In Vivo PK Properties of Selected Compounds in Rats and Dogs<sup>a</sup></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">species</th><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>0–<i>t</i></sub><a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (ng h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub><a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>T</i><sub>1/2</sub><a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (h)</th><th class="colsep0 rowsep0" align="center" char=".">Cl<a class="ref internalNav" href="#t6fn5" aria-label="e">e</a> (mL/(kg min))</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>dss</sub><a class="ref internalNav" href="#t6fn6" aria-label="f">f</a> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">%F<a class="ref internalNav" href="#t6fn7" aria-label="g">g</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="5" align="left"><b>33e</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">rat</td><td class="colsep0 rowsep0" align="left">10/IV<a class="ref internalNav" href="#t6fn8" aria-label="h">h</a></td><td class="colsep0 rowsep0" align="char" char=".">104 412</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.82</td><td class="colsep0 rowsep0" align="char" char=".">1.57</td><td class="colsep0 rowsep0" align="char" char=".">0.482</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10/PO<a class="ref internalNav" href="#t6fn9" aria-label="i">i</a></td><td class="colsep0 rowsep0" align="char" char=".">23 567</td><td class="colsep0 rowsep0" align="char" char=".">2264</td><td class="colsep0 rowsep0" align="char" char=".">3.71</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">22.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">100/PO</td><td class="colsep0 rowsep0" align="char" char=".">478 011</td><td class="colsep0 rowsep0" align="char" char=".">35 430</td><td class="colsep0 rowsep0" align="char" char=".">5.58</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">45.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="2" align="left">dog</td><td class="colsep0 rowsep0" align="left">2.5/IV</td><td class="colsep0 rowsep0" align="char" char=".">9103</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">3.49</td><td class="colsep0 rowsep0" align="char" char=".">4.91</td><td class="colsep0 rowsep0" align="char" char=".">1.00</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">5.0/PO</td><td class="colsep0 rowsep0" align="char" char=".">17 517</td><td class="colsep0 rowsep0" align="char" char=".">2859</td><td class="colsep0 rowsep0" align="char" char=".">3.65</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">96.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" rowspan="3" align="left"><b>39e</b></td><td class="colsep0 rowsep0" rowspan="3" align="left">rat</td><td class="colsep0 rowsep0" align="left">10/IV</td><td class="colsep0 rowsep0" align="char" char=".">89 577</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">4.93</td><td class="colsep0 rowsep0" align="char" char=".">1.82</td><td class="colsep0 rowsep0" align="char" char=".">0.675</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10/PO</td><td class="colsep0 rowsep0" align="char" char=".">46 598</td><td class="colsep0 rowsep0" align="char" char=".">4430</td><td class="colsep0 rowsep0" align="char" char=".">4.38</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">52.0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">100/PO</td><td class="colsep0 rowsep0" align="char" char=".">452 211</td><td class="colsep0 rowsep0" align="char" char=".">32 069</td><td class="colsep0 rowsep0" align="char" char=".">8.63</td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char="."> </td><td class="colsep0 rowsep0" align="char" char=".">52.7</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Sprague-Dawley rat and Beagle dog, <i>n</i> = 3.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">AUC<sub>0–<i>t</i></sub>, area under the concentration–time curve up to the last sampling time.</p></div><div class="footnote" id="t6fn3"><sup><sup>c</sup></sup><p class="last"><i>C</i><sub>max</sub>, maximum plasma concentration.</p></div><div class="footnote" id="t6fn4"><sup><sup>d</sup></sup><p class="last"><i>T</i><sub>1/2</sub>, elimination half-life.</p></div><div class="footnote" id="t6fn5"><sup><sup>e</sup></sup><p class="last">Cl, clearance.</p></div><div class="footnote" id="t6fn6"><sup><sup>f</sup></sup><p class="last"><i>V</i><sub>dss</sub>, volume of distribution at steady state.</p></div><div class="footnote" id="t6fn7"><sup><sup>g</sup></sup><p class="last"><i>F</i>, bioavailability.</p></div><div class="footnote" id="t6fn8"><sup><sup>h</sup></sup><p class="last">IV, intravenous.</p></div><div class="footnote" id="t6fn9"><sup><sup>i</sup></sup><p class="last">PO, per oral.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Solubility of <b>3</b>, <b>33e</b>, and <b>39e</b> in Different Matrices</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center">maximal soluble concentration (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">intestinal juice</th><th class="colsep0 rowsep0" align="center">gastric juice</th><th class="colsep0 rowsep0" align="center">water</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">139</td><td class="colsep0 rowsep0" align="left">121</td><td class="colsep0 rowsep0" align="left">128</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="left">204</td><td class="colsep0 rowsep0" align="left">151</td><td class="colsep0 rowsep0" align="left">277</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39e</b></td><td class="colsep0 rowsep0" align="left">11.3</td><td class="colsep0 rowsep0" align="left">9.4</td><td class="colsep0 rowsep0" align="left">10.2</td></tr></tbody></table></div></div><div class="NLM_p">Compounds <b>33e</b>, <b>39a</b>, <b>39d</b>, <b>39e</b>, and <b>51</b> were tested for inhibition of the hERG K<sup>+</sup> channel to preliminarily evaluate QT prolongation risk (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>), and all of these compounds exhibited no inhibition of the hERG K<sup>+</sup> channel at the highest tested concentration (40 μM). Compound <b>33e</b> was also evaluated for inhibition of cytochrome P450 (CYP450) enzymes to rule out the risk of drug–drug interactions.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>, a very low inhibition of the tested CYP450 enzymes, including CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4-M, and CYP3A4-T, was observed.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. hERG K<sup>+</sup> Channel Inhibition by Selected Compounds</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39a</b></td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39d</b></td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39e</b></td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">>40</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cisapride</td><td class="colsep0 rowsep0" align="left">0.19</td></tr></tbody></table></div></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. CYP450 Inhibition by <b>33e</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="6" align="center" char=".">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">CYP1A2</th><th class="colsep0 rowsep0" align="center">CYP2C19</th><th class="colsep0 rowsep0" align="center">CYP2C9</th><th class="colsep0 rowsep0" align="center">CYP2D6</th><th class="colsep0 rowsep0" align="center">CYP3A4-M<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">CYP3A4-T<a class="ref internalNav" href="#t9fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="char" char=".">13.0</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>25</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Midazolam was used as the substrate.</p></div><div class="footnote" id="t9fn2"><sup><sup>b</sup></sup><p class="last">Testosterone was used as the substrate.</p></div></div></div><div class="NLM_p">Because of the homology between prokaryotic topoisomerase II and eukaryotic topoisomerase II, low selectivity between the two can lead to undesired toxic effects in mammalian cells, including carcinogenesis and genotoxic effects.<a onclick="showRef(event, 'ref29 ref30 ref31 ref32'); return false;" href="javascript:void(0);" class="ref ref29 ref30 ref31 ref32">(29−32)</a> One example of this phenomenon is compound <b>2</b>, which was observed to be genotoxic, and the development of this compound was thus discontinued.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The relationship between the inhibition of mammalian topoisomerase IIα and genotoxicity has been reported in a mouse micronucleus chromosome aberration assay and a mouse lymphoma assay in the literature.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> We tested our compounds for inhibition of both human Topo IIα and <i>S. aureus</i> gyrase. As shown in <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a></a>, all of the SPTs exhibited no inhibition of human Topo IIα (IC<sub>50</sub> > 200 μM), except for compound <b>39i</b>, which exhibited very low inhibition (IC<sub>50</sub> = 128.4 μM). At the maximum tested concentration of 200 μM, <b>33e</b> exhibited 15% inhibition of human Topo IIα compared to 35% for compound <b>3</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf" class="ext-link">Table S3 and Figure S1</a>). Ciprofloxacin, a classical fluoroquinolone antibacterial agent, exhibited moderate inhibition of human Topo IIα (IC<sub>50</sub> = 153.6 μM), while doxorubicin, an inhibitor of human Topo II that is used for the treatment of cancer, exhibited high inhibition (IC<sub>50</sub> = 0.6 μM). For <i>S. aureus</i> gyrase, all of the tested compounds that we synthesized exhibited higher enzyme inhibition activity (IC<sub>50</sub>s = 7.8–15.6 μM) than compound <b>3</b> (IC<sub>50</sub> = 24.3 μM), with compound <b>33e</b> exhibiting the highest potency (IC<sub>50</sub> = 7.8 μM). These results are consistent with the antibacterial activity described above and indicate that compound <b>33e</b> has an acceptable selectivity between <i>S. aureus</i> gyrase and human Topo IIα.</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Inhibition of Human Topo IIα and <i>S. aureus</i> Gyrase</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">IC<sub>50</sub> (μM)</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">human Topo IIα</th><th class="colsep0 rowsep0" align="center"><i>S. aureus</i> gyrase</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">24.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">7.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39e</b></td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">12.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33f</b></td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">15.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39d</b></td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">15.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39b</b></td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">15.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">>200</td><td class="colsep0 rowsep0" align="left">9.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39i</b></td><td class="colsep0 rowsep0" align="left">128.4</td><td class="colsep0 rowsep0" align="left">9.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">doxorubicin</td><td class="colsep0 rowsep0" align="left">0.6</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t10fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ciprofloxacin</td><td class="colsep0 rowsep0" align="left">153.6</td><td class="colsep0 rowsep0" align="left">120.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">novobiocin</td><td class="colsep0 rowsep0" align="left">NT</td><td class="colsep0 rowsep0" align="left">0.04</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t10fn1"><div class="footnote" id="t10fn1"><sup><sup>a</sup></sup><p class="last">NT, not tested.</p></div></div></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> Binding Mode of Compounds <b>3</b> and <b>33e</b> with <i>S. aureus</i> Gyrase</h3><div class="NLM_p">Molecular docking has emerged as a promising methodology to delineate the binding mode of small molecular inhibitors.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> Herein, molecular docking study was performed to compare the differences in the binding modes between <b>3</b> and <b>33e</b>. The crystal structure of DNA-cleavage complexes with <i>S. aureus</i> gyrase was fetched from the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>, PDB entry: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM">5CDM</a>, 2.50 Å resolution), which contained compound <b>1</b> (QPT-1) in binding sites. For all of the three compounds, the central keto oxygen of the barbituric acid moiety formed a hydrogen bond with residue Asp437 and the NH of the barbituric acid moiety showed extensive water-bridged interactions with the adjacent residues like D437, Ptr123, and nucleotides (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). The results showed that compounds <b>3</b> and <b>33e</b> had similar interaction patterns to QPT-1 in barbituric acid moiety, demonstrating the reliability of our docking model. The cyclopropane fused at the oxazolidinone 5 position in <b>33e</b> showed additional hydrophobic contact with the side chain of N476 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), which may account for its superior antibacterial activity and enzymatic activity. Also because the oxazolidinone locates in a small pocket, several larger substitutions at the oxazolidinone 4 or 5 position will lead to steric clashes in the binding pocket, which was in accordance with decreases in the enzymatic activities or antibacterial activities of compounds <b>33f</b> (cyclobutane), <b>33g</b> (cyclopentane), <b>33j</b> (phenyl), and <b>33k</b> (benzyl).</div><figure id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0005.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking results for compounds <b>3</b> and <b>33e</b> within the <i>S. aureus</i> gyrase. (A, B) <b>3</b> and <b>33e</b> in the binding pocket. The pocket was represented as an electrostatic potential surface. QPT-1, <b>3</b>, and <b>33e</b> are shown as white, yellow, and cyan sticks, respectively. The figure is generated with PyMOL version 1.3r1 (Schrodinger, 2010). (C, D) Detailed binding modes of <b>3</b> and <b>33e</b> with <i>S. aureus</i> gyrase. The structural waters are shown in cyan spheres. The figure is generated using LigPlot+ version 1.4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> In Vivo Efficacy</h3><div class="NLM_p">Compounds <b>33e</b> and <b>39e</b> were assessed for antibacterial efficacy in a mouse model of systemic infection using MSSA or MRSA strain. Compound <b>3</b> and linezolid were chosen as the positive controls. ABT was coadministered with compound <b>3</b> to inhibit CYP enzymes for the reasons mentioned above.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> As shown in <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a></a>, both compounds <b>33e</b> (ED<sub>50</sub> = 8.37 mg/kg) and <b>39e</b> (ED<sub>50</sub> = 9.59 mg/kg) exhibited higher potencies than <b>3</b> (ED<sub>50</sub> = 11.03 mg/kg) in the MSSA infection model. In the MRSA infection model, the efficacies of compounds <b>33e</b> (ED<sub>50</sub> = 3.87 mg/kg) and <b>39e</b> (ED<sub>50</sub> = 2.54 mg/kg) further improved and were superior to the efficacies of <b>3</b> (ED<sub>50</sub> = 11.51 mg/kg) and linezolid (ED<sub>50</sub> = 4.83 mg/kg). Given the acceptable selectivity of enzyme and improved PK properties, compound <b>33e</b> is a potential drug candidate for further development.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. In Vivo Efficacy of Compounds <b>33e</b> and <b>39e</b> in the Mouse Model of Systemic Infection</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="(" /></col><col align="left" /></col><col align="char" char="(" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center">MSSA</th><th class="rowsep1 colsep0" colspan="2" align="center">MRSA</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">MIC (mg/L)</th><th class="colsep0 rowsep0" align="center" char="(">ED<sub>50</sub> (mg/kg)<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a> (95% CI)</th><th class="colsep0 rowsep0" align="center">MIC (mg/L)</th><th class="colsep0 rowsep0" align="center" char="(">ED<sub>50</sub> (mg/kg)<a class="ref internalNav" href="#t11fn1" aria-label="a">a</a> (95% CI)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33e</b></td><td class="colsep0 rowsep0" align="left">≤0.03</td><td class="colsep0 rowsep0" align="char" char="(">8.37 (3.99–22.51)</td><td class="colsep0 rowsep0" align="left"><0.03–0.06</td><td class="colsep0 rowsep0" align="char" char="(">3.87 (2.22–5.65)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39e</b></td><td class="colsep0 rowsep0" align="left"><0.03–0.06</td><td class="colsep0 rowsep0" align="char" char="(">9.59 (5.21–22.73)</td><td class="colsep0 rowsep0" align="left"><0.03–0.25</td><td class="colsep0 rowsep0" align="char" char="(">2.54 (0.11–3.71)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" align="left">0.125–0.25</td><td class="colsep0 rowsep0" align="char" char="(">11.03 (6.04–33.82)</td><td class="colsep0 rowsep0" align="left">0.03–1</td><td class="colsep0 rowsep0" align="char" char="(">11.51 (7.28–25.79)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">linezolid</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="(">4.53 (1.48–8.28)</td><td class="colsep0 rowsep0" align="left">NT<a class="ref internalNav" href="#t11fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="char" char="(">4.83 (2.78–7.31)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t11fn1"><div class="footnote" id="t11fn1"><sup><sup>a</sup></sup><p class="last">The efficacy criterion, ED<sub>50</sub>, was calculated as the dose at which the mouse survival rate was 50%, and the numbers in parentheses are 95% confidence ranges.</p></div><div class="footnote" id="t11fn2"><sup><sup>b</sup></sup><p class="last">NT, not tested.</p></div></div></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15514" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15514" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In conclusion, the SARs of a series of SPTs were explored via structural modification of the known lead compound <b>3</b>. Changes in the benzisoxazole scaffold and the spiropyrimidinetrione core structure both led to complete loss of antibacterial activity. Various substituents were tolerated at the benzisoxazole 3 position, but replacement of the fluorine atom on the benzisoxazole with a nitrile group was harmful for antibacterial activity. The incorporation of spirocyclopropane at the oxazolidinone 5 position or the use of 2-thiazolidinone instead of oxazolidinone afforded a series of novel compounds that exhibited excellent antibacterial activity against the tested strains, including compounds <b>33e</b>, <b>39a</b>, <b>39d</b>, <b>39e</b>, <b>39h</b>, <b>39i</b>, and <b>51</b>. Among these compounds, <b>33e</b> and <b>39e</b> exhibited the best antibacterial activity, which was 2- to 32-fold higher than that of lead compound <b>3</b>, as well as excellent PK properties, including high AUCs, high <i>C</i><sub>max</sub> values, and long half-lives in mice, compared to other tested compounds. Compound <b>33e</b> had high aqueous solubility and also exhibited good PK profiles in rats and dogs. Species selectivity between pathogen and mammalian enzymes gave the preliminary insight into genotoxicity of <b>33e</b>. Molecular docking of <b>3</b> and <b>33e</b> in <i>S. aureus</i> gyrase indicated that the improved activity of <b>33e</b> was attributed to the additional hydrophobic interaction. Furthermore, <b>33e</b> exhibited potent in vivo efficacies in mouse models of systemic MSSA or MRSA infections. Overall, compound <b>33e</b> represents a promising drug candidate for further preclinical studies.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21665" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21665" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Chemistry</h3><div class="NLM_p">All solvents and chemicals were used as purchased without further purification. Inert atmosphere operations were conducted under argon in flame-dried glassware. Room temperature refers to 20–25 °C. All reaction mixtures were monitored using thin-layer chromatography (TLC) on silica gel F-254 TLC plates. Column chromatography was carried out using silica gel (200–300 mesh). Specific rotation was obtained on a Rudolph Autopol VI automatic polarimeter at a wavelength of 589 nM. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker 400 NMR or a Bruker 500 NMR spectrometer using solvent residue as the internal standards. Chemical shifts (δ) are reported in parts per million (ppm), and coupling constants (<i>J</i>) are reported in hertz (Hz). Electron ionization (EI)-mass spectrometry (MS) images were obtained on a Finnigan MAT95 spectrometer, and electrospray ionization (ESI)-MS images were obtained on a Krats MS 80 mass spectrometer. Purification of all final compounds was conducted by preparative reverse-phase high-performance liquid chromatography (HPLC) (SunFire C<sup>18</sup>OBD 100 mm × 30 mm; particle size, 5 μm) with acetonitrile/H<sub>2</sub>O as the mobile phase. Purity of all final compounds was determined by analytical HPLC (PLATISIL ODS 250 mm × 4.6 mm, particle size 5 μm) with acetonitrile/H<sub>2</sub>O as the mobile phase. A purity of >95% was achieved for all tested compounds. Detailed synthetic procedure and spectral characterization for all intermediates are provided in the <a href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf" class="ext-link">Supporting Information</a>.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> <i>rel</i>-(2′<i>R</i>,4′<i>S</i>,4a′<i>S</i>)-12′-Fluoro-2′,4′,8′-trimethyl-1′,2′,4′,4a′-tetrahydro-2<i>H</i>,6′<i>H</i>-spiro[pyrimidine-5,5′-[1,4]oxazino[4′,3′:1,6]pyrido[3,2-<i>g</i>]quinazoline]-2,4,6(1<i>H</i>,3<i>H</i>)-trione ((±)-<b>16a</b>)</h4><div class="NLM_p last">Compound <b>15a</b> (100 mg, 0.330 mmol) was dissolved in toluene (5 mL) and acetic acid (0.5 mL). Barbituric acid was added at room temperature. The resulting mixture was stirred at 90 °C for 2 h, cooled to room temperature, and concentrated directly in vacuo. The residue was purified by HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 30 → 80% B) to give 68 mg (50%) of (±)-<b>16a</b> as a yellow solid. <sup>1</sup>H NMR (400 MHz, dimethyl sulfoxide (DMSO)-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 11.58 (s, 1H), 8.91 (s, 1H), 7.70 (s, 1H), 4.25 (d, <i>J</i> = 12.1 Hz, 1H), 4.02 (d, <i>J</i> = 8.8 Hz, 1H), 3.90–3.81 (m, 1H), 3.74–3.67 (m, 2H), 3.16–3.08 (m, 2H), 2.73 (s, 3H), 1.17 (d, <i>J</i> = 5.7 Hz, 3H), 0.92 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.03, 168.91, 166.54, 155.37, 150.60, 142.04 (d, <i>J</i> = 244.1 Hz), 141.84 (d, <i>J</i> = 11.2 Hz), 137.12, 128.37, 120.22, 117.89, 73.42, 72.93, 65.47, 57.39 (d, <i>J</i> = 10.1 Hz), 53.62, 39.54, 22.29, 19.35, 19.30. MS (EI) <i>m</i>/<i>z</i>: 413 (M<sup>+</sup>). High-resolution mass spectrometry (HRMS) (EI): Anal. calcd for C<sub>20</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>4</sub>: 413.1499, found: 413.1489.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> <i>rel</i>-(2′<i>R</i>,4′<i>S</i>,4a′<i>S</i>)-12′-Fluoro-2′,4′-dimethyl-8′-morpholino-1′,2′,4′,4a′-tetrahydro-2<i>H</i>,6′<i>H</i>-spiro[pyrimidine-5,5′-[1,4]oxazino[4′,3′:1,6]pyrido[3,2-<i>g</i>]quinazoline]-2,4,6(1<i>H</i>,3<i>H</i>)-trione ((±)-<b>16b</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>16a</b> using <b>15b</b> (148 mg, 0.396 mmol) and barbituric acid (61 mg, 0.475 mmol) to afford 166 mg (87%) of the title compound ((±)-<b>16b</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 60 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 11.53 (s, 1H), 8.54 (s, 1H), 7.46 (s, 1H), 4.18 (d, <i>J</i> = 12.0 Hz, 1H), 3.97 (d, <i>J</i> = 8.8 Hz, 1H), 3.85–3.78 (m, 3H), 3.77–3.70 (m, 3H), 3.69–3.61 (m, 3H), 3.54–3.46 (m, 2H), 3.13–3.00 (m, 2H), 1.16 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.23, 168.86, 163.95, 154.81, 150.72, 143.82 (d, <i>J</i> = 11.3 Hz), 143.06 (d, <i>J</i> = 242.7 Hz), 136.41 (d, <i>J</i> = 3.9 Hz), 125.37 (d, <i>J</i> = 3.9 Hz), 119.83, 109.22, 73.42, 72.95, 67.20 (2), 65.26, 57.41 (d, <i>J</i> = 9.6 Hz), 53.6, 50.88 (2), 39.67, 19.35, 19.33. MS (EI) <i>m</i>/<i>z</i>: 484 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>23</sub>H<sub>25</sub>FN<sub>6</sub>O<sub>5</sub>: 484.1870, found: 484.1872.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> <i>rel</i>-(2′<i>R</i>,4′<i>S</i>,4a′<i>S</i>)-12′-Fluoro-2′,4′-dimethyl-8′-thiomorpholino-1′,2′,4′,4a′-tetrahydro-2<i>H</i>,6′<i>H</i>-spiro[pyrimidine-5,5′-[1,4]oxazino[4′,3′:1,6]pyrido[3,2-<i>g</i>]quinazoline]-2,4,6(1<i>H</i>,3<i>H</i>)-trione ((±)-<b>16c</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>16a</b> using <b>15c</b> (170 mg, 0.436 mmol) and barbituric acid (73 mg, 0.566 mmol) to afford 191 mg (88%) of the title compound ((±)-<b>16c</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 60 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 11.51 (s, 1H), 8.53 (s, 1H), 7.36 (s, 1H), 4.17 (d, <i>J</i> = 11.9 Hz, 1H), 3.97 (d, <i>J</i> = 8.8 Hz, 1H), 3.88–3.75 (m, 6H), 3.71–3.62 (m, 1H), 3.13–3.01 (m, 2H), 2.95–2.87 (m, 2H), 2.79–2.71 (m, 2H), 1.16 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.22, 168.82, 164.49, 154.72, 150.68, 143.89 (d, <i>J</i> = 11.4 Hz), 143.07 (d, <i>J</i> = 242.7 Hz), 136.48 (d, <i>J</i> = 3.7 Hz), 125.36, 119.77, 109.36, 73.43, 72.96, 65.28, 57.44 (d, <i>J</i> = 9.7 Hz), 53.58, 52.99 (2), 39.62, 27.71 (2), 19.35, 19.33. MS (EI) <i>m</i>/<i>z</i>: 500 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>23</sub>H<sub>25</sub>FN<sub>6</sub>O<sub>4</sub>S: 500.1642, found: 500.1644.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> <i>rel</i>-(2′<i>R</i>,4′<i>S</i>,4a′<i>S</i>)-12′-Fluoro-2′,4′-dimethyl-8′-(3-oxomorpholino)-1′,2′,4′,4a′-tetrahydro-2<i>H</i>,6′<i>H</i>-spiro[pyrimidine-5,5′-[1,4]oxazino[4′,3′:1,6]pyrido[3,2-<i>g</i>]quinazoline]-2,4,6(1<i>H</i>,3<i>H</i>)-trione ((±)-<b>16d</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>16a</b> using <b>15d</b> (64 mg, 0.165 mmol) and barbituric acid (28 mg, 0.214 mmol) to afford 69 mg (84%) of the title compound ((±)-<b>16d</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 60 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.96 (s, 1H), 11.61 (s, 1H), 9.03 (s, 1H), 7.39 (s, 1H), 4.42–4.23 (m, 3H), 4.12–4.04 (m, 4H), 3.90–3.83 (m, 1H), 3.81–3.75 (m, 1H), 3.74–3.66 (m, 2H), 3.21–3.08 (m, 2H), 1.18 (d, <i>J</i> = 6.2 Hz, 3H), 0.92 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.25, 168.18, 167.59, 159.55, 155.03, 149.93, 143.43 (d, <i>J</i> = 11.4 Hz), 141.05 (d, <i>J</i> = 243.6 Hz), 137.18, 128.29, 119.62, 113.45, 72.81, 72.28, 68.14, 64.74, 63.83, 56.80 (d, <i>J</i> = 10.1 Hz), 52.55, 47.99, 38.67, 18.65, 18.60. MS (EI) <i>m</i>/<i>z</i>: 498 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>23</sub>H<sub>23</sub>FN<sub>6</sub>O<sub>6</sub>: 498.1663, found: 498.1660.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> <i>rel</i>-(2′<i>R</i>,4′<i>S</i>,4a′<i>S</i>)-12′-Fluoro-2′,4′-dimethyl-8′-(1<i>H</i>-1,2,4-triazol-1-yl)-1′,2′,4′,4a′-tetrahydro-2<i>H</i>,6′<i>H</i>-spiro[pyrimidine-5,5′-[1,4]oxazino[4′,3′:1,6]pyrido[3,2-<i>g</i>]quinazoline]-2,4,6(1<i>H</i>,3<i>H</i>)-trione ((±)-<b>20</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>16a</b> using <b>19</b> (98 mg, 0.275 mmol) and barbituric acid (46 mg, 0.358 mmol) to afford 65 mg (51%) of the title compound ((±)-<b>20</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 60 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.91 (s, 1H), 11.55 (s, 1H), 9.55 (s, 1H), 9.03 (s, 1H), 8.50 (s, 1H), 8.45 (s, 1H), 4.31 (d, <i>J</i> = 11.9 Hz, 1H), 4.05 (d, <i>J</i> = 9.0 Hz, 1H), 3.91 (d, <i>J</i> = 14.6 Hz, 1H), 3.89–3.83 (m, 1H), 3.73–3.66 (m, 1H), 3.22–3.14 (m, 1H), 3.09 (d, <i>J</i> = 13.7 Hz, 1H), 1.19 (d, <i>J</i> = 6.2 Hz, 3H), 0.93 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.93, 168.94, 154.97, 154.63, 152.34 (d, <i>J</i> = 3.0 Hz), 150.58, 146.73, 145.26 (d, <i>J</i> = 11.4 Hz), 141.70 (d, <i>J</i> = 238.1 Hz), 138.26 (d, <i>J</i> = 3.1 Hz), 130.22 (d, <i>J</i> = 4.3 Hz), 120.63, 108.96, 73.51, 72.92, 65.79, 57.43 (d, <i>J</i> = 10.9 Hz), 53.21, 39.16, 19.35, 19.26. MS (EI) <i>m</i>/<i>z</i>: 466 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>21</sub>H<sub>19</sub>FN<sub>8</sub>O<sub>4</sub>: 466.1513, found: 466.1500.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> <i>rel</i>-(2′<i>R</i>,4′<i>S</i>,4a′<i>S</i>)-12′-Fluoro-2′,4′-dimethyl-8′-(2-oxooxazolidin-3-yl)-1′,2′,4′,4a′-tetrahydro-2<i>H</i>,6′<i>H</i>-spiro[pyrimidine-5,5′-[1,4]oxazino[4′,3′:1,6]pyrido[3,2-<i>g</i>]quinazoline]-2,4,6(1<i>H</i>,3<i>H</i>)-trione ((±)-<b>24</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>16a</b> using <b>23</b> (90 mg, 0.24 mmol) and barbituric acid (40 mg, 0.313 mmol) to afford 85 mg (73%) of the title compound ((±)-<b>24</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.90 (s, 1H), 11.53 (s, 1H), 8.90 (s, 1H), 7.56 (s, 1H), 4.63–4.58 (m, 1H), 4.53 (dd, <i>J</i> = 16.5, 8.0 Hz, 1H), 4.44 (dd, <i>J</i> = 17.7, 8.8 Hz, 1H), 4.26 (d, <i>J</i> = 12.0 Hz, 1H), 4.18–4.11 (m, 1H), 4.03 (d, <i>J</i> = 8.9 Hz, 1H), 3.90–3.82 (m, 1H), 3.75–3.66 (m, 2H), 3.19–3.07 (m, 2H), 1.18 (d, <i>J</i> = 6.2 Hz, 3H), 0.91 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.25, 168.18, 155.70, 154.23, 149.90, 142.68 (d, <i>J</i> = 237.1 Hz), 140.25, 137.08 (d, <i>J</i> = 3.5 Hz), 126.73, 120.72, 110.89 (d, <i>J</i> = 0.9 Hz), 110.00, 72.77, 72.28, 64.74, 63.92, 56.77 (d, <i>J</i> = 12.2 Hz), 52.73, 46.16, 38.75, 18.67, 18.61. MS (EI) <i>m</i>/<i>z</i>: 484 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>22</sub>H<sub>21</sub>FN<sub>6</sub>O<sub>6</sub>: 484.1507, found: 484.1510.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>S</i>)-4-methyl-2-oxooxazolidin-3-yl)-1,2,4,4a-tetrahydro-6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,4′-[1,2,6]thiadiazinane]-3′,5′-dione 1′,1′-dioxide (<b>26a</b>)</h4><div class="NLM_p last">Compound <b>25</b> (200 mg, 0.530 mmol) was dissolved in acetic acid (4 mL) and water (1 mL). To the mixture, 1,2,6-thiadiazinane-3,5-dione 1,1-dioxide (95 mg, 0.583 mmol) was added at room temperature. The resulting mixture was stirred at 110 °C for 3 h and then cooled to room temperature. The mixture was extracted with ethyl acetate and the organic phase was washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the filtrate was concentrated in vacuo. The residue was purified by HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 30 → 80% B) to give 206 mg (74%) of <b>26a</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.37 (s, 1H), 7.32 (s, 1H), 6.70 (s, 1H), 4.74–4.60 (m, 2H), 4.26–4.16 (m, 2H), 4.06 (d, <i>J</i> = 12.8 Hz, 1H), 3.95–3.85 (m, 1H), 3.79–3.70 (m, 1H), 3.28 (d, <i>J</i> = 14.1 Hz, 1H), 3.10–3.00 (m, 1H), 2.74 (d, <i>J</i> = 11.7 Hz, 1H), 1.40 (d, <i>J</i> = 5.5 Hz, 3H), 1.13 (d, <i>J</i> = 6.0 Hz, 3H), 0.86 (d, <i>J</i> = 6.2 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.03, 168.48, 154.68, 153.91 (d, <i>J</i> = 12.8 Hz), 152.45, 136.04, 133.68 (d, <i>J</i> = 237.5 Hz), 124.62, 117.58, 106.63, 73.65, 72.08, 70.58, 65.20, 57.04 (d, <i>J</i> = 8.8 Hz), 53.52, 52.89, 38.15, 22.95, 18.75, 18.34. MS (ESI) <i>m</i>/<i>z</i>: 522.2 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>21</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>8</sub>S (M – H)<sup>−</sup>: 522.1100, found: 522.1104.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>S</i>)-4-methyl-2-oxooxazolidin-3-yl)-2′-thioxo-1,2,2′,3′,4,4a-hexahydro-4′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-4′,6′(1′<i>H</i>)-dione (<b>26b</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of <b>26a</b> using <b>25</b> (150 mg, 0.398 mmol) and 2-thioxodihydropyrimidine-4,6(1<i>H</i>,5<i>H</i>)-dione (63 mg, 0.438 mmol) to afford 110 mg (55%) of the title compound (<b>26b</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.93 (s, 1H), 12.61 (s, 1H), 7.60 (s, 1H), 4.74–4.61 (m, 2H), 4.18 (dd, <i>J</i> = 7.7, 5.0 Hz, 1H), 4.10 (d, <i>J</i> = 12.8 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.84–3.74 (m, 1H), 3.68–3.58 (m, 2H), 3.12 (t, <i>J</i> = 12.4 Hz, 1H), 2.97 (d, <i>J</i> = 14.4 Hz, 1H), 1.42 (d, <i>J</i> = 5.9 Hz, 3H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.88 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 178.76, 169.36, 165.93, 154.55, 153.89 (d, <i>J</i> = 12.8 Hz), 152.61, 135.28, 133.87 (d, <i>J</i> = 239.1 Hz), 122.45, 118.76, 107.52, 72.48, 72.20, 70.69, 65.07, 56.69 (d, <i>J</i> = 8.9 Hz), 53.84, 53.04, 38.88, 18.74, 18.57, 17.80. MS (ESI) <i>m</i>/<i>z</i>: 502.2 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>22</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M + H)<sup>+</sup>: 504.1348, found: 504.1360.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-1′,2,3′,4-tetramethyl-8-((<i>S</i>)-4-methyl-2-oxooxazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>26c</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of <b>26a</b> using <b>25</b> (200 mg, 0.530 mmol) and 1,3-dimethylpyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione (91 mg, 0.583 mmol) to afford 220 mg (80%) of the title compound (<b>26c</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 60 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.55 (s, 1H), 4.74–4.60 (m, 2H), 4.19 (dd, <i>J</i> = 7.5, 4.9 Hz, 1H), 4.11 (d, <i>J</i> = 12.6 Hz, 1H), 4.00 (d, <i>J</i> = 8.6 Hz, 1H), 3.85–3.75 (m, 1H), 3.69–3.60 (m, 2H), 3.26 (s, 3H), 3.16–3.08 (m, 1H), 3.01 (s, 3H), 2.93 (d, <i>J</i> = 14.1 Hz, 1H), 1.43 (d, <i>J</i> = 5.8 Hz, 3H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.85 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.83, 166.44, 154.60, 153.91 (d, <i>J</i> = 12.9 Hz), 152.58, 150.62, 135.25, 133.79 (d, <i>J</i> = 239.1 Hz), 122.53, 118.67, 107.34, 72.66, 72.14, 70.65, 65.60, 56.83 (d, <i>J</i> = 9.4 Hz), 53.87, 52.98, 39.66, 29.68, 28.83, 18.74, 18.60, 17.75. MS (EI) <i>m</i>/<i>z</i>: 515 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>24</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>7</sub>: 515.1816, found: 515.1818.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> <i>rel</i>-(2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(2-oxo-1,3-oxazinan-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione ((±)-<b>33a</b>)</h4><div class="NLM_p last">Compound <b>31a</b> (122 mg, 0.323 mmol) was dissolved in acetic acid (4 mL) and water (1 mL). To the mixture, barbituric acid (54 mg, 0.420 mmol) was added at room temperature. The resulting mixture was stirred at 110 °C for 3 h and then cooled to room temperature. The mixture was extracted with ethyl acetate and the organic phase was washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the filtrate was concentrated in vacuo. The residue was purified by HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) gave (±)-<b>33a</b> 95 mg (60%). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.49 (s, 1H), 7.23 (s, 1H), 4.43 (t, <i>J</i> = 5.3 Hz, 2H), 4.10 (d, <i>J</i> = 12.5 Hz, 1H), 3.96–3.86 (m, 3H), 3.83–3.76 (m, 1H), 3.70–3.64 (m, 1H), 3.61 (d, <i>J</i> = 14.6 Hz, 1H), 3.14–3.06 (m, 1H), 2.92 (d, <i>J</i> = 14.3 Hz, 1H), 2.19–2.11 (m, 2H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.14, 168.86, 158.38, 154.30 (d, <i>J</i> = 13.1 Hz), 151.57, 150.67, 135.61, 134.43 (d, <i>J</i> = 238.9 Hz), 123.50, 118.90, 109.55, 73.29, 72.86, 68.49, 65.53, 57.48 (d, <i>J</i> = 9.7 Hz), 54.04, 48.39, 39.71, 22.72, 19.33, 19.32. MS (EI) <i>m</i>/<i>z</i>: 487 (M<sup>+</sup>). HRMS (EI) <i>m</i>/<i>z</i> Anal. calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>7</sub>: 487.1503, found: 487.1503.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> <i>rel</i>-(2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-(4,4-Dimethyl-2-oxooxazolidin-3-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione ((±)-<b>33b</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>31b</b> (110 mg, 0.281 mmol) and barbituric acid (47 mg, 0.365 mmol) to afford 60 mg (43%) of the title compound ((±)-<b>33b</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 11.55 (s, 1H), 7.28 (s, 1H), 4.34 (s, 2H), 4.10 (d, <i>J</i> = 12.8 Hz, 1H), 3.94 (d, <i>J</i> = 8.9 Hz, 1H), 3.85–3.75 (m, 1H), 3.71–3.65 (m, 1H), 3.62 (d, <i>J</i> = 14.7 Hz, 1H), 3.15–3.07 (m, 1H), 2.93 (d, <i>J</i> = 13.8 Hz, 1H), 1.52 (s, 6H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.08, 168.89, 155.12, 154.03 (d, <i>J</i> = 12.8 Hz), 152.98, 150.61, 136.02, 134.49 (d, <i>J</i> = 239.4 Hz), 123.98, 118.30, 109.56, 76.97, 73.30, 72.87, 65.58, 62.74, 57.48 (d, <i>J</i> = 8.8 Hz), 54.00, 39.67, 25.21, 25.01, 19.34, 19.29. MS (EI) <i>m</i>/<i>z</i>: 501 (M<sup>+</sup>). HRMS (EI) <i>m</i>/<i>z</i> Anal. calcd for C<sub>23</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>7</sub>: 501.1660, found: 501.1648.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> <i>rel</i>-(2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-oxo-6-oxa-4-azaspiro[2.4]heptan-4-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione ((±)-<b>33c</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>31c</b> (100 mg, 0.256 mmol) and barbituric acid (43 mg, 0.334 mmol) to afford 94 mg (58%) of the title compound ((±)-<b>33c</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 11.56 (s, 1H), 7.27 (s, 1H), 4.61 (dd, <i>J</i> = 17.9, 8.5 Hz, 2H), 4.10 (d, <i>J</i> = 13.0 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.75 (m, 1H), 3.71–3.60 (m, 2H), 3.16–3.07 (m, 1H), 2.92 (d, <i>J</i> = 14.5 Hz, 1H), 1.43 (t, <i>J</i> = 5.7 Hz, 2H), 1.14 (d, <i>J</i> = 6.2 Hz, 3H), 0.92–0.85 (m, 5H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.10, 168.91, 155.70, 154.06 (d, <i>J</i> = 13.0 Hz), 152.23, 150.68, 136.20, 134.47 (d, <i>J</i> = 239.9 Hz), 124.37, 117.94, 109.22, 73.29, 72.87, 71.80, 65.58, 57.47 (d, <i>J</i> = 8.0 Hz), 54.01, 43.90, 39.61, 19.34, 19.30, 9.10, 7.99. MS (EI) <i>m</i>/<i>z</i>: 499 (M<sup>+</sup>). HRMS (EI) <i>m</i>/<i>z</i> Anal. calcd for C<sub>23</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>7</sub>: 499.1503, found: 499.1497.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> <i>rel</i>-(2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(2-thioxooxazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione ((±)-<b>33d</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>31d</b> (100 mg, 0.264 mmol) and barbituric acid (44 mg, 0.343 mmol) to afford 100 mg (77%) of the title compound ((±)-<b>33d</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.69 (s, 2H), 7.52 (s, 1H), 4.59–4.46 (m, 2H), 4.19–3.98 (m, 3H), 3.87 (d, <i>J</i> = 8.8 Hz, 1H), 3.79–3.71 (m, 1H), 3.69–3.60 (m, 1H), 3.54 (d, <i>J</i> = 14.4 Hz, 1H), 3.06–2.98 (m, 1H), 2.86 (d, <i>J</i> = 14.6 Hz, 1H), 1.12 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 177.85, 172.17, 168.79, 154.71, 150.66, 145.63 (d, <i>J</i> = 12.2 Hz), 141.98 (d, <i>J</i> = 237.6 Hz), 137.35 (d, <i>J</i> = 4.6 Hz), 123.83, 118.95 (d, <i>J</i> = 3.4 Hz), 108.50, 73.55, 72.86, 70.82, 65.13, 57.14 (d, <i>J</i> = 10.8 Hz), 53.55, 45.35, 38.97, 19.48, 19.31. MS (EI) <i>m</i>/<i>z</i>: 489 (M<sup>+</sup>). HRMS (EI) <i>m</i>/<i>z</i> Anal. calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>6</sub>S: 489.1118, found: 489.1107.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>rel</i>-(2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione ((±)-<b>33e</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>31e</b> (70 mg, 0.180 mmol) and barbituric acid (26 mg, 0.198 mmol) to afford 76 mg (85%) of the title compound ((±)-<b>33e</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 11.46 (s, 1H), 7.76 (s, 1H), 4.29–4.21 (m, 2H), 4.11 (d, <i>J</i> = 12.9 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.78 (br s, 1H), 3.72–3.62 (m, 2H), 3.17–3.06 (m, 1H), 2.92 (d, <i>J</i> = 14.1 Hz, 1H), 1.24–1.19 (m, 2H), 1.15 (d, <i>J</i> = 6.3 Hz, 3H), 1.00–0.95 (m, 2H), 0.90 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.40, 168.15, 154.20 (d, <i>J</i> = 12.8 Hz), 153.79, 153.17, 149.98, 135.30, 133.76 (d, <i>J</i> = 238.8 Hz), 122.85, 118.83, 106.52, 72.58, 72.14, 64.88, 62.33, 56.73 (d, <i>J</i> = 9.3 Hz), 53.38, 50.71, 39.02, 18.64, 18.61, 10.32, 10.26. MS (EI) <i>m</i>/<i>z</i>: 499 (M<sup>+</sup>). HRMS (EI) <i>m</i>/<i>z</i> Anal. calcd for C<sub>23</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>7</sub>: 499.1503, found: 499.1503.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>33e</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>32e</b> (300 mg, 0.770 mmol) and barbituric acid (109 mg, 0.848 mmol) to afford 332 mg (86%) of the title compound (<b>33e</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 11.45 (s, 1H), 7.73 (s, 1H), 4.25–4.19 (m, 2H), 4.08 (d, <i>J</i> = 12.5 Hz, 1H), 3.92 (d, <i>J</i> = 8.8 Hz, 1H), 3.80–3.74 (m, 1H), 3.68–3.62 (m, 2H), 3.13–3.06 (m, 1H), 2.88 (d, <i>J</i> = 14.2 Hz, 1H), 1.19 (t, <i>J</i> = 6.7 Hz, 2H), 1.13 (d, <i>J</i> = 6.2 Hz, 3H), 0.97–0.94 (m, 2H), 0.87 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.92, 167.68, 153.72 (d, <i>J</i> = 12.9 Hz), 153.31, 152.68, 149.52, 134.81, 133.27 (d, <i>J</i> = 238.8 Hz), 122.36, 118.37, 106.02, 72.10, 71.66, 64.39, 61.86, 56.24 (d, <i>J</i> = 9.1 Hz), 52.90, 50.22, 38.52, 18.17, 18.14, 9.85, 9.79. MS (EI) <i>m</i>/<i>z</i>: 499 (M<sup>+</sup>). HRMS (EI) <i>m</i>/<i>z</i> Anal. calcd for C<sub>23</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>7</sub>: 499.1503, found: 499.1503. [α]<sub>D</sub><sup>20</sup> = −169 (<i>c</i> = 1; MeOH).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(6-oxo-5-oxa-7-azaspiro[3.4]octan-7-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>33f</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>32f</b> (92 mg, 0.228 mmol) and barbituric acid (32 mg, 0.251 mmol) to afford 99 mg (85%) of the title compound (<b>33f</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.73 (s, 1H), 11.47 (s, 1H), 7.70 (s, 1H), 4.23 (s, 2H), 4.10 (d, <i>J</i> = 12.5 Hz, 1H), 3.93 (d, <i>J</i> = 8.8 Hz, 1H), 3.84–3.74 (m, 1H), 3.71–3.62 (m, 2H), 3.17–3.05 (m, 1H), 2.91 (d, <i>J</i> = 13.9 Hz, 1H), 2.50–2.32 (m, 4H), 1.89–1.63 (m, 2H), 1.15 (d, <i>J</i> = 6.3 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.41, 168.15, 154.12 (d, <i>J</i> = 12.9 Hz), 153.34, 153.24, 150.00, 135.26, 133.76 (d, <i>J</i> = 238.8 Hz), 122.77, 118.81, 106.65, 81.39, 72.57, 72.13, 64.87, 56.73 (d, <i>J</i> = 9.4 Hz), 55.57, 53.37, 39.01, 34.95, 34.79, 18.64, 18.61, 11.96. MS (EI) <i>m</i>/<i>z</i>: 513 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>24</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>7</sub>: 513.1660, found: 513.1663.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(2-oxo-1-oxa-3-azaspiro[4.4]nonan-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>33g</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>32g</b> (99 mg, 0.237 mmol) and barbituric acid (34 mg, 0.261 mmol) to afford 94 mg (75%) of the title compound (<b>33g</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 11.46 (s, 1H), 7.73 (s, 1H), 4.14–4.08 (m, 3H), 3.93 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.74 (m, 1H), 3.70–3.62 (m, 2H), 3.15–3.07 (m, 1H), 2.91 (d, <i>J</i> = 13.7 Hz, 1H), 2.12–2.04 (m, 2H), 1.96–1.87 (m, 2H), 1.80–1.71 (m, 4H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.96, 167.69, 153.68 (d, <i>J</i> = 12.9 Hz), 153.06, 152.90, 149.54, 134.78, 133.29 (d, <i>J</i> = 238.8 Hz), 122.23, 118.53, 106.19, 90.29, 72.12, 71.68, 64.42, 56.27 (d, <i>J</i> = 8.9 Hz), 53.33, 52.92, 38.55, 37.72, 37.55, 23.11, 23.08, 18.19, 18.17. MS (EI) <i>m</i>/<i>z</i>: 527 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>25</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>7</sub>: 527.1816, found: 527.1821.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(6-oxo-2,5-dioxa-7-azaspiro[3.4]octan-7-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>33h</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>32h</b> (93 mg, 0.229 mmol) and barbituric acid (33 mg, 0.252 mmol) to afford 101 mg (86%) of the title compound (<b>33h</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 30 → 80% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.63 (s, 2H), 7.73 (s, 1H), 4.86–4.76 (m, 4H), 4.43–4.36 (m, 2H), 4.10 (d, <i>J</i> = 12.5 Hz, 1H), 3.93 (d, <i>J</i> = 8.9 Hz, 1H), 3.83–3.74 (m, 1H), 3.72–3.60 (m, 2H), 3.18–3.05 (m, 1H), 2.90 (d, <i>J</i> = 13.7 Hz, 1H), 1.14 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.46, 168.17, 154.15 (d, <i>J</i> = 13.0 Hz), 152.88, 152.86, 150.07, 135.28, 133.74 (d, <i>J</i> = 238.9 Hz), 122.83, 118.85, 106.49, 81.72, 81.52, 80.54, 72.57, 72.12, 64.90, 56.68 (d, <i>J</i> = 9.2 Hz), 53.38, 52.55, 39.02, 18.62, 18.62. MS (EI) <i>m</i>/<i>z</i>: 515 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>23</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>8</sub>: 515.1452, found: 515.1458.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(2-oxothiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39a</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38a</b> (78 mg, 0.21 mmol) and barbituric acid (35 mg, 0.27 mmol) to afford 85 mg (84%) of the title compound (<b>39a</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.47 (s, 1H), 7.42 (s, 1H), 4.23 (t, <i>J</i> = 7.2 Hz, 2H), 4.10 (d, <i>J</i> = 12.5 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.74 (m, 1H), 3.71–3.55 (m, 4H), 3.15–3.06 (m, 1H), 2.91 (d, <i>J</i> = 13.7 Hz, 1H), 1.14 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 172.04, 171.38, 168.12, 154.01 (d, <i>J</i> = 7.2 Hz), 153.95 (d, <i>J</i> = 3.9 Hz), 149.96, 135.24, 133.78 (d, <i>J</i> = 239.0 Hz), 122.84, 118.67, 107.34, 72.56, 72.14, 64.82, 56.73 (d, <i>J</i> = 9.0 Hz), 53.39, 49.95, 38.98, 27.22, 18.64, 18.61. MS (EI) <i>m</i>/<i>z</i>: 489 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>21</sub>H<sub>20</sub>FN<sub>5</sub>O<sub>6</sub>S: 489.1118, found: 489.1124.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>S</i>)-4-methyl-2-oxothiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39b</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38b</b> (97 mg, 0.25 mmol) and barbituric acid (35 mg, 0.27 mmol) to afford 80 mg (64%) of the title compound (<b>39b</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.52 (s, 1H), 7.33 (s, 1H), 4.76–4.66 (m, 1H), 4.10 (d, <i>J</i> = 13.0 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.86 (dd, <i>J</i> = 11.1, 7.2 Hz, 1H), 3.82–3.74 (m, 1H), 3.71–3.59 (m, 2H), 3.25 (dd, <i>J</i> = 11.2, 3.9 Hz, 1H), 3.16–3.06 (m, 1H), 2.91 (d, <i>J</i> = 14.4 Hz, 1H), 1.46 (d, <i>J</i> = 6.2 Hz, 3H), 1.15 (d, <i>J</i> = 6.3 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.44, 171.38, 168.19, 153.79 (d, <i>J</i> = 12.8 Hz), 153.34, 149.93, 135.25, 133.75 (d, <i>J</i> = 239.3 Hz), 123.09, 118.11, 108.07, 72.59, 72.15, 64.84, 57.53, 56.74 (d, <i>J</i> = 9.8 Hz), 53.33, 38.95, 34.21, 18.64, 18.60, 18.40. MS (EI) <i>m</i>/<i>z</i>: 503 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>6</sub>S: 503.1275, found: 503.1269.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>R</i>)-4-methyl-2-oxothiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39c</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38c</b> (82 mg, 0.21 mmol) and barbituric acid (30 mg, 0.23 mmol) to afford 65 mg (62%) of the title compound (<b>39c</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.46 (s, 1H), 7.31 (s, 1H), 4.74–4.66 (m, 1H), 4.10 (d, <i>J</i> = 12.6 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.89 (dd, <i>J</i> = 11.1, 7.1 Hz, 1H), 3.84–3.74 (m, 1H), 3.70–3.62 (m, 2H), 3.23 (dd, <i>J</i> = 11.1, 2.9 Hz, 1H), 3.15–3.06 (m, 1H), 2.91 (d, <i>J</i> = 13.8 Hz, 1H), 1.49 (d, <i>J</i> = 6.3 Hz, 3H), 1.15 (d, <i>J</i> = 6.3 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.38, 171.23, 168.11, 153.74 (d, <i>J</i> = 12.9 Hz), 153.43, 149.95, 135.31, 133.84 (d, <i>J</i> = 239.3 Hz), 123.10, 118.09, 108.03, 72.57, 72.15, 64.82, 57.88, 56.75 (d, <i>J</i> = 9.3 Hz), 53.35, 38.91, 34.43, 18.64, 18.61, 18.27. MS (EI) <i>m</i>/<i>z</i>: 503 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>6</sub>S: 503.1275, found: 503.1273.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>R</i>)-5-methyl-2-oxothiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39d</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38d</b> (63 mg, 0.16 mmol) and barbituric acid (23 mg, 0.18 mmol) to afford 67 mg (83%) of the title compound (<b>39d</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.48 (s, 1H), 7.43 (s, 1H), 4.36 (dd, <i>J</i> = 10.6, 7.0 Hz, 1H), 4.20–4.06 (m, 2H), 3.97–3.86 (m, 2H), 3.84–3.74 (m, 1H), 3.72–3.61 (m, 2H), 3.16–3.06 (m, 1H), 2.91 (d, <i>J</i> = 14.2 Hz, 1H), 1.50 (d, <i>J</i> = 6.6 Hz, 3H), 1.14 (d, <i>J</i> = 6.3 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.48, 171.39, 168.15, 154.04, 153.94, 149.95, 135.26, 133.75 (d, <i>J</i> = 238.9 Hz), 122.83, 118.62, 107.33, 72.59, 72.14, 64.81, 56.75 (d, <i>J</i> = 8.9 Hz), 56.52, 53.30, 38.96, 38.67, 21.42, 18.65, 18.61. MS (EI) <i>m</i>/<i>z</i>: 503 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>6</sub>S: 503.1275, found: 503.1267.</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>S</i>)-5-methyl-2-oxothiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39e</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38e</b> (175 mg, 0.45 mmol) and barbituric acid (60 mg, 0.47 mmol) to afford 181 mg (80%) of the title compound (<b>39e</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.47 (s, 1H), 7.42 (s, 1H), 4.35 (dd, <i>J</i> = 10.6, 6.9 Hz, 1H), 4.25–4.15 (m, 1H), 4.10 (d, <i>J</i> = 12.9 Hz, 1H), 3.97–3.86 (m, 2H), 3.83–3.74 (m, 1H), 3.71–3.60 (m, 2H), 3.16–3.06 (m, 1H), 2.91 (d, <i>J</i> = 14.3 Hz, 1H), 1.50 (d, <i>J</i> = 6.6 Hz, 3H), 1.15 (d, <i>J</i> = 6.3 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.03, 170.91, 167.65, 153.53 (d, <i>J</i> = 5.4 Hz), 153.49 (d, <i>J</i> = 5.8 Hz), 149.49, 134.79, 133.30 (d, <i>J</i> = 238.9 Hz), 122.38, 118.18, 106.87, 72.09, 71.67, 64.34, 56.25 (d, <i>J</i> = 9.3 Hz), 56.16, 52.91, 38.48, 38.45, 20.11, 18.17, 18.14. MS (EI) <i>m</i>/<i>z</i>: 503 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>6</sub>S: 503.1275, found: 503.1258.</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-((<i>S</i>)-4-Ethyl-2-oxothiazolidin-3-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39f</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38f</b> (170 mg, 0.42 mmol) and barbituric acid (59 mg, 0.46 mmol) to afford 135 mg (62%) of the title compound (<b>39f</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 11.51 (s, 1H), 7.33 (s, 1H), 4.56 (ddd, <i>J</i> = 11.6, 7.6, 3.7 Hz, 1H), 4.10 (d, <i>J</i> = 12.6 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.87–3.74 (m, 2H), 3.70–3.59 (m, 2H), 3.38 (dd, <i>J</i> = 11.4, 3.9 Hz, 1H), 3.15–3.06 (m, 1H), 2.91 (d, <i>J</i> = 13.9 Hz, 1H), 1.91–1.76 (m, 2H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.96–0.84 (m, 6H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.62, 171.39, 168.18, 153.82 (d, <i>J</i> = 12.9 Hz), 153.43, 149.90, 135.28, 133.76 (d, <i>J</i> = 239.5 Hz), 123.19, 117.98, 108.10, 72.59, 72.16, 64.84, 62.17, 56.79, 53.33, 38.91, 31.07, 24.51, 18.64, 18.60, 9.41. MS (ESI) <i>m</i>/<i>z</i>: 516.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 516.1359, found: 516.1351.</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-((<i>R</i>)-4-Ethyl-2-oxothiazolidin-3-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39g</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38g</b> (140 mg, 0.34 mmol) and barbituric acid (52 mg, 0.41 mmol) to afford 105 mg (59%) of the title compound (<b>39g</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.48 (s, 1H), 7.31 (s, 1H), 4.53 (ddd, <i>J</i> = 11.2, 7.7, 3.2 Hz, 1H), 4.09 (d, <i>J</i> = 12.6 Hz, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.87–3.75 (m, 2H), 3.71–3.62 (m, 2H), 3.37 (dd, <i>J</i> = 10.9, 2.6 Hz, 1H), 3.14–3.05 (m, 1H), 2.91 (d, <i>J</i> = 14.0 Hz, 1H), 1.95–1.79 (m, 2H), 1.14 (d, <i>J</i> = 6.2 Hz, 3H), 0.93 (t, <i>J</i> = 7.5 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.02, 170.93, 167.68, 153.32 (d, <i>J</i> = 12.8 Hz), 153.03, 149.51, 134.85, 133.36 (d, <i>J</i> = 239.4 Hz), 122.70, 117.57, 107.61, 72.13, 71.70, 64.36, 62.20, 56.29 (d, <i>J</i> = 9.3 Hz), 52.88, 38.46, 30.71, 23.85, 18.20, 18.15, 9.11. MS (ESI) <i>m</i>/<i>z</i>: 516.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 516.1359, found: 516.1360.</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-((<i>R</i>)-5-Ethyl-2-oxothiazolidin-3-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1’<i>H</i>,3’<i>H</i>)-trione (<b>39h</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38h</b> (150 mg, 0.37 mmol) and barbituric acid (57 mg, 0.44 mmol) to afford 130 mg (68%) of the title compound (<b>39h</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.73 (s, 2H), 7.41 (s, 1H), 4.35 (dd, <i>J</i> = 10.4, 6.7 Hz, 1H), 4.08 (d, <i>J</i> = 12.7 Hz, 1H), 4.04–3.99 (m, 1H), 3.98–3.90 (m, 2H), 3.86–3.73 (m, 1H), 3.70–3.61 (m, 2H), 3.15–3.00 (m, 1H), 2.89 (d, <i>J</i> = 14.3 Hz, 1H), 1.89–1.84 (m, 1H), 1.82–1.71 (m, 1H), 1.13 (d, <i>J</i> = 6.2 Hz, 3H), 0.97 (t, <i>J</i> = 7.3 Hz, 3H), 0.88 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.39, 171.21, 168.15, 154.05, 153.95, 149.94, 135.25, 133.75 (d, <i>J</i> = 239.0 Hz), 122.81, 118.59, 107.33, 72.60, 72.13, 64.82, 56.75 (d, <i>J</i> = 9.2 Hz), 54.64, 53.31, 45.30, 38.98, 28.49, 18.64, 18.60, 11.82. MS (ESI) <i>m</i>/<i>z</i>: 516.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 516.1359, found: 516.1366.</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-((<i>S</i>)-5-Ethyl-2-oxothiazolidin-3-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39i</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38i</b> (75 mg, 0.18 mmol) and barbituric acid (28 mg, 0.22 mmol) to afford 63 mg (66%) of the title compound (<b>39i</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.69 (s, 2H), 7.41 (s, 1H), 4.34 (dd, <i>J</i> = 10.6, 7.0 Hz, 1H), 4.11–4.03 (m, 2H), 3.95 (dd, <i>J</i> = 11.3, 7.6 Hz, 2H), 3.82–3.74 (m, 1H), 3.70–3.59 (m, 2H), 3.15–3.06 (m, 1H), 2.90 (d, <i>J</i> = 14.1 Hz, 1H), 1.88 (dd, <i>J</i> = 7.4, 6.1 Hz, 1H), 1.83–1.72 (m, 1H), 1.14 (d, <i>J</i> = 6.2 Hz, 3H), 0.97 (t, <i>J</i> = 7.3 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.40, 171.17, 168.13, 154.00 (d, <i>J</i> = 13.0 Hz), 153.90, 149.98, 135.25, 133.76 (d, <i>J</i> = 239.1 Hz), 122.85, 118.62, 107.33, 72.57, 72.13, 64.83, 56.73 (d, <i>J</i> = 9.3 Hz), 54.80, 53.37, 45.52, 38.98, 28.05, 18.63, 18.59, 11.93. MS (ESI) <i>m</i>/<i>z</i>: 516.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 516.1359, found: 516.1366.</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>S</i>)-2-oxo-5-phenylthiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39j</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38j</b> (100 mg, 0.22 mmol) and barbituric acid (34 mg, 0.26 mmol) to afford 80 mg (64%) of the title compound (<b>39j</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 60 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.85 (s, 1H), 11.48 (s, 1H), 7.59–7.55 (m, 2H), 7.47 (s, 1H), 7.45–7.35 (m, 3H), 5.45 (t, <i>J</i> = 7.7 Hz, 1H), 4.59 (dd, <i>J</i> = 10.8, 7.4 Hz, 1H), 4.34 (dd, <i>J</i> = 10.8, 8.1 Hz, 1H), 4.10 (d, <i>J</i> = 12.6 Hz, 1H), 3.95 (d, <i>J</i> = 8.8 Hz, 1H), 3.84–3.75 (m, 1H), 3.72–3.63 (m, 2H), 3.16–3.08 (m, 1H), 2.93 (d, <i>J</i> = 14.0 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.94, 170.37, 167.69, 153.59 (d, <i>J</i> = 12.8 Hz), 153.35, 149.54, 137.93, 134.92, 133.36 (d, <i>J</i> = 239.1 Hz), 129.03 (2), 128.53, 127.70 (2), 122.56, 118.10, 106.89, 72.12, 71.70, 64.39, 56.28 (d, <i>J</i> = 8.9 Hz), 55.93, 52.96, 46.22, 38.52, 18.20, 18.17. MS (ESI) <i>m</i>/<i>z</i>: 564.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>27</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 564.1359, found: 564.1358.</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-((<i>S</i>)-4-Benzyl-2-oxothiazolidin-3-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39k</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38k</b> (166 mg, 0.35 mmol) and barbituric acid (54 mg, 0.43 mmol) to afford 121 mg (59%) of the title compound (<b>39k</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 60 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.85 (s, 1H), 11.54 (s, 1H), 7.39 (s, 1H), 7.35–7.30 (m, 2H), 7.29–7.23 (m, 3H), 4.89–4.81 (m, 1H), 4.11 (d, <i>J</i> = 12.5 Hz, 1H), 3.95 (d, <i>J</i> = 8.8 Hz, 1H), 3.84–3.77 (m, 1H), 3.75–3.62 (m, 3H), 3.29–3.22 (m, 2H), 3.14–3.03 (m, 2H), 2.91 (d, <i>J</i> = 14.0 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.91 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.36 (2), 168.12, 153.89 (dd, <i>J</i> = 13.0, 5.0 Hz), 153.39, 149.93, 136.72, 135.19, 133.69 (d, <i>J</i> = 239.3 Hz), 129.84 (2), 129.05 (2), 127.32, 122.97, 118.38, 107.83, 72.56, 72.11, 64.82, 62.04, 56.71 (d, <i>J</i> = 9.2 Hz), 53.31, 38.94, 36.95, 31.04, 18.60, 18.56. MS (ESI) <i>m</i>/<i>z</i>: 578.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>28</sub>H<sub>25</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 578.1515, found: 578.1522.</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-(5-oxo-6-thia-4-azaspiro[2.4]heptan-4-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39l</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38l</b> (63 mg, 0.16 mmol) and barbituric acid (22 mg, 0.17 mmol) to afford 50 mg (63%) of the title compound (<b>39l</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 50 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.86 (s, 1H), 11.54 (s, 1H), 7.07 (s, 1H), 4.10 (d, <i>J</i> = 12.8 Hz, 1H), 3.95 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.73 (m, 2H), 3.71–3.61 (m, 3H), 3.18–3.07 (m, 1H), 2.93 (d, <i>J</i> = 13.8 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 1.13–1.08 (m, 2H), 0.98–0.92 (m, 2H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.90, 170.88, 167.72, 153.05 (d, <i>J</i> = 12.9 Hz), 151.65, 149.44, 135.20, 133.41 (d, <i>J</i> = 240.6 Hz), 124.02, 115.28, 109.27, 72.13, 71.75, 64.41, 56.34 (d, <i>J</i> = 9.5 Hz), 52.87, 44.87, 38.29, 36.11, 18.21, 18.15, 10.14, 9.56. MS (ESI) <i>m</i>/<i>z</i>: 514.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>21</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 514.1202, found: 514.1204.</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((3a<i>S</i>,6a<i>R</i>)-2-oxotetrahydro-2<i>H</i>-cyclopenta[<i>d</i>]thiazol-3(3a<i>H</i>)-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39m</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38m</b> (143 mg, 0.34 mmol) and barbituric acid (53 mg, 0.41 mmol) to afford 120 mg (66%) of the title compound (<b>39m</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 50 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.71 (s, 2H), 7.37 (s, 1H), 4.97–4.92 (m, 1H), 4.40–4.34 (m, 1H), 4.08 (d, <i>J</i> = 12.9 Hz, 1H), 3.92 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.73 (m, 1H), 3.71–3.57 (m, 2H), 3.14–3.02 (m, 1H), 2.89 (d, <i>J</i> = 14.2 Hz, 1H), 2.16–2.02 (m, 2H), 1.89–1.75 (m, 3H), 1.73–1.62 (m, 1H), 1.13 (d, <i>J</i> = 6.1 Hz, 3H), 0.88 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.38, 171.26, 168.15, 153.94 (d, <i>J</i> = 12.9 Hz), 153.66, 149.90, 135.19, 133.75 (d, <i>J</i> = 239.4 Hz), 122.85, 118.42, 107.85, 72.60, 72.15, 65.59, 64.82, 56.74 (d, <i>J</i> = 9.3 Hz), 53.31, 44.79, 38.97, 35.07, 33.12, 23.54, 18.62, 18.56. MS (ESI) <i>m</i>/<i>z</i>: 528.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>24</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 528.1359, found: 528.1367.</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((3a<i>S</i>,7a<i>R</i>)-2-oxohexahydrobenzo[<i>d</i>]thiazol-3(2<i>H</i>)-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39n</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38n</b> (40 mg, 0.09 mmol) and barbituric acid (14 mg, 0.11 mmol) to afford 32 mg (64%) of the title compound (<b>39n</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 50 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.65 (s, 2H), 7.32 (s, 1H), 4.53–4.46 (m, 1H), 4.40 (dd, <i>J</i> = 9.7, 4.7 Hz, 1H), 4.09 (d, <i>J</i> = 12.8 Hz, 1H), 3.92 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.74 (m, 1H), 3.69–3.60 (m, 2H), 3.13–3.05 (m, 1H), 2.88 (d, <i>J</i> = 14.3 Hz, 1H), 2.19–2.10 (m, 1H), 1.99–1.92 (m, 2H), 1.88–1.77 (m, 1H), 1.57–1.47 (m, 3H), 1.36–1.26 (m, 1H), 1.13 (d, <i>J</i> = 6.1 Hz, 3H), 0.88 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.53, 171.47, 168.24, 153.77 (d, <i>J</i> = 13.0 Hz), 153.40, 150.03, 135.28, 133.73 (d, <i>J</i> = 239.3 Hz), 123.21, 117.90, 108.07, 72.61, 72.14, 64.88, 61.83, 56.76 (d, <i>J</i> = 9.3 Hz), 53.27, 45.39, 38.95, 27.53, 26.06, 21.75, 20.97, 18.64, 18.60. MS (EI) <i>m</i>/<i>z</i>: 543 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>25</sub>H<sub>26</sub>FN<sub>5</sub>O<sub>6</sub>S: 543.1588, found: 543.1562.</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((3a<i>R</i>,6a<i>S</i>)-2-oxotetrahydro-2<i>H</i>-cyclopenta[<i>d</i>]thiazol-3(3a<i>H</i>)-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>39o</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>38o</b> (180 mg, 0.43 mmol) and barbituric acid (60 mg, 0.47 mmol) to afford 182 mg (80%) of the title compound (<b>39o</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 50 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 11.52 (s, 1H), 7.37 (s, 1H), 4.96–4.89 (m, 1H), 4.47–4.39 (m, 1H), 4.10 (d, <i>J</i> = 14.0 Hz, 1H), 3.93 (d, <i>J</i> = 8.6 Hz, 1H), 3.83–3.73 (m, 1H), 3.71–3.61 (m, 2H), 3.16–3.06 (m, 1H), 2.90 (d, <i>J</i> = 14.4 Hz, 1H), 2.18–2.04 (m, 2H), 1.96–1.78 (m, 3H), 1.74–1.63 (m, 1H), 1.14 (d, <i>J</i> = 6.1 Hz, 3H), 0.89 (d, <i>J</i> = 6.2 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.38, 171.15, 168.13, 153.90 (d, <i>J</i> = 12.8 Hz), 153.75, 149.94, 135.25, 133.76 (d, <i>J</i> = 239.1 Hz), 123.05, 118.33, 107.97, 72.58, 72.14, 65.93, 64.85, 56.74 (d, <i>J</i> = 9.2 Hz), 53.35, 45.21, 38.97, 34.60, 33.17, 23.47, 18.64, 18.61. MS (ESI) <i>m</i>/<i>z</i>: 528.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>24</sub>H<sub>23</sub>FN<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 528.1359, found: 528.1367.</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-((<i>R</i>)-5-(hydroxymethyl)-2-oxothiazolidin-3-yl)-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3’<i>H</i>)-trione (<b>50</b>)</h4><div class="NLM_p last">Compound <b>45</b> (104 mg, 0.25 mmol) was dissolved in ethanol (6 mL) and 6 M HCl aqueous solution (2 mL). To the mixture, barbituric acid (36 mg, 0.28 mmol) was add at room temperature. The resulting mixture was stirred at 100 °C for 4 h and then cooled to room temperature. The mixture was extracted with ethyl acetate and the organic phase was washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the filtrate was concentrated in vacuo. The residue was purified by HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 20 → 70% B) to give 115 mg (87%) of <b>50</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.49 (s, 1H), 7.44 (s, 1H), 5.43 (t, <i>J</i> = 5.4 Hz, 1H), 4.28 (dd, <i>J</i> = 9.5, 6.2 Hz, 1H), 4.16–4.05 (m, 3H), 3.93 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.74 (m, 1H), 3.73–3.58 (m, 4H), 3.16–3.06 (m, 1H), 2.91 (d, <i>J</i> = 14.3 Hz, 1H), 1.14 (d, <i>J</i> = 6.1 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.39, 171.27, 168.15, 154.07, 153.95, 149.97, 135.24, 133.74 (d, <i>J</i> = 238.9 Hz), 122.83, 118.75, 107.30, 72.57, 72.13, 64.84, 63.45, 56.73 (d, <i>J</i> = 8.9 Hz), 53.36, 51.40, 45.07, 38.99, 18.64, 18.6. MS (EI) <i>m</i>/<i>z</i>: 519 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>22</sub>H<sub>22</sub>FN<sub>5</sub>O<sub>7</sub>S: 519.1224, found: 519.1227.</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-((<i>R</i>)-5-(methoxymethyl)-2-oxothiazolidin-3-yl)-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>51</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>47</b> (103 mg, 0.24 mmol) and barbituric acid (34 mg, 0.27 mmol) to afford 110 mg (85%) of the title compound (<b>51</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.81 (s, 1H), 11.49 (s, 1H), 7.44 (s, 1H), 4.34–4.26 (m, 2H), 4.10 (d, <i>J</i> = 12.6 Hz, 1H), 4.07–3.99 (m, 1H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.74 (m, 1H), 3.74–3.56 (m, 4H), 3.13 (s, 3H), 3.15–3.06 (m, 1H), 2.91 (d, <i>J</i> = 14.0 Hz, 1H), 1.14 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.40, 170.99, 168.15, 154.04 (d, <i>J</i> = 12.9 Hz), 153.89, 149.99, 135.27, 133.74 (d, <i>J</i> = 239.0 Hz), 122.87, 118.72, 107.24, 73.87, 72.57, 72.13, 64.84, 58.90, 56.73 (d, <i>J</i> = 9.0 Hz), 53.36, 51.45, 42.26, 38.98, 18.64, 18.61. MS (EI) <i>m</i>/<i>z</i>: 533 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>23</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>7</sub>S: 533.1380, found: 533.1390.</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-8-((<i>R</i>)-5-(Azidomethyl)-2-oxothiazolidin-3-yl)-11-fluoro-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>52</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>49</b> (60 mg, 0.14 mmol) and barbituric acid (20 mg, 0.15 mmol) to afford 60 mg (80%) of the title compound (<b>52</b>) as the major eluting component from reverse-phase HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.49 (s, 1H), 7.46 (s, 1H), 4.36 (dd, <i>J</i> = 10.9, 7.5 Hz, 1H), 4.28 (dt, <i>J</i> = 13.6, 5.1 Hz, 1H), 4.14–4.05 (m, 2H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.89–3.77 (m, 3H), 3.69–3.62 (m, 2H), 3.16–3.06 (m, 1H), 2.91 (d, <i>J</i> = 13.9 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.94, 170.04, 167.71, 153.61 (d, <i>J</i> = 12.9 Hz), 153.37, 149.53, 134.82, 133.25 (d, <i>J</i> = 239.0 Hz), 122.43, 118.32, 106.74, 72.13, 71.69, 64.33 (d, <i>J</i> = 16.7 Hz), 56.27 (d, <i>J</i> = 9.3 Hz), 53.72, 52.89, 51.68, 42.04, 38.50, 18.20, 18.16. MS (EI) <i>m</i>/<i>z</i>: 544 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>22</sub>H<sub>21</sub>FN<sub>8</sub>O<sub>6</sub>S: 544.1289, found: 544.1290.</div></div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i69" class="anchor-spacer"></div><h4 class="article-section__title" id="_i69"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-8-((<i>R</i>)-5-(fluoromethyl)-2-oxothiazolidin-3-yl)-2,4-dimethyl-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>57</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>56</b> (110 mg, 0.27 mmol) and barbituric acid (41 mg, 0.32 mmol) to afford 90 mg (65%) of the title compound (<b>57</b>) as the major eluting component from reverse-phase HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.49 (s, 1H), 7.46 (s, 1H), 4.78 (d, <i>J</i> = 5.6 Hz, 1H), 4.66 (d, <i>J</i> = 4.0 Hz, 1H), 4.43–4.35 (m, 2H), 4.16–4.08 (m, 2H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.75 (m, 1H), 3.70–3.62 (m, 2H), 3.15–3.07 (m, 1H), 2.91 (d, <i>J</i> = 13.9 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.39, 170.44, 168.15, 154.08 (d, <i>J</i> = 12.7 Hz), 153.80, 149.96, 135.28, 133.69 (d, <i>J</i> = 239.0 Hz), 122.91, 118.77, 107.17, 84.17 (d, <i>J</i> = 171.1 Hz), 72.58, 72.13, 64.85, 56.73 (d, <i>J</i> = 10.0 Hz), 53.33, 50.77 (d, <i>J</i> = 5.9 Hz), 41.86 (d, <i>J</i> = 20.6 Hz), 38.97, 18.64, 18.61. MS (ESI) <i>m</i>/<i>z</i>: 520.0 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>22</sub>H<sub>20</sub>F<sub>2</sub>N<sub>5</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 520.1108, found: 520.1112.</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i70" class="anchor-spacer"></div><h4 class="article-section__title" id="_i70"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>R</i>)-2-oxo-5-((trifluoromethoxy)methyl)thiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>61</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>60</b> (62 mg, 0.130 mmol) and barbituric acid (19 mg, 0.144 mmol) to afford 38 mg (50%) of the title compound (<b>61</b>) as the major eluting component from reverse-phase HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.83 (s, 1H), 11.49 (s, 1H), 7.46 (s, 1H), 4.54–4.47 (m, 1H), 4.46–4.37 (m, 3H), 4.16–4.07 (m, 2H), 3.94 (d, <i>J</i> = 8.7 Hz, 1H), 3.83–3.75 (m, 1H), 3.71–3.61 (m, 2H), 3.17–3.05 (m, 1H), 2.91 (d, <i>J</i> = 14.2 Hz, 1H), 1.15 (d, <i>J</i> = 6.1 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.40, 170.22, 168.16, 154.07 (d, <i>J</i> = 12.8 Hz), 153.78, 149.98, 135.29, 133.69 (d, <i>J</i> = 239.0 Hz), 122.91, 121.58 (q, <i>J</i> = 254.5 Hz), 118.80, 107.14, 72.58, 72.14, 69.42, 64.85, 56.73 (d, <i>J</i> = 9.3 Hz), 53.33, 50.96, 40.94, 38.93, 18.65, 18.62. MS (ESI) <i>m</i>/<i>z</i>: 586.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>20</sub>F<sub>4</sub>N<sub>5</sub>O<sub>7</sub>S (M – H)<sup>−</sup>: 586.1025, found: 586.1022.</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i71" class="anchor-spacer"></div><h4 class="article-section__title" id="_i71"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-8-((<i>R</i>)-5-((methylsulfonyl)methyl)-2-oxothiazolidin-3-yl)-1,2,4,4a-tetrahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-2′,4′,6′(1′<i>H</i>,3′<i>H</i>)-trione (<b>67</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>66</b> (40 mg, 0.085 mmol) and barbituric acid (12 mg, 0.093 mmol) to afford 30 mg (60%) of the title compound (<b>67</b>) as the major eluting component from reverse-phase HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 30 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.84 (s, 1H), 11.47 (s, 1H), 7.43 (s, 1H), 4.67–4.58 (m, 1H), 4.43 (dd, <i>J</i> = 11.0, 7.3 Hz, 1H), 4.21 (dd, <i>J</i> = 10.9, 7.1 Hz, 1H), 4.11 (d, <i>J</i> = 12.9 Hz, 1H), 4.00–3.92 (m, 2H), 3.77 (dd, <i>J</i> = 14.2, 7.6 Hz, 2H), 3.71–3.63 (m, 2H), 3.16–3.06 (m, 4H), 2.92 (d, <i>J</i> = 14.2 Hz, 1H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.38, 170.67, 168.12, 154.04 (d, <i>J</i> = 12.9 Hz), 153.78, 149.95, 135.31, 133.75 (d, <i>J</i> = 239.1 Hz), 122.90, 118.72, 107.23, 72.57, 72.13, 64.87, 57.14, 56.74 (d, <i>J</i> = 9.4 Hz), 53.82, 53.39, 41.43, 38.95, 36.97, 18.63, 18.60. MS (EI) <i>m</i>/<i>z</i>: 581 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>23</sub>H<sub>24</sub>FN<sub>5</sub>O<sub>8</sub>S<sub>2</sub>: 581.1050, found: 581.1052.</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i72" class="anchor-spacer"></div><h4 class="article-section__title" id="_i72"> <i>N</i>-(((<i>S</i>)-3-((2<i>R</i>,4<i>S</i>,4a<i>S</i>)-11-Fluoro-2,4-dimethyl-2′,4′,6′-trioxo-1,1′,2,3′,4,4a,4′,6′-octahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidin]-8-yl)-2-oxothiazolidin-5-yl)methyl)acetamide (<b>69</b>)</h4><div class="NLM_p last">Compound <b>68</b> (65 mg, 0.13 mmol) was dissolved in dichloromethane (5 mL) and ethyl acetate (1 mL). Acetic anhydride (0.013 mL, 0.14 mmol) and DIPEA (0.031 mL, 0.19 mmol) were added. The reaction mixture was stirred at room temperature for 1 h and quenched by water. The resulting mixture was extracted with ethyl acetate and the organic phase was washed with water and brine, dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered, and the filtrate was concentrated in vacuo. The residue was purified by HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 30 → 90% B) to give 60 mg (86%) of <b>69</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 11.50 (s, 1H), 8.30 (t, <i>J</i> = 5.8 Hz, 1H), 7.43 (s, 1H), 4.30 (dd, <i>J</i> = 10.7, 7.1 Hz, 1H), 4.16–4.03 (m, 3H), 3.94 (d, <i>J</i> = 8.8 Hz, 1H), 3.83–3.75 (m, 1H), 3.71–3.59 (m, 2H), 3.44 (t, <i>J</i> = 6.5 Hz, 2H), 3.15–3.05 (m, 1H), 2.91 (d, <i>J</i> = 14.2 Hz, 1H), 1.82 (s, 3H), 1.15 (d, <i>J</i> = 6.2 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.40, 171.00, 170.34, 168.16, 153.99 (d, <i>J</i> = 13.0 Hz), 153.92, 149.98, 135.24, 133.72 (d, <i>J</i> = 239.1 Hz), 122.86, 118.70, 107.32, 72.59, 72.14, 64.84, 56.73 (d, <i>J</i> = 8.9 Hz), 53.34, 52.57, 43.06, 42.42, 38.97, 22.94, 18.65, 18.62. MS (ESI) <i>m</i>/<i>z</i>: 559.1 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>24</sub>H<sub>24</sub>FN<sub>6</sub>O<sub>7</sub>S (M – H)<sup>−</sup>: 559.1417, found: 559.1424.</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i73" class="anchor-spacer"></div><h4 class="article-section__title" id="_i73"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-2,4-Dimethyl-2′,4′,6′-trioxo-8-(5-oxo-4-oxa-6-azaspiro[2.4]heptan-6-yl)-1,1′,2,3′,4,4a,4′,6′-octahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-11-carbonitrile (<b>79a</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>78a</b> (17 mg, 0.043 mmol) and barbituric acid (6 mg, 0.047 mmol) to afford 10 mg (46%) of the title compound (<b>79a</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 30 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.75 (s, 2H), 8.08 (s, 1H), 4.56 (d, <i>J</i> = 13.4 Hz, 1H), 4.23 (s, 2H), 4.05 (d, <i>J</i> = 8.9 Hz, 1H), 3.87–3.80 (m, 1H), 3.75 (d, <i>J</i> = 14.6 Hz, 1H), 3.70–3.63 (m, 1H), 3.26 (dd, <i>J</i> = 14.6, 10.3 Hz, 1H), 2.86 (d, <i>J</i> = 14.3 Hz, 1H), 1.20 (t, <i>J</i> = 7.1 Hz, 2H), 1.18 (d, <i>J</i> = 6.2 Hz, 3H), 0.97 (t, <i>J</i> = 7.1 Hz, 2H), 0.92 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.22, 168.39, 166.83, 153.87, 153.32, 151.45, 150.24, 127.89, 121.77, 115.55, 104.11, 76.30, 72.83, 72.72, 66.01, 62.47, 56.45, 52.58, 50.54, 38.31, 18.52, 18.16, 10.30, 10.24. MS (EI) <i>m</i>/<i>z</i>: 506 (M<sup>+</sup>). HRMS (EI): Anal. calcd for C<sub>24</sub>H<sub>22</sub>N<sub>6</sub>O<sub>7</sub>: 506.1550, found: 506.1563.</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i74" class="anchor-spacer"></div><h4 class="article-section__title" id="_i74"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-2,4-Dimethyl-8-((<i>S</i>)-4-methyl-2-oxooxazolidin-3-yl)-2′,4′,6′-trioxo-1,1′,2,3′,4,4a,4′,6′-octahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-11-carbonitrile (<b>79b</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>78b</b> (50 mg, 0.13 mmol) and barbituric acid (18 mg, 0.14 mmol) to afford 35 mg (54%) of the title compound (<b>79b</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.88 (s, 1H), 11.57 (s, 1H), 7.93 (s, 1H), 4.72–4.61 (m, 2H), 4.56 (dd, <i>J</i> = 14.3, 1.3 Hz, 1H), 4.19 (dd, <i>J</i> = 8.0, 5.3 Hz, 1H), 4.05 (d, <i>J</i> = 8.9 Hz, 1H), 3.87–3.79 (m, 1H), 3.73 (d, <i>J</i> = 14.6 Hz, 1H), 3.65 (dq, <i>J</i> = 12.8, 6.3 Hz, 1H), 3.27 (dd, <i>J</i> = 14.6, 10.4 Hz, 1H), 2.89 (d, <i>J</i> = 14.5 Hz, 1H), 1.42 (d, <i>J</i> = 6.0 Hz, 3H), 1.18 (d, <i>J</i> = 6.2 Hz, 3H), 0.92 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.97, 168.19, 166.56, 154.63, 152.77, 151.48, 149.88, 127.72, 121.66, 115.51, 104.94, 76.44, 72.86, 72.69, 70.80, 65.94, 56.49, 52.93, 52.65, 38.29, 18.54, 18.15, 17.74. MS (ESI) <i>m</i>/<i>z</i>: 493.2 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>21</sub>N<sub>6</sub>O<sub>7</sub> (M – H)<sup>−</sup>: 493.1477, found: 493.1477.</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i75" class="anchor-spacer"></div><h4 class="article-section__title" id="_i75"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-2,4-Dimethyl-8-((<i>R</i>)-5-methyl-2-oxooxazolidin-3-yl)-2′,4′,6′-trioxo-1,1′,2,3′,4,4a,4′,6′-octahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-11-carbonitrile (<b>79c</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>78c</b> (82 mg, 0.21 mmol) and barbituric acid (30 mg, 0.24 mmol) to afford 34 mg (32%) of the title compound (<b>79c</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 40 → 90% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.77 (s, 1H), 11.64 (s, 1H), 8.08 (s, 1H), 5.02–4.92 (m, 1H), 4.60–4.54 (m, 1H), 4.22 (dd, <i>J</i> = 9.5, 8.3 Hz, 1H), 4.04 (d, <i>J</i> = 8.9 Hz, 1H), 3.88–3.81 (m, 1H), 3.77 (d, <i>J</i> = 14.7 Hz, 1H), 3.74–3.62 (m, 2H), 3.27 (dd, <i>J</i> = 14.7, 10.3 Hz, 1H), 2.85 (dd, <i>J</i> = 14.5, 1.2 Hz, 1H), 1.46 (d, <i>J</i> = 6.2 Hz, 3H), 1.19 (d, <i>J</i> = 6.3 Hz, 3H), 0.93 (d, <i>J</i> = 6.4 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 170.98, 168.12, 166.72, 154.18, 153.44, 151.29, 149.90, 128.07, 121.48, 115.52, 104.19, 76.22, 73.07, 72.78, 72.64, 65.95, 56.39, 52.60, 51.24, 38.22, 20.32, 18.48, 18.10. MS (ESI) <i>m</i>/<i>z</i>: 493.2 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>21</sub>N<sub>6</sub>O<sub>7</sub> (M – H)<sup>−</sup>: 493.1477, found: 493.1480.</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i76" class="anchor-spacer"></div><h4 class="article-section__title" id="_i76"> (2<i>R</i>,4<i>S</i>,4a<i>S</i>)-2,4-Dimethyl-8-((<i>S</i>)-5-methyl-2-oxothiazolidin-3-yl)-2′,4′,6′-trioxo-1,1′,2,3′,4,4a,4′,6′-octahydro-2′<i>H</i>,6<i>H</i>-spiro[isoxazolo[4,5-<i>g</i>][1,4]oxazino[4,3-<i>a</i>]quinoline-5,5′-pyrimidine]-11-carbonitrile (<b>82</b>)</h4><div class="NLM_p last">Prepared following the procedure described for the preparation of (±)-<b>33a</b> using <b>81</b> (66 mg, 0.17 mmol) and barbituric acid (25 mg, 0.20 mmol) to afford 52 mg (62%) of the title compound (<b>82</b>) as the major eluting component from HPLC (solvent A, H<sub>2</sub>O; solvent B, acetonitrile; gradient, 30 → 80% B) purification. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 11.82 (s, 1H), 11.62 (s, 1H), 7.77 (s, 1H), 4.56 (d, <i>J</i> = 13.0 Hz, 1H), 4.35 (dd, <i>J</i> = 10.6, 7.0 Hz, 1H), 4.20 (dt, <i>J</i> = 13.5, 6.7 Hz, 1H), 4.05 (d, <i>J</i> = 8.8 Hz, 1H), 3.94–3.80 (m, 2H), 3.77–3.71 (m, 1H), 3.66 (dq, <i>J</i> = 12.6, 6.2 Hz, 1H), 3.27 (dd, <i>J</i> = 14.6, 10.3 Hz, 1H), 2.86 (d, <i>J</i> = 13.4 Hz, 1H), 1.50 (d, <i>J</i> = 6.6 Hz, 3H), 1.19 (d, <i>J</i> = 6.5 Hz, 3H), 0.93 (d, <i>J</i> = 6.3 Hz, 3H). <sup>13</sup>C NMR (151 MHz, DMSO-<i>d</i><sub>6</sub>) δ 171.28, 170.54, 167.69, 166.16, 153.64, 150.99, 149.47, 127.39, 121.17, 115.08, 104.49, 75.88, 72.40, 72.23, 65.45, 56.01, 55.96, 52.20, 38.52, 37.76, 20.18, 18.09, 17.71. MS (ESI) <i>m</i>/<i>z</i>: 509.2 (M – H)<sup>−</sup>. HRMS (ESI): Anal. calcd for C<sub>23</sub>H<sub>21</sub>N<sub>6</sub>O<sub>6</sub>S (M – H)<sup>−</sup>: 509.1249, found: 509.1256.</div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> Minimum Inhibitory Concentration Testing</h3><div class="NLM_p last">The minimum inhibitory concentrations (MICs) of the target compounds against Gram-positive bacteria were determined using compound <b>3</b> and levofloxacin as positive controls. MIC values were determined using the broth microdilution protocol according to the methods of the Clinical and Laboratory Standards Institute (CLSI). All of the tested compounds except for levofloxacin (dissolved in H<sub>2</sub>O) were dissolved in DMSO to prepare a stock solution with a concentration of 64 μg/mL, and serial 2-fold dilutions were prepared from the stock solutions by addition of culture broth to reach concentrations ranging from 64 to 0.03 μg/mL. The tested organisms were incubated in Müeller–Hinton broth medium at 35–37 °C for 18–20 h, then the MIC values were determined. Sterile defibrinated sheep blood was added to culture broth to make final 5% sterile defibrinated sheep blood concentration when testing PRSP. MIC values of the target compounds against <i>N. gonorrhoeae</i> were determined using an agar dilution method according to the methods of the CLSI. All compounds were dissolved in DMSO and diluted with sterile water to provide the concentration range of 4–0.002 μg/mL. The tested organisms were incubated in agar medium at 36 ± 1 °C for 20–24 h, then the MIC values were determined.</div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> Pharmacokinetic Studies</h3><div class="NLM_p last">The pharmacokinetic properties of selected compounds were studied in mice, rats, and dogs. For mice, the tested compounds were dissolved in the mixture solvent (2% DMSO + 98% (0.5% methylcellulose (MC))) and administered orally at a dose of 10 mg/kg. Serial specimens were collected via the retrobulbar vein 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after administration and quantified by liquid chromatography (LC)/tandem mass spectrometry (MS/MS). For rat, the tested compounds were dissolved in mixture solvent (5% DMSO + 95% (0.5% MC)) and administered orally at a dose of 10 or 100 mg/kg, or dissolved in mixture solvent (5% DMSO + 10% Solutol + 10% EtOH + 75% saline) and administered intravenously at a dose of 10 mg/kg. Serial specimens were collected via the retrobulbar vein 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, and 24 h after administration and quantified by LC/MS/MS. For dog, the tested compounds were dissolved in the mixture solvent (4% DMSO + 96% (0.5% MC)) and administered orally at a dose of 5 mg/kg or dissolved in (5% DMSO + 5% Solutol + 90% saline) administered intravenously at a dose of 10 mg/kg. Serial specimens were collected via the retrobulbar vein 5 min, 15 min, 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 10 h, and 24 h after administration and quantified by LC/MS/MS. Pharmacokinetic parameters were calculated from the mean plasma concentration by noncompartmental analysis. Mean results were determined for each experiment with three mice, three rats, or three dogs.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> Solubility</h3><div class="NLM_p last">NaCl (20 mg) and 12 M HCl aqueous solution (70 μL) were mixed and the mixture was diluted to 10 mL with water to prepare gastric juice (pH = 1.2). KH<sub>2</sub>PO<sub>4</sub> (68 mg) was dissolved in 2500 μL of water, followed by the addition of 770 μL of 0.2 M NaOH aqueous solution and 5 mL of water, 0.2 M NaOH aqueous solution or 0.2 M HCl aqueous solution was used to adjust the pH of the mixture to 6.8 ± 0.1, and the mixture was diluted to 10 mL with water to prepare intestinal juice. Tested compound (3 mg) was added to a different matrix (500 μL), followed by shaking the mixtures at 37 °C for 24 h. Then, the mixtures were centrifuged for 30 min, and supernatants were centrifuged again for 30 min. Finally, the supernatants were diluted 1:1 by water and centrifuged for 5 min. Analysis was carried out by LC/MS/MS.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> hERG Inhibition Assay</h3><div class="NLM_p last">Cell culture and compound preparation: hERG-CHO cells were cultured in T175 flasks to maximum 70–80% confluence at 37 °C in a 5% CO<sub>2</sub> incubator. The culture media (F-12 medium supplemented with 10% fetal bovine serum, 100 μg/mL G418, and 100 μg/mL hygromycin B) was removed and washed with 7 mL of phosphate-buffered saline, followed by dissociation with 3 mL of Detachine reagent in a 37 °C incubator for 3 min and replacing with 7 mL of serum-free media to gently resuspend cells by pipetting up and down several times. Finally, the cells were harvested by 800 rpm centrifuge and adjusted to 2–5 million/mL cells for automated Qpatch 16X experiments. Before assay, 20 mM DMSO stock solutions were diluted with an external solution to the desired concentrations and the DMSO concentration is 0.2%, which has no effect on hERG currents. Automated QPatch recording: The hERG current was recorded in the whole-cell patch clamp configuration on QPatch 16X using single-hole QPlate. The cells were voltage-clamped at a holding potential of −80 mV. The hERG current was activated by depolarizing at +20 mV for 5 s, after which the current was taken back to −50 mV for 5 s to remove the inactivation and observe the deactivating tail current. The peak size of tail current was used to quantify hERG current amplitude. Raw data have been included in the statistics as membrane resistance <i>R</i><sub>m</sub> > 100 MΩ and tail current amplitude > 400 pA. The composition of the external solution is as follows (in mM, pH 7.4): 145 NaCl, 4 KCl, 2 CaCl<sub>2</sub>, 1 MgCl<sub>2</sub>, 10 glucose, and 10 <i>N</i>-(2-hydroxyethyl)piperazine-<i>N</i>′-ethanesulfonic acid (HEPES), and that of the internal solution is (in mM, pH 7.2): 120 KCl, 5.374 CaCl<sub>2</sub>, 1.75 MgCl<sub>2</sub>, 10 HEPES, 5 ethylene glycol-bis(β-aminoethyl ether)-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetraacetic acid, and 4 Na–ATP.</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> CYP450 Inhibition Assay</h3><div class="NLM_p last">The CYP450 inhibition assays were conducted using the methods previously reported.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Experiments were performed in 96-well plates. Each well contained 20 μL of human liver microsomes (final concentration of human liver microsomes is 0.3 mg/mL) and 50 μL of test compound or positive control compound mixture and 20 μL of probe substrates in 0.1 M Tris (pH 7.4). Phenacetin (CYP1A2), tolbutamide (CYP2C9), mephenytoin (CYP2C19), dextromethorphan (CYP2D6), midazolam (CYP3A4 (M)), and testosterone (CYP3A4 (T)) were used as the specific CYP substrates in this assay. After preincubation at 37 °C for 10 min, the reaction initiated with the addition of 10 μL of NADPH to make it 1 mM final concentration. Plates, with a final incubation volume of 100 μL per well, were incubated at 37 °C for 15 min and then the reactions were quenched by the addition of 100 μL of acetonitrile with a mixture of internal standard (propranolol, nadolol) (50 nM). After the reactions were terminated, the plates were centrifuged and supernatants were analyzed by LC/MS/MS.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> Human Topo IIα Decatenation Assay</h3><div class="NLM_p last">All test compounds were dissolved to be 10 mM stocks in 100% DMSO, and the stocks were diluted to 5 mM with a final 50% DMSO concentration using sterile water. The reference compound doxorubicin was diluted to 5 mM with a final 50% DMSO concentration. Etoposide was diluted to 50 mM with a final 50% DMSO concentration. Ciprofloxacin was diluted to 12.5 mM with a final 50% DMSO concentration. Then, serial dilutions in 96-well V-bottom plates were conducted according to the final assay top dose designed. The diluted compounds or 50% DMSO (1 μL) were transferred to assay plates. The reaction mixture was prepared on ice and added to assay plates, 19 μL per well (4 μL 5× reaction buffer, 130 ng Catenated DNA and H<sub>2</sub>O to 19 μL). Enzyme stock (4 U/μL) was diluted 1:40 using reaction buffer (containing 50 mM Tris–HCl pH 8.0, 10 mM MgCl<sub>2</sub>, 0.5 mM dithiothreitol, 120 mM KCl, 0.5 mM ATP, 30 μg/mL bovine serum albumin (BSA); 5× reaction buffer contained 250 mM Tris–HCl pH 8.0, 50 mM MgCl<sub>2</sub>, 2.5 mM dithiothreitol, 600 mM KCl, 2.5 mM ATP, 150 μg/mL BSA); then, 5 μL of diluted enzyme was added to assay plates. The mixtures were incubated at 35 °C for 30 min. Reactions were stopped by adding a stop buffer. Gel electrophoresis was performed using 0.9% agarose and stained using 2.3 μg/mL ethidium bromide solution for 10 min. Gel images were captured and the band density was measured using ImageJ. Percent inhibition versus compound concentration was plotted and the IC<sub>50</sub> was determined using GraphPad Prism 5.</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> <i>S. aureus</i> Gyrase Supercoiling Assay</h3><div class="NLM_p last">Compounds were dissolved to be 10 mM stocks in 100% DMSO, and the reference compounds novobiocin and ciprofloxacin were dissolved to be 0.25 and 50 mM with 100% DMSO, respectively. Then, serial dilution was conducted in 96-well V-bottom plates according to the final assay top dose designed. Two no-drug wells were set as control. The diluted compounds or 100% DMSO (0.4 μL) were transferred to assay plates. The reaction mixture was prepared on ice and added to assay plates, 16.6 μL per well (4 μL 5× reaction buffer, 100 ng of Relaxed pHOT-1 DNA and H<sub>2</sub>O to 16.6 μL). Enzyme stock (2 U/μL) was diluted 1:5 using reaction buffer (containing 40 mM HEPES–KOH pH 7.6, 10 mM magnesium acetate, 10 mM dithiothreitol, 500 mM potassium glutamate, 50 μg/mL BSA, 2 mM ATP; 5× reaction buffer contained 200 mM HEPES–KOH pH 7.6, 50 mM magnesium acetate, 50 mM dithiothreitol, 2500 mM potassium glutamate, 250 μg/mL BSA, 10 mM ATP); then, 3 μL of diluted enzyme was added to assay plates. The mixtures were incubated at 35 °C for 60 min. Reactions were stopped by adding a stop buffer. Gel electrophoresis was performed using 0.9% agarose and was stained using 2.3 μg/mL ethidium bromide solution for 10 min. Gel images were captured and the band density was measured using ImageJ. Percent inhibition versus compound concentration is plotted and the IC<sub>50</sub> was determined using GraphPad Prism 5.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> Molecular Docking</h3><div class="NLM_p last">Molecular docking was conducted as previously described.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The protein and ligand status were optimized in Protein Preparation Wizard panel and LigPrep panel integrated in Maestro (version 9.0; Schrödinger) with parameters set as default. The receptor grid was set as the enclosing box with the centroid of QPT-1. Glide SP mode was applied for the following docking procedures. At most five poses per ligand were produced for further analysis.</div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> Murine Systemic Infection Model</h3><div class="NLM_p last">Clinical Isolate of MSSA or MRSA. Kunming mice (half male and half female) weighing between 18 and 22 g were used in this study, with 5–10 mice in each group. A lethal systemic infection was given to the mice by intraperitoneal injection of 0.5 mL of inoculum of MSSA (3 × 10<sup>4</sup> CFU/mL) or MRSA (3 × 10<sup>6</sup> CFU/mL). Compounds were administered subcutaneously at 0.5 and 4.0 h postinfection at doses of 2.5, 5, 10, and 20 mg/kg for <b>33e</b>, <b>39e</b>, <b>3</b> and linezolid. For <b>3</b>, 2 h prior to infection, the mice received an administration of 50 mg/kg ABT orally to inhibit cytochrome P450 activity, and they received a second 50 mg/kg administration 12 h later. No ABT was administered for similar experiments with other compounds. The ED<sub>50</sub> was calculated 7–14 days after treatment by the method of Bliss. The protocol for this study was reviewed and approved by the Institutional Animal Care and Use Committee of Sichuan Primed Bio-Tech Group Co., Ltd.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i86"><a href="/doi/suppl/10.1021/acs.jmedchem.8b01750" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_00524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_00524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.8b01750" class="ext-link">10.1021/acs.jmedchem.8b01750</a>.<ul class="NLM_list-list_type-label"><li><p class="inline">Preparation of all intermediates; NMR and mass spectra of representative final compounds; MIC data for compounds (±)-<b>16a</b>–<b>d</b>, (±)-<b>20</b>, (±)-<b>24</b>, and <b>26a</b>–<b>c</b>; gel image of <i>S. aureus</i> gyrase supercoiling assay and human Topo IIα decatenation assay; and detailed data for inhibition of human topo IIα from compounds <b>33e</b> and ETX0914 (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf">jm8b01750_si_001.pdf (3.14 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_002.csv">jm8b01750_si_002.csv (4.74 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.8b01750" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35868" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35868" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Xianli Zhou</span> - <span class="hlFld-Affiliation affiliation">School
of Life Science and Engineering, Southwest
Jiaotong University, Chengdu, Sichuan Province 610031, China</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#097361667c7165497a7e637d7c276c6d7c276a67"><span class="__cf_email__" data-cfemail="e49e8c8b919c88a497938e9091ca818091ca878a">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yushe Yang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1007-2492" title="Orcid link">http://orcid.org/0000-0002-1007-2492</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#9ce5efe5fdf2fbdcf1fdf5f0b2eff4fff2ffb2fdffb2fff2"><span class="__cf_email__" data-cfemail="fc858f859d929bbc919d9590d28f949f929fd29d9fd29f92">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chenghui Shi</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yinyong Zhang</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">School
of Life Science and Engineering, Southwest
Jiaotong University, Chengdu, Sichuan Province 610031, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ting Wang</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology, Sichuan Primed Bio-Tech
Group Co., Ltd., Chengdu, Sichuan Province 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Wenchao Lu</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuhua Zhang</span> - <span class="hlFld-Affiliation affiliation">Department
of Microbiology, Sichuan Primed Bio-Tech
Group Co., Ltd., Chengdu, Sichuan Province 610041, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Guo</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qian Chen</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cheng Luo</span> - <span class="hlFld-Affiliation affiliation">State
Key Laboratory of Drug Research, Shanghai
Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China</span>; 
    <span class="hlFld-Affiliation affiliation">University
of Chinese Academy of Sciences, Beijing 100049, China</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3864-8382" title="Orcid link">http://orcid.org/0000-0003-3864-8382</a></span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>C.S. and Y.Z. contributed equally to this work.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e9168-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i88">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37237" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37237" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">This work was supported by grants from the Chinese Academy of Sciences (CASIMM0120162010) and the National Science and Technology Major Project “Key New Drug Creation and Manufacturing Program”, China (2018ZX09711002).</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">ABT</td><td class="NLM_def"><p class="first last">aminobenzotriazole</p></td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last">1,1′-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">CFU</td><td class="NLM_def"><p class="first last">colony-forming units</p></td></tr><tr><td class="NLM_term">CYP450</td><td class="NLM_def"><p class="first last">cytochrome P450 enzyme</p></td></tr><tr><td class="NLM_term">DTT</td><td class="NLM_def"><p class="first last">1,4-dithiothreitol</p></td></tr><tr><td class="NLM_term">DIAD</td><td class="NLM_def"><p class="first last">diisopropyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DIPEA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-diisopropylethylamine</p></td></tr><tr><td class="NLM_term">MsCl</td><td class="NLM_def"><p class="first last">methanesulfonyl chloride</p></td></tr><tr><td class="NLM_term">MSSA</td><td class="NLM_def"><p class="first last">methicillin-sensitive <i>Staphylococcus aureus</i></p></td></tr><tr><td class="NLM_term">MSSE</td><td class="NLM_def"><p class="first last">methicillin-sensitive <i>Staphycoccus epidermidis</i></p></td></tr><tr><td class="NLM_term">MRSE</td><td class="NLM_def"><p class="first last">methicillin-resistant <i>Staphylococcus epidermidis</i></p></td></tr><tr><td class="NLM_term">PRSP</td><td class="NLM_def"><p class="first last">penicillin-resistant <i>Streptococcus pneumoniae</i></p></td></tr><tr><td class="NLM_term">S<sub>N</sub>Ar</td><td class="NLM_def"><p class="first last">nucleophilic aromatic substitution</p></td></tr><tr><td class="NLM_term">Spy</td><td class="NLM_def"><p class="first last"><i>Streptococcus pyogenes</i></p></td></tr><tr><td class="NLM_term">SPTs</td><td class="NLM_def"><p class="first last">spiropyrimidinetriones</p></td></tr><tr><td class="NLM_term">TBSCl</td><td class="NLM_def"><p class="first last"><i>tert</i>-butyldimethylsilyl chloride</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_70464" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_70464" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 36 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span> <i>Antimicrobial
Resistance: Global Report on Surveillance</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2014</span>. <a href="http://www.who.int/antimicrobial-resistance/publications/surveillancereport/en/" class="extLink">http://www.who.int/antimicrobial-resistance/publications/surveillancereport/en/</a> (accessed Nov 11, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Antimicrobial%0AResistance%3A+Global+Report+on+Surveillance%3B+World+Health+Organization%3A+Geneva%2C+2014.+http%3A%2F%2Fwww.who.int%2Fantimicrobial-resistance%2Fpublications%2Fsurveillancereport%2Fen%2F+%28accessed+Nov+11%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DAntimicrobial%250AResistance%253A%2520Global%2520Report%2520on%2520Surveillance%26pub%3DWorld%2520Health%2520Organization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spellberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheld, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J.</span></span> <span> </span><span class="NLM_article-title">The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1086/524891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1086%2F524891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18171244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FgslGitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2008&pages=155-164&author=B.+Spellbergauthor=R.+Guidosauthor=D.+Gilbertauthor=J.+Bradleyauthor=H.+W.+Boucherauthor=W.+M.+Scheldauthor=J.+G.+Bartlettauthor=J.+Edwards&title=The+epidemic+of+antibiotic-resistant+infections%3A+a+call+to+action+for+the+medical+community+from+the+Infectious+Diseases+Society+of+America&doi=10.1086%2F524891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America</span></div><div class="casAuthors">Spellberg Brad; Guidos Robert; Gilbert David; Bradley John; Boucher Helen W; Scheld W Michael; Bartlett John G; Edwards John Jr</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The ongoing explosion of antibiotic-resistant infections continues to plague global and US health care.  Meanwhile, an equally alarming decline has occurred in the research and development of new antibiotics to deal with the threat.  In response to this microbial "perfect storm," in 2001, the federal Interagency Task Force on Antimicrobial Resistance released the "Action Plan to Combat Antimicrobial Resistance; Part 1: Domestic" to strengthen the response in the United States.  The Infectious Diseases Society of America (IDSA) followed in 2004 with its own report, "Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews," which proposed incentives to reinvigorate pharmaceutical investment in antibiotic research and development.  The IDSA's subsequent lobbying efforts led to the introduction of promising legislation in the 109 th US Congress (January 2005-December 2006).  Unfortunately, the legislation was not enacted.  During the 110 th Congress, the IDSA has continued to work with congressional leaders on promising legislation to address antibiotic-resistant infection.  Nevertheless, despite intensive public relations and lobbying efforts, it remains unclear whether sufficiently robust legislation will be enacted.  In the meantime, microbes continue to become more resistant, the antibiotic pipeline continues to diminish, and the majority of the public remains unaware of this critical situation.  The result of insufficient federal funding; insufficient surveillance, prevention, and control; insufficient research and development activities; misguided regulation of antibiotics in agriculture and, in particular, for food animals; and insufficient overall coordination of US (and international) efforts could mean a literal return to the preantibiotic era for many types of infections.  If we are to address the antimicrobial resistance crisis, a concerted, grassroots effort led by the medical community will be required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5IgYdIVkSKVf1XRtfYM0dfW6udTcc2ebXg8FYX9IlQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FgslGitw%253D%253D&md5=52bb108e9c29dc9da3031f7127cba99f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1086%2F524891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F524891%26sid%3Dliteratum%253Aachs%26aulast%3DSpellberg%26aufirst%3DB.%26aulast%3DGuidos%26aufirst%3DR.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DBoucher%26aufirst%3DH.%2BW.%26aulast%3DScheld%26aufirst%3DW.%2BM.%26aulast%3DBartlett%26aufirst%3DJ.%2BG.%26aulast%3DEdwards%26aufirst%3DJ.%26atitle%3DThe%2520epidemic%2520of%2520antibiotic-resistant%2520infections%253A%2520a%2520call%2520to%2520action%2520for%2520the%2520medical%2520community%2520from%2520the%2520Infectious%2520Diseases%2520Society%2520of%2520America%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D46%26spage%3D155%26epage%3D164%26doi%3D10.1086%2F524891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span> <span> </span><span class="NLM_article-title">Antibacterial drug discovery in the resistance era</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/nature17042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2Fnature17042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=26791724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=336-343&author=E.+D.+Brownauthor=G.+D.+Wright&title=Antibacterial+drug+discovery+in+the+resistance+era&doi=10.1038%2Fnature17042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial drug discovery in the resistance era</span></div><div class="casAuthors">Brown, Eric D.; Wright, Gerard D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">336-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The looming antibiotic resistance crisis has penetrated the consciousness of clinicians, researchers, policymakers, politicians and the public at large.  The evolution and widespread distribution of antibiotic resistance elements in bacterial pathogens has made diseases that were once easily treatable deadly again.  Unfortunately, accompanying the rise in global resistance is a failure in antibacterial drug discovery.  Lessons from the history of antibiotic discovery and fresh understanding of antibiotic action and the cell biol. of microorganisms have the potential to deliver twenty-first century medicines that are able to control infection in the resistance era.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKJH_K99a5abVg90H21EOLACvtfcHk0lgQ0klY8wxBGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D&md5=62e0454601a242db039e60d77be26406</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature17042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17042%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BD.%26atitle%3DAntibacterial%2520drug%2520discovery%2520in%2520the%2520resistance%2520era%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D336%26epage%3D343%26doi%3D10.1038%2Fnature17042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguž, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Ragu%C5%BEauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0licuCKk_CjK3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRagu%25C5%25BE%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span> <i>Global
Priority List of Antibiotic-Resistant Bacteria To Guide Research,
Discovery, and Development of New Antibiotics</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>. <a href="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf" class="extLink">http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf</a> (accessed Nov 11, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global%0APriority+List+of+Antibiotic-Resistant+Bacteria+To+Guide+Research%2C%0ADiscovery%2C+and+Development+of+New+Antibiotics%3B+World+Health+Organization%3A+Geneva%2C+2017.+http%3A%2F%2Fwww.who.int%2Fmedicines%2Fpublications%2FWHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf+%28accessed+Nov+11%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%250APriority%2520List%2520of%2520Antibiotic-Resistant%2520Bacteria%2520To%2520Guide%2520Research%252C%250ADiscovery%252C%2520and%2520Development%2520of%2520New%2520Antibiotics%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, I. M.</span></span> <span> </span><span class="NLM_article-title">Current and future treatment options for community-associated MRSA infection</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1442826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1080%2F14656566.2018.1442826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=29480032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFWrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=457-470&author=A.+Khanauthor=B.+Wilsonauthor=I.+M.+Gould&title=Current+and+future+treatment+options+for+community-associated+MRSA+infection&doi=10.1080%2F14656566.2018.1442826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future treatment options for community-associated MRSA infection</span></div><div class="casAuthors">Khan, A.; Wilson, B.; Gould, I. M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-470</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Community-assocd. MRSA (CA-MRSA) represents a global epidemic which beautifully encapsulates the fascinating ability of bacterial organisms to adapt quickly on an evolutionary basis to the extreme selective pressure of antibiotic exposure.  In stark contrast to Healthcare-assocd. MRSA (HA-MRSA), it has become apparent that CA-MRSA is less straight forward of a challenge in terms of controlling its transmission, and has forced clinicians to adjust empiric management of clin. syndromes such as skin and soft tissue infection (SSTI) as well as pneumonia.: This review details the history and epidemiol. of CA-MRSA, while covering both current and future treatment options that are and may be available to clinicians.  The authors reviewed both historic and more recent literature on this ever-evolving topic.: While development of new anti-MRSA agents should be encouraged, the importance of antimicrobial stewardship in the battle to stay ahead of the curve with regards to the ongoing control of the MRSA epidemic should be emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreCiRGwopdprVg90H21EOLACvtfcHk0lgenZKq9-JoMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFWrtLg%253D&md5=44b2013a1eb6dd7dc1a0af0d1059e02a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1442826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1442826%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DB.%26aulast%3DGould%26aufirst%3DI.%2BM.%26atitle%3DCurrent%2520and%2520future%2520treatment%2520options%2520for%2520community-associated%2520MRSA%2520infection%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D457%26epage%3D470%26doi%3D10.1080%2F14656566.2018.1442826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Structure and mechanism of DNA topoisomerase II</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/379225a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2F379225a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=8538787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADyaK28Xmtl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=1996&pages=225-232&author=J.+M.+Bergerauthor=S.+J.+Gamblinauthor=S.+C.+Harrisonauthor=J.+C.+Wang&title=Structure+and+mechanism+of+DNA+topoisomerase+II&doi=10.1038%2F379225a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and mechanism of DNA topoisomerase II</span></div><div class="casAuthors">Berger, James M.; Gamblin, Steven J.; Harrison, Stephen C.; Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">6562</span>),
    <span class="NLM_cas:pages">225-32</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of a large fragment of yeast type II DNA topoisomerase reveals a heart-shaped dimeric protein with a large central hole.  It provides a mol. model of the enzyme as an ATP-modulated clamp with two sets of jaws at opposite ends, connected by multiple joints.  An enzyme with bound DNA can admit a second DNA duplex through one set of jaws, transport it through the cleaved first duplex, and expel it through the other set of jaws.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx1Jz5DLrCobVg90H21EOLACvtfcHk0ljVjACPlyHFVQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmtl2gsg%253D%253D&md5=5f3522c462cb3af85c6d2230f3a79002</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F379225a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F379225a0%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26aulast%3DHarrison%26aufirst%3DS.%2BC.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DStructure%2520and%2520mechanism%2520of%2520DNA%2520topoisomerase%2520II%26jtitle%3DNature%26date%3D1996%26volume%3D379%26spage%3D225%26epage%3D232%26doi%3D10.1038%2F379225a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dea, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, H. A.</span></span> <span> </span><span class="NLM_article-title">DNA gyrase: an enzyme that introduces superhelical turns into DNA</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3872</span>– <span class="NLM_lpage">3876</span>, <span class="refDoi"> DOI: 10.1073/pnas.73.11.3872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1073%2Fpnas.73.11.3872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=186775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADyaE2sXjvFWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=3872-3876&author=M.+Gellertauthor=K.+Mizuuchiauthor=M.+H.+O%E2%80%99Deaauthor=H.+A.+Nash&title=DNA+gyrase%3A+an+enzyme+that+introduces+superhelical+turns+into+DNA&doi=10.1073%2Fpnas.73.11.3872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">DNA gyrase:  An enzyme that introduces superhelical turns into DNA</span></div><div class="casAuthors">Gellert, Martin; Mizuuchi, Kiyoshi; O'Dea, Mary H.; Nash, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3872-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Relaxed closed-circular DNA was converted to neg. supercoiled DNA by DNA gyrase.  This enzyme was purified from Escherichia coli cells.  The reaction required ATP and Mg2+ and was stimulated by spermidine.  The enzyme acted equally well on relaxed closed-circular colicin E1, bacteriophage λ, and simian virus 40 DNA.  The final superhelix d. of the DNA could be considerably greater than that found in intracellularly supercoiled DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWknjnsm_VqrVg90H21EOLACvtfcHk0lh_ff3sQceX1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXjvFWmsQ%253D%253D&md5=adc7a9bfe9d48cba5143727e982e7b81</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.3872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.3872%26sid%3Dliteratum%253Aachs%26aulast%3DGellert%26aufirst%3DM.%26aulast%3DMizuuchi%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Dea%26aufirst%3DM.%2BH.%26aulast%3DNash%26aufirst%3DH.%2BA.%26atitle%3DDNA%2520gyrase%253A%2520an%2520enzyme%2520that%2520introduces%2520superhelical%2520turns%2520into%2520DNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D3872%26epage%3D3876%26doi%3D10.1073%2Fpnas.73.11.3872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sissi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, M.</span></span> <span> </span><span class="NLM_article-title">In front of and behind the replication fork: bacterial type IIA topoisomerases</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">2001</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1007/s00018-010-0299-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1007%2Fs00018-010-0299-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=20165898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsFyrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=2001-2024&author=C.+Sissiauthor=M.+Palumbo&title=In+front+of+and+behind+the+replication+fork%3A+bacterial+type+IIA+topoisomerases&doi=10.1007%2Fs00018-010-0299-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In front of and behind the replication fork: bacterial type IIA topoisomerases</span></div><div class="casAuthors">Sissi, Claudia; Palumbo, Manlio</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2001-2024</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Topoisomerases are vital enzymes specialized in controlling DNA topol., in particular supercoiling and decatenation, to properly handle nucleic acid packing and cell dynamics.  The type IIA enzymes act by cleaving both strands of a double helix and having another strand from the same or another mol. cross the DNA gate before a re-sealing event completes the catalytic cycle.  Here, we will consider the two types of IIA prokaryotic topoisomerases, DNA Gyrase and Topoisomerase IV, as crucial regulators of bacterial cell cycle progression.  Their synergistic action allows control of chromosome packing and grants occurrence of functional transcription and replication processes.  In addn. to displaying a fascinating mol. mechanism of action, which transduces chem. energy into mech. energy by means of large conformational changes, these enzymes represent attractive pharmacol. targets for antibacterial chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1ESOZ27csO7Vg90H21EOLACvtfcHk0ljr7zihxQemRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsFyrurg%253D&md5=beddf7151ca953f43ced56b17baa9f7c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00018-010-0299-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-010-0299-5%26sid%3Dliteratum%253Aachs%26aulast%3DSissi%26aufirst%3DC.%26aulast%3DPalumbo%26aufirst%3DM.%26atitle%3DIn%2520front%2520of%2520and%2520behind%2520the%2520replication%2520fork%253A%2520bacterial%2520type%2520IIA%2520topoisomerases%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2010%26volume%3D67%26spage%3D2001%26epage%3D2024%26doi%3D10.1007%2Fs00018-010-0299-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacobbe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patey, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, M. E.</span></span> <span> </span><span class="NLM_article-title">In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1128/AAC.04124-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.04124-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=25385112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ais70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=467-474&author=M.+D.+Hubandauthor=P.+A.+Bradfordauthor=L.+G.+Ottersonauthor=G.+S.+Basarabauthor=A.+C.+Kutschkeauthor=R.+A.+Giacobbeauthor=S.+A.+Pateyauthor=R.+A.+Almauthor=M.+R.+Johnstoneauthor=M.+E.+Potter&title=In+vitro+antibacterial+activity+of+AZD0914%2C+a+new+spiropyrimidinetrione+DNA+gyrase%2Ftopoisomerase+inhibitor+with+potent+activity+against+Gram-positive%2C+fastidious+Gram-negative%2C+and+atypical+bacteria&doi=10.1128%2FAAC.04124-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria</span></div><div class="casAuthors">Huband, Michael D.; Bradford, Patricia A.; Otterson, Linda G.; Basarab, Gregory S.; Kutschke, Amy C.; Giacobbe, Robert A.; Patey, Sara A.; Alm, Richard A.; Johnstone, Michele R.; Potter, Marie E.; Miller, Paul F.; Mueller, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">467-474/1-467-474/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AZD0914 is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-pos. (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-neg. (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with known resistance to fluoroquinolones.  AZD0914 works via inhibition of DNA biosynthesis and accumulation of double-strand cleavages; this mechanism of inhibition differs from those of other marketed antibacterial compds.  AZD0914 stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand cleaved DNA to form fused circular DNA.  Whereas this mechanism is similar to that seen with fluoroquinolones, it is mechanistically distinct.  AZD0914 exhibited low frequencies of spontaneous resistance in S. aureus, and if mutants were obtained, the mutations mapped to gyrB.  Addnl., no cross-resistance was obsd. for AZD0914 against recent bacterial clin. isolates demonstrating resistance to fluoroquinolones or other drug classes, including macrolides, β-lactams, glycopeptides, and oxazolidinones.  AZD0914 was bactericidal in both min. bactericidal concn. and in vitro time-kill studies.  In in vitro checkerboard/synergy testing with 17 comparator antibacterials, only additivity/indifference was obsd.  The potent in vitro antibacterial activity (including activity against fluoroquinolone-resistant isolates), low frequency of resistance, lack of cross-resistance, and bactericidal activity of AZD0914 support its continued development. Staphylococcus Streptococcus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFPxzzSNWQwbVg90H21EOLACvtfcHk0ljr7zihxQemRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ais70%253D&md5=cdd3b247d62ce74d50a10347d88b0a1b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.04124-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04124-14%26sid%3Dliteratum%253Aachs%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DBradford%26aufirst%3DP.%2BA.%26aulast%3DOtterson%26aufirst%3DL.%2BG.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DKutschke%26aufirst%3DA.%2BC.%26aulast%3DGiacobbe%26aufirst%3DR.%2BA.%26aulast%3DPatey%26aufirst%3DS.%2BA.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DJohnstone%26aufirst%3DM.%2BR.%26aulast%3DPotter%26aufirst%3DM.%2BE.%26atitle%3DIn%2520vitro%2520antibacterial%2520activity%2520of%2520AZD0914%252C%2520a%2520new%2520spiropyrimidinetrione%2520DNA%2520gyrase%252Ftopoisomerase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520Gram-positive%252C%2520fastidious%2520Gram-negative%252C%2520and%2520atypical%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D467%26epage%3D474%26doi%3D10.1128%2FAAC.04124-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in <i>Neisseria gonorrhoeae</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1128/AAC.04456-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.04456-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1478-1486&author=R.+A.+Almauthor=S.+D.+Lahiriauthor=A.+Kutschkeauthor=L.+G.+Ottersonauthor=R.+E.+McLaughlinauthor=J.+D.+Whiteakerauthor=L.+A.+Lewisauthor=X.+Suauthor=M.+D.+Hubandauthor=H.+Gardnerauthor=J.+P.+Mueller&title=Characterization+of+the+novel+DNA+gyrase+inhibitor+AZD0914%3A+low+resistance+potential+and+lack+of+cross-resistance+in+Neisseria+gonorrhoeae&doi=10.1128%2FAAC.04456-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.04456-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04456-14%26sid%3Dliteratum%253Aachs%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DL.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DWhiteaker%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520novel%2520DNA%2520gyrase%2520inhibitor%2520AZD0914%253A%2520low%2520resistance%2520potential%2520and%2520lack%2520of%2520cross-resistance%2520in%2520Neisseria%2520gonorrhoeae%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1478%26epage%3D1486%26doi%3D10.1128%2FAAC.04456-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biedenbach, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonge, B. L. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, P. A.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6053</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1128/AAC.01016-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.01016-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=6053-6063&author=D.+J.+Biedenbachauthor=M.+D.+Hubandauthor=M.+Hackelauthor=B.+L.+M.+D.+Jongeauthor=D.+F.+Sahmauthor=P.+A.+Bradford&title=In+vitro+activity+of+AZD0914%2C+a+novel+bacterial+DNA+gyrase%2Ftopoisomerase+IV+inhibitor%2C+against+clinically+relevant+Gram-positive+and+fastidious+Gram-negative+pathogens&doi=10.1128%2FAAC.01016-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.01016-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01016-15%26sid%3Dliteratum%253Aachs%26aulast%3DBiedenbach%26aufirst%3DD.%2BJ.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DHackel%26aufirst%3DM.%26aulast%3DJonge%26aufirst%3DB.%2BL.%2BM.%2BD.%26aulast%3DSahm%26aufirst%3DD.%2BF.%26aulast%3DBradford%26aufirst%3DP.%2BA.%26atitle%3DIn%2520vitro%2520activity%2520of%2520AZD0914%252C%2520a%2520novel%2520bacterial%2520DNA%2520gyrase%252Ftopoisomerase%2520IV%2520inhibitor%252C%2520against%2520clinically%2520relevant%2520Gram-positive%2520and%2520fastidious%2520Gram-negative%2520pathogens%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D6053%26epage%3D6063%26doi%3D10.1128%2FAAC.01016-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skepner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hromockyj, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzner, J. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1128/AAC.00247-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.00247-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18519725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2806-2812&author=A.+A.+Millerauthor=G.+L.+Bundyauthor=J.+E.+Mottauthor=J.+E.+Skepnerauthor=T.+P.+Boyleauthor=D.+W.+Harrisauthor=A.+E.+Hromockyjauthor=K.+R.+Marottiauthor=G.+E.+Zurenkoauthor=J.+B.+Munzner&title=Discovery+and+characterization+of+QPT-1%2C+the+progenitor+of+a+new+class+of+bacterial+topoisomerase+inhibitors&doi=10.1128%2FAAC.00247-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors</span></div><div class="casAuthors">Miller, Alita A.; Bundy, Gordon L.; Mott, John E.; Skepner, Jill E.; Boyle, Timothy P.; Harris, Douglas W.; Hromockyj, Alexander E.; Marotti, Keith R.; Zurenko, Gary E.; Munzner, Jennifer B.; Sweeney, Michael T.; Bammert, Gary F.; Hamel, Judith C.; Ford, Charles W.; Zhong, Wei-Zhu; Graber, David R.; Martin, Gary E.; Han, Fusen; Dolak, Lester A.; Seest, Eric P.; Ruble, J. Craig; Kamilar, Gregg M.; Palmer, John R.; Banitt, Lee S.; Hurd, Alexander R.; Barbachyn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2806-2812</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">QPT-1 was discovered in a compd. library by high-throughput screening and triage for substances with whole-cell antibacterial activity.  This totally synthetic compd. is an unusual barbituric acid deriv. whose activity resides in the (-)-enantiomer.  QPT-1 had activity against a broad spectrum of pathogenic, antibiotic-resistant bacteria, was nontoxic to eukaryotic cells, and showed oral efficacy in a murine infection model, all before any medicinal chem. optimization.  Biochem. and genetic characterization showed that the QPT-1 targets the β subunit of bacterial type II topoisomerases via a mechanism of inhibition distinct from the mechanisms of fluoroquinolones and novobiocin.  Given these attributes, this compd. represents a promising new class of antibacterial agents.  The success of this reverse genomics effort demonstrates the utility of exploring strategies that are alternatives to target-based screens in antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoPSHAUxaaj7Vg90H21EOLACvtfcHk0liOWXoC2tTR6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D&md5=c459d15b895768ec27648222ad03d20d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.00247-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00247-08%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DA.%2BA.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DMott%26aufirst%3DJ.%2BE.%26aulast%3DSkepner%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DT.%2BP.%26aulast%3DHarris%26aufirst%3DD.%2BW.%26aulast%3DHromockyj%26aufirst%3DA.%2BE.%26aulast%3DMarotti%26aufirst%3DK.%2BR.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DMunzner%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520QPT-1%252C%2520the%2520progenitor%2520of%2520a%2520new%2520class%2520of%2520bacterial%2520topoisomerase%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2806%26epage%3D2812%26doi%3D10.1128%2FAAC.00247-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span>; <span class="NLM_string-name">Dobrowolski, P. J.</span>; <span class="NLM_string-name">Hagen, S. E.</span>; <span class="NLM_string-name">Heimbach, T. H.</span>; <span class="NLM_string-name">Hurd, A. R.</span>; <span class="NLM_string-name">Johnson, T. A.</span>; <span class="NLM_string-name">McNamara, D. J.</span>; <span class="NLM_string-name">Ruble, J. C.</span>; <span class="NLM_string-name">Sherry, D. A.</span>; <span class="NLM_string-name">Thomasco, L. M.</span>; <span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Antibacterials Agent</span>. PCT Patent <span class="NLM_patent">WO2006120563A2</span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+R.+Barbachyn&author=P.+J.+Dobrowolski&author=S.+E.+Hagen&author=T.+H.+Heimbach&author=A.+R.+Hurd&author=T.+A.+Johnson&author=D.+J.+McNamara&author=J.+C.+Ruble&author=D.+A.+Sherry&author=L.+M.+Thomasco&author=P.+L.+Toogood&title=Antibacterials+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DAntibacterials%2520Agent%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span>; <span class="NLM_string-name">Sherry, D. A.</span>; <span class="NLM_string-name">McNamara, D. J.</span>; <span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">8-Pyrazinyl-5-Spiropyrimidinetrione-Oxazinoquinoline Derivatives as Antibacterial Agents</span>. PCT Patent <span class="NLM_patent">WO2007072151A1</span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+A.+Johnson&author=D.+A.+Sherry&author=D.+J.+McNamara&author=P.+L.+Toogood&title=8-Pyrazinyl-5-Spiropyrimidinetrione-Oxazinoquinoline+Derivatives+as+Antibacterial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26atitle%3D8-Pyrazinyl-5-Spiropyrimidinetrione-Oxazinoquinoline%2520Derivatives%2520as%2520Antibacterial%2520Agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haimes, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9095</span>, <span class="refDoi"> DOI: 10.1021/jm501174m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501174m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9078-9095&author=G.%0AS.+Basarabauthor=P.+Brassilauthor=P.+Doigauthor=V.+Galulloauthor=H.+B.+Haimesauthor=G.+Kernauthor=A.+Kutschkeauthor=J.+McNultyauthor=V.+J.+Schuckauthor=G.+Stoneauthor=M.+Gowravaram&title=Novel+DNA+gyrase+inhibiting+spiropyrimidinetriones+with+a+benzisoxazole+scaffold%3A+SAR+and+in+vivo+characterization&doi=10.1021%2Fjm501174m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization</span></div><div class="casAuthors">Basarab, Gregory S.; Brassil, Patrick; Doig, Peter; Galullo, Vincent; Haimes, Howard B.; Kern, Gunther; Kutschke, Amy; McNulty, John; Schuck, Virna J. A.; Stone, Gregory; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9078-9095</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The compds. described herein with a spirocyclic architecture fused to a benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the inhibition of precursor thymidine into DNA during cell growth.  Activity resided in the configurationally lowest energy (2S,4R,4aR) diastereomer.  Highly active compds. against Staphylococcus aureus had sufficiently high soly., high plasma protein free fraction, and favorable pharmacokinetics to suggest that in vivo efficacy could be demonstrated, which was realized with compd. I in S. aureus mouse infection models.  A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic margin could be achieved.  Importantly, I was not cross-resistant with other DNA gyrase inhibitors such as fluoroquinolone and aminocoumarin antibacterials.  Hence, this class shows considerable promise for the treatment of infections caused by multidrug resistant bacteria, including S. aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpvqD0DFpAALVg90H21EOLACvtfcHk0lhBQBWllJxgdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE&md5=7eccef41b07e14842d79665591364050</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm501174m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501174m%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DHaimes%26aufirst%3DH.%2BB.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%26aulast%3DStone%26aufirst%3DG.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DNovel%2520DNA%2520gyrase%2520inhibiting%2520spiropyrimidinetriones%2520with%2520a%2520benzisoxazole%2520scaffold%253A%2520SAR%2520and%2520in%2520vivo%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9078%26epage%3D9095%26doi%3D10.1021%2Fjm501174m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">6282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6264-6282&author=G.%0AS.+Basarabauthor=P.+Doigauthor=V.+Galulloauthor=G.+Kernauthor=A.+Kimzeyauthor=A.+Kutschkeauthor=J.+P.+Newmanauthor=M.+Morningstarauthor=J.+Muellerauthor=L.+Ottersonauthor=K.+Vishwanathanauthor=F.+Zhouauthor=M.+Gowravaram&title=Discovery+of+novel+DNA+gyrase+inhibiting+spiropyrimidinetriones%3A+benzisoxazole+fusion+with+N-linked+oxazolidinone+substituents+leading+to+a+clinical+candidate+%28ETX0914%29&doi=10.1021%2Facs.jmedchem.5b00863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span></div><div class="casAuthors">Basarab, Gregory S.; Doig, Peter; Galullo, Vincent; Kern, Gunther; Kimzey, Amy; Kutschke, Amy; Newman, Joseph P.; Morningstar, Marshall; Mueller, John; Otterson, Linda; Vishwanathan, Karthick; Zhou, Fei; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6264-6282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrione architecture fused to a benzisoxazole scaffold shows potent activity against Gram-pos. and fastidious Gram-neg. bacteria.  Here, the authors describe a series of N-linked oxazolidinone substituents on the benzisoxazole that improve upon the antibacterial activity of initially described compds. of the class, show favorable PK properties, and demonstrate efficacy in an in vivo Staphylococcus aureus infection model.  Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-pos. and a Gram-neg. organisms was demonstrated.  Compds. showed a clean in vitro toxicity profile, including no genotoxicity and no bone marrow toxicity at the highest evaluated concns. or other issues that have been problematic for some fluoroquinolones.  Compd. I was identified for advancement into human clin. trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes including the potent activity and the favorable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8zOqBRUJg7Vg90H21EOLACvtfcHk0lj6twQ06QPelg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL&md5=67b21b269a0dfdf74b7e93196d8dfc4e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00863%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DOtterson%26aufirst%3DL.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%2520DNA%2520gyrase%2520inhibiting%2520spiropyrimidinetriones%253A%2520benzisoxazole%2520fusion%2520with%2520N-linked%2520oxazolidinone%2520substituents%2520leading%2520to%2520a%2520clinical%2520candidate%2520%2528ETX0914%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6264%26epage%3D6282%26doi%3D10.1021%2Facs.jmedchem.5b00863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. V.</span></span> <span> </span><span class="NLM_article-title">Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">11827</span> <span class="refDoi"> DOI: 10.1038/srep11827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2Fsrep11827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=26168713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=G.+S.+Basarabauthor=G.+H.+Kernauthor=J.+McNultyauthor=J.+P.+Muellerauthor=K.+Lawrenceauthor=K.+Vishwanathanauthor=R.+A.+Almauthor=K.+Barvianauthor=P.+Doigauthor=V.+Galulloauthor=H.+Gardnerauthor=M.+Gowravaramauthor=M.+Hubandauthor=A.+Kimzeyauthor=M.+Morningstarauthor=A.+Kutschkeauthor=S.+D.+Lahiriauthor=M.+Perrosauthor=R.+Singhauthor=V.+J.+Schuckauthor=R.+Tommasiauthor=G.+Walkupauthor=J.+V.+Newman&title=Responding+to+the+challenge+of+untreatable+gonorrhea%3A+ETX0914%2C+a+first-in-class+agent+with+a+distinct+mechanism-of-action+against+bacterial+type+II+topoisomerases&doi=10.1038%2Fsrep11827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases</span></div><div class="casAuthors">Basarab, Gregory S.; Kern, Gunther H.; McNulty, John; Mueller, John P.; Lawrence, Kenneth; Vishwanathan, Karthick; Alm, Richard A.; Barvian, Kevin; Doig, Peter; Galullo, Vincent; Gardner, Humphrey; Gowravaram, Madhusudhan; Huband, Michael; Kimzey, Amy; Morningstar, Marshall; Kutschke, Amy; Lahiri, Sushmita D.; Perros, Manos; Singh, Renu; Schuck, Virna J. A.; Tommasi, Ruben; Walkup, Grant; Newman, Joseph V.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11827</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance.  ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition against bacterial type II topoisomerases.  Incorporating an oxazolidinone on the scaffold mitigated toxicol. issues often seen with topoisomerase inhibitors.  Organisms resistant to other topoisomerase inhibitors were not cross-resistant with ETX0914 nor were spontaneous resistant mutants to ETX0914 cross-resistant with other topoisomerase inhibitor classes, including the widely used fluoroquinolone class.  Preclin. evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissues and efficacy in a murine Staphylococcus aureus infection model that served as a surrogate for predicting efficacious exposures for the treatment of Neisseria gonorrhoeae infections.  A wide safety margin to the efficacious exposure in toxicol. evaluations supported progression to Phase 1.  Dosing ETX0914 in human volunteers showed sufficient exposure and minimal adverse effects to expect a highly efficacious anti-gonorrhea therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpiUrCSFU1rVg90H21EOLACvtfcHk0li-Kc8rXyHZrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE&md5=0a681c2bd92414d798b03a9c712e138e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsrep11827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep11827%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DKern%26aufirst%3DG.%2BH.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DBarvian%26aufirst%3DK.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DGowravaram%26aufirst%3DM.%26aulast%3DHuband%26aufirst%3DM.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DPerros%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWalkup%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DJ.%2BV.%26atitle%3DResponding%2520to%2520the%2520challenge%2520of%2520untreatable%2520gonorrhea%253A%2520ETX0914%252C%2520a%2520first-in-class%2520agent%2520with%2520a%2520distinct%2520mechanism-of-action%2520against%2520bacterial%2520type%2520II%2520topoisomerases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep11827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0ljt93gds7mzTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srikannathasan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosberry, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">10048</span> <span class="refDoi"> DOI: 10.1038/ncomms10048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2Fncomms10048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=26640131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&author=P.+F.+Chanauthor=V.+Srikannathasanauthor=J.+Huangauthor=H.+Cuiauthor=A.+P.+Fosberryauthor=M.+Guauthor=M.+M.+Hannauthor=M.+Hibbsauthor=P.+Homesauthor=K.+Ingraham&title=Structural+basis+of+DNA+gyrase+inhibition+by+antibacterial+QPT-1%2C+anticancer+drug+etoposide+and+moxifloxacin&doi=10.1038%2Fncomms10048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin</span></div><div class="casAuthors">Chan, Pan F.; Srikannathasan, Velupillai; Huang, Jianzhong; Cui, Haifeng; Fosberry, Andrew P.; Gu, Minghua; Hann, Michael M.; Hibbs, Martin; Homes, Paul; Ingraham, Karen; Pizzollo, Jason; Shen, Carol; Shillings, Anthony J.; Spitzfaden, Claus E.; Tanner, Robert; Theobald, Andrew J.; Stavenger, Robert A.; Bax, Benjamin D.; Gwynn, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10048</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New antibacterials are needed to tackle antibiotic-resistant bacteria.  Type IIA topoisomerases (topo2As), the targets of fluoroquinolones, regulate DNA topol. by creating transient double-strand DNA breaks.  Here we report the first co-crystal structures of the antibacterial QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA gyrase, showing binding at the same sites in the cleaved DNA as the fluoroquinolone moxifloxacin.  Unlike moxifloxacin, QPT-1 and etoposide interact with conserved GyrB TOPRIM residues rationalizing why QPT-1 can overcome fluoroquinolone resistance.  Our data show etoposide's antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agents act similarly.  Anal. of multiple DNA gyrase co-crystal structures, including asym. cleavage complexes, led to a 'pair of swing-doors' hypothesis in which the movement of one DNA segment regulates cleavage and religation of the second DNA duplex.  This mechanism can explain QPT-1's bacterial specificity.  Structure-based strategies for developing topo2A antibacterials are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY_mF0ShDkkbVg90H21EOLACvtfcHk0lhR5X_yUuPTdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL&md5=1e358e6e0e9454967cf2aa2e01a0306b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms10048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10048%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DP.%2BF.%26aulast%3DSrikannathasan%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DFosberry%26aufirst%3DA.%2BP.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DHibbs%26aufirst%3DM.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DIngraham%26aufirst%3DK.%26atitle%3DStructural%2520basis%2520of%2520DNA%2520gyrase%2520inhibition%2520by%2520antibacterial%2520QPT-1%252C%2520anticancer%2520drug%2520etoposide%2520and%2520moxifloxacin%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26doi%3D10.1038%2Fncomms10048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mátyus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Éliás, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapolcsányi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonka-Bálint, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halász-Dajka, B.</span></span> <span> </span><span class="NLM_article-title">Ring-closure reactions of <i>ortho</i>-vinyl-<i>tert</i>-anilines and (Di)aza-heterocyclic analogues via the <i>tert</i>-amino effect: recent developments</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2006</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2639</span>, <span class="refDoi"> DOI: 10.1055/s-2006-942490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1055%2Fs-2006-942490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2006&publication_year=2006&pages=2625-2639&author=P.+M%C3%A1tyusauthor=O.+%C3%89li%C3%A1sauthor=P.+Tapolcs%C3%A1nyiauthor=A.+Polonka-B%C3%A1lintauthor=B.+Hal%C3%A1sz-Dajka&title=Ring-closure+reactions+of+ortho-vinyl-tert-anilines+and+%28Di%29aza-heterocyclic+analogues+via+the+tert-amino+effect%3A+recent+developments&doi=10.1055%2Fs-2006-942490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-942490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-942490%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A1tyus%26aufirst%3DP.%26aulast%3D%25C3%2589li%25C3%25A1s%26aufirst%3DO.%26aulast%3DTapolcs%25C3%25A1nyi%26aufirst%3DP.%26aulast%3DPolonka-B%25C3%25A1lint%26aufirst%3DA.%26aulast%3DHal%25C3%25A1sz-Dajka%26aufirst%3DB.%26atitle%3DRing-closure%2520reactions%2520of%2520ortho-vinyl-tert-anilines%2520and%2520%2528Di%2529aza-heterocyclic%2520analogues%2520via%2520the%2520tert-amino%2520effect%253A%2520recent%2520developments%26jtitle%3DSynthesis%26date%3D2006%26volume%3D2006%26spage%3D2625%26epage%3D2639%26doi%3D10.1055%2Fs-2006-942490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Yachenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhareva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyudya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltsov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morzherin, Y.</span></span> <span> </span><span class="NLM_article-title">The <i>tert</i>-amino effect in heterocyclic chemistry. Synthesis of spiro heterocycles</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.3390/10091101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.3390%2F10091101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18007375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WmsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1101-1108&author=E.+D%E2%80%99Yachenkoauthor=T.+Glukharevaauthor=L.+Dyudyaauthor=O.+Eltsovauthor=Y.+Morzherin&title=The+tert-amino+effect+in+heterocyclic+chemistry.+Synthesis+of+spiro+heterocycles&doi=10.3390%2F10091101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The tert-amino effect in heterocyclic chemistry. Synthesis of spiro heterocycles</span></div><div class="casAuthors">D'yachenko, Elisaveta V.; Glukhareva, Tatiana V.; Dyudya, Lyudmila V.; Eltsov, Oleg V.; Morzherin, Yury Yu.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1101-1108</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  The tert-amino reaction effect was examd.  A new method to synthesize spiro heterocycles is presented.  The tert-amino effect could be applied to the formation of spiro-fused heterocycles.  The formation of spiro compds. proceeds in most cases in good yields in a 1-pot reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4waXqp_8qa7Vg90H21EOLACvtfcHk0lhfmFhS2-1CnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WmsrfN&md5=45dace56623d8dee541849f93f5a5b2f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3390%2F10091101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252F10091101%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Yachenko%26aufirst%3DE.%26aulast%3DGlukhareva%26aufirst%3DT.%26aulast%3DDyudya%26aufirst%3DL.%26aulast%3DEltsov%26aufirst%3DO.%26aulast%3DMorzherin%26aufirst%3DY.%26atitle%3DThe%2520tert-amino%2520effect%2520in%2520heterocyclic%2520chemistry.%2520Synthesis%2520of%2520spiro%2520heterocycles%26jtitle%3DMolecules%26date%3D2005%26volume%3D10%26spage%3D1101%26epage%3D1108%26doi%3D10.3390%2F10091101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (−)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3997</span>, <span class="refDoi"> DOI: 10.1021/ja808014h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808014h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=3991-3997&author=J.+C.+Rubleauthor=A.+R.+Hurdauthor=T.+A.+Johnsonauthor=D.+A.+Sherryauthor=M.+R.+Barbachynauthor=P.+L.+Toogoodauthor=G.+L.+Bundyauthor=D.+R.+Graberauthor=G.+M.+Kamilar&title=Synthesis+of+%28%E2%88%92%29-PNU-286607+by+asymmetric+cyclization+of+alkylidene+barbiturates&doi=10.1021%2Fja808014h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span></div><div class="casAuthors">Ruble, J. Craig; Hurd, Alexander R.; Johnson, Timothy A.; Sherry, Debra A.; Barbachyn, Michael R.; Toogood, Peter L.; Bundy, Gordon L.; Graber, David R.; Kamilar, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3991-3997</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PNU 286607 I, a oxazinoquinolinespiropyrimidinetrione inhibitor of bacterial DNA gyrase for potential use as an antibacterial agent against antibiotic-resistant bacterial strains, is prepd. in two steps from 2-fluoro-5-nitrobenzaldehyde and (R,R)-2,6-dimethylmorpholine by nucleophilic arom. substitution followed by condensation with barbituric acid and a concomitant stereoselective cyclization of the benzylidenepyrimidinetrione.  The stereoselectivities and mechanism of the condensation and cyclization reactions (based on the rearrangements of vinyl anilines, known in the literature as the "tert-amino effect") are investigated using the NMR spectroscopic anal. of the reactions of racemic substrates and the reactions of racemic and nonracemic deuterated substrates; based on the data obtained, the asym. synthesis of I is developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwZZhoPHBHrVg90H21EOLACvtfcHk0lirR9neCn6Z6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D&md5=f837986da667a40ce19753baa9d58125</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja808014h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808014h%26sid%3Dliteratum%253Aachs%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DSherry%26aufirst%3DD.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520%2528%25E2%2588%2592%2529-PNU-286607%2520by%2520asymmetric%2520cyclization%2520of%2520alkylidene%2520barbiturates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D3991%26epage%3D3997%26doi%3D10.1021%2Fja808014h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activities of novel spiropyrimidinetrione compounds</span>. <i>Chin. J. Synth. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">652</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=653-652&author=Y.+Y.+Zhangauthor=C.+H.+Shiauthor=X.+L.+Zhou&title=Synthesis+and+antibacterial+activities+of+novel+spiropyrimidinetrione+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DShi%26aufirst%3DC.%2BH.%26aulast%3DZhou%26aufirst%3DX.%2BL.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activities%2520of%2520novel%2520spiropyrimidinetrione%2520compounds%26jtitle%3DChin.%2520J.%2520Synth.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D653%26epage%3D652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzietti, R. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span> <span> </span><span class="NLM_article-title">Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.3109/00498254.2016.1156186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.3109%2F00498254.2016.1156186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=27122100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFegt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=31-49&author=J.+Guoauthor=C.+Joubranauthor=R.+A.+Luziettiauthor=G.+S.+Basarabauthor=S.+W.+Grimmauthor=K.+Vishwanathan&title=Absorption%2C+distribution%2C+metabolism+and+elimination+of+14C-ETX0914%2C+a+novel+inhibitor+of+bacterial+type-II+topoisomerases+in+rodents&doi=10.3109%2F00498254.2016.1156186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents</span></div><div class="casAuthors">Guo, Jian; Joubran, Camil; Luzietti, Ricardo A., Jr.; Basarab, Gregory S.; Grimm, Scott W.; Vishwanathan, Karthick</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-49</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. ETX0914 is a novel bacterial topoisomerase inhibitor that has a novel mode-of-inhibition and is in clin. development for the treatment of infections caused by Neisseria gonorrhoeae.2.  The in vitro biotransformation studies of ETX0914 using mouse, rat, dog and human hepatocytes showed moderate intrinsic clearance in mouse and rat and low intrinsic clearance in dog and human.3.  Following i.v. administration of [14C]-ETX0914 in rats, the mean recovery of administered dose in urine, bile and feces was approx. 15%, 55% and 24%, resp.  Unchanged ETX0914 recovered in urine and bile was less than 5% of the dose, indicating that ETX0914 underwent extensive metab. in rats.  Metabolites M1, M2, M4, M6 and M12 detected in both rat and mouse urine samples were not detected in mouse urine when predosed with 1-aminobenzotriazole, indicating that these metabolites were cytochrome P 450 mediated products.  The major fecal metabolites obsd. in rats were not formed when ETX0914 was incubated with fresh feces from germ free rats under sterile condition or in incubations with rat intestinal microsome and cytosol, suggesting that most likely ETX0914 was directly excreted into gut lumen where metabolites were formed as intestinal microflora-mediated products.  The major sites of metab. by CYP enzymes were in the morpholine and oxazolidinone rings while it was benzisoxazole redn. with the gut microflora.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAwVcjl4pZwrVg90H21EOLACvtfcHk0lilCH-ZaxowVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFegt7w%253D&md5=e8ae0f9a16326a3b21dffc779285ecc6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3109%2F00498254.2016.1156186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2016.1156186%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DJoubran%26aufirst%3DC.%26aulast%3DLuzietti%26aufirst%3DR.%2BA.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DGrimm%26aufirst%3DS.%2BW.%26aulast%3DVishwanathan%26aufirst%3DK.%26atitle%3DAbsorption%252C%2520distribution%252C%2520metabolism%2520and%2520elimination%2520of%252014C-ETX0914%252C%2520a%2520novel%2520inhibitor%2520of%2520bacterial%2520type-II%2520topoisomerases%2520in%2520rodents%26jtitle%3DXenobiotica%26date%3D2017%26volume%3D47%26spage%3D31%26epage%3D49%26doi%3D10.3109%2F00498254.2016.1156186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span> <span> </span><span class="NLM_article-title">Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7902</span>– <span class="NLM_lpage">7917</span>, <span class="refDoi"> DOI: 10.1021/jm100762r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+H.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-containing+pharmaceuticals%3A+efficacious+roles+of+the+nitrile+pharmacophore&doi=10.1021%2Fjm100762r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0lgSkDD0CrZM5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%2BH.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-containing%2520pharmaceuticals%253A%2520efficacious%2520roles%2520of%2520the%2520nitrile%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917%26doi%3D10.1021%2Fjm100762r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaman, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L. M.</span></span> <span> </span><span class="NLM_article-title">The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.093229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1124%2Fjpet.105.093229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=16192315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=336-348&author=R.+S.+Obachauthor=R.+L.+Walskyauthor=K.+Venkatakrishnanauthor=E.+A.+Gamanauthor=J.+B.+Houstonauthor=L.+M.+Tremaine&title=The+utility+of+in+vitro+cytochrome+P450+inhibition+data+in+the+prediction+of+drug-drug+interactions&doi=10.1124%2Fjpet.105.093229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions</span></div><div class="casAuthors">Obach, R. Scott; Walsky, Robert L.; Venkatakrishnan, Karthik; Gaman, Emily A.; Houston, J. Brian; Tremaine, Larry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">336-348</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The accuracy of in vitro inhibition parameters in scaling to in vivo drug-drug interactions (DDI) was examd. for over 40 drugs using seven human P 450-selective marker activities in pooled human liver microsomes.  These data were combined with other parameters (systemic Cmax, estd. hepatic inlet Cmax, fraction unbound, and fraction of the probe drug cleared by the inhibited enzyme) to predict increases in exposure to probe drugs, and the predictions were compared with in vivo DDI gathered from clin. studies reported in the scientific literature.  For drugs that had been tested as precipitants of drug interactions for more than one P 450 in vivo, the order of inhibitory potencies in vitro generally aligned with the magnitude of the in vivo interactions.  With the exception of many drugs known to be mechanism-based inactivators, the use of in vitro IC50, the fraction of the affected drug metabolized by the target enzyme [fm(CYP)] and an est. of free hepatic inlet Cmax, was generally successful in identifying those drugs that cause at least a 2-fold increase in the exposure to P 450 marker substrate drugs.  For CYP3A, incorporation of inhibition of both hepatic and intestinal metab. was needed for the prediction of DDI.  Many CYP3A inhibitors showed a different inhibitory potency for three different CYP3A marker activities; however, these differences generally did not alter the conclusions regarding whether a drug would cause a CYP3A DDI in vivo.  Overall, these findings support the conclusion that P 450 in vitro inhibition data are valuable in designing clin. DDI study strategies and can be used to predict the magnitudes of DDI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGUhOqooYvvbVg90H21EOLACvtfcHk0ljm_AlXhsV7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslCisg%253D%253D&md5=988174eb3bb0d41655508395b1f982dd</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.093229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.093229%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DGaman%26aufirst%3DE.%2BA.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DTremaine%26aufirst%3DL.%2BM.%26atitle%3DThe%2520utility%2520of%2520in%2520vitro%2520cytochrome%2520P450%2520inhibition%2520data%2520in%2520the%2520prediction%2520of%2520drug-drug%2520interactions%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D336%26epage%3D348%26doi%3D10.1124%2Fjpet.105.093229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balani, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLauchlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surapaneni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upthagrove, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z. P.</span></span> <span> </span><span class="NLM_article-title">Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the IQ DMLG metabolite group</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.059345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1124%2Fdmd.114.059345" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=620-630&author=H.+B.+Yuauthor=S.+K.+Balaniauthor=W.+C.+Chenauthor=D.+H.+Cuiauthor=L.+Heauthor=W.+G.+Humphreysauthor=J.+L.+Maoauthor=W.+G.+Laiauthor=A.+J.+Leeauthor=H.+K.+Limauthor=C.+MacLauchlinauthor=C.+Prakashauthor=S.+Surapaneniauthor=S.+Tseauthor=A.+Upthagroveauthor=R.+L.+Walskyauthor=B.+Wenauthor=Z.+P.+Zeng&title=Contribution+of+metabolites+to+P450+inhibition-based+drug-drug+interactions%3A+scholarship+from+the+IQ+DMLG+metabolite+group&doi=10.1124%2Fdmd.114.059345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.059345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.059345%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BB.%26aulast%3DBalani%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DCui%26aufirst%3DD.%2BH.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DMao%26aufirst%3DJ.%2BL.%26aulast%3DLai%26aufirst%3DW.%2BG.%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DMacLauchlin%26aufirst%3DC.%26aulast%3DPrakash%26aufirst%3DC.%26aulast%3DSurapaneni%26aufirst%3DS.%26aulast%3DTse%26aufirst%3DS.%26aulast%3DUpthagrove%26aufirst%3DA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DZeng%26aufirst%3DZ.%2BP.%26atitle%3DContribution%2520of%2520metabolites%2520to%2520P450%2520inhibition-based%2520drug-drug%2520interactions%253A%2520scholarship%2520from%2520the%2520IQ%2520DMLG%2520metabolite%2520group%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D620%26epage%3D630%26doi%3D10.1124%2Fdmd.114.059345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smart, D. J.</span></span> <span> </span><span class="NLM_article-title">Genotoxicity of topoisomerase II inhibitors: an anti-infective perspective</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2008.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1016%2Fj.tox.2008.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18840496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGhurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2008&pages=192-198&author=D.+J.+Smart&title=Genotoxicity+of+topoisomerase+II+inhibitors%3A+an+anti-infective+perspective&doi=10.1016%2Fj.tox.2008.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of topoisomerase II inhibitors: An anti-infective perspective</span></div><div class="casAuthors">Smart, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">192-198</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  At present, an inevitable consequence of a chem.'s inhibitory activity on key regulators of DNA topol. in bacteria, the type II topoisomerases, is a less pronounced effect on their eukaryotic counterparts.  In the context of anti-infectives drug development, this may pose a risk to patient safety as inhibition of eukaryotic type II topoisomerases (TOPO II) can result in the generation of DNA double-strand breaks (DSBs), which have the potential to manifest as mutations, chromosome breakage or cell death.  The biol. effects of several TOPO II inhibitors in mammalian cells are described herein; their modulation of DSB damage response parameters is examd. and evidence for the existence of a threshold concept for genotoxicity and its relevance in safety assessment is discussed.  The potential utility of γH2AX, a promising and highly sensitive mol. marker for DSBs, in a novel genotoxicity pre-screen' to conventional assays is also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7tXpVQAjrbVg90H21EOLACvtfcHk0ljm_AlXhsV7AA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGhurrE&md5=b307b9975485e5cd71709c7c16cfd07a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2008.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2008.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DSmart%26aufirst%3DD.%2BJ.%26atitle%3DGenotoxicity%2520of%2520topoisomerase%2520II%2520inhibitors%253A%2520an%2520anti-infective%2520perspective%26jtitle%3DToxicology%26date%3D2008%26volume%3D254%26spage%3D192%26epage%3D198%26doi%3D10.1016%2Fj.tox.2008.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">11014</span>– <span class="NLM_lpage">11019</span>, <span class="refDoi"> DOI: 10.1073/pnas.0704002104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1073%2Fpnas.0704002104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=17578914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=11014-11019&author=A.+M.+Azarovaauthor=L.+L.+Yiauthor=C.+P.+Linauthor=Y.+C.+Tsaiauthor=Y.+N.+Lauauthor=J.+C.+Wangauthor=L.+F.+Liu&title=Roles+of+DNA+topoisomerase+II+isozymes+in+chemotherapy+and+secondary+malignancies&doi=10.1073%2Fpnas.0704002104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span></div><div class="casAuthors">Azarova, Anna M.; Lyu, Yi Lisa; Lin, Chao-Po; Tsai, Yuan-Chin; Lau, Johnson Yiu-Nam; Wang, James C.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">11014-11019</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clin. use.  However, Top2-based chemotherapy has been assocd. with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients.  This assocn. is suggestive of a link between carcinogenesis and Top2-mediated DNA damage.  We show here that VP-16-induced carcinogenesis involves mainly the β rather than the isoenzyme of Top2.  In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is significantly higher in TOP2β+ than in skin-specific top2β-knockout mice.  Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are Top2β-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degrdn. of the Top2β-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements.  VP-16 cytotoxicity in transformed cells expressing both Top2 isoenzymes is, however, primarily Top2α-dependent.  These results point to the importance of developing Top2-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqEXje8wQTrVg90H21EOLACvtfcHk0li5dXuf_trUMw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D&md5=f10976e9b0dbb918158916036a0349a7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0704002104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0704002104%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DYi%26aufirst%3DL.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DTsai%26aufirst%3DY.%2BC.%26aulast%3DLau%26aufirst%3DY.%2BN.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DRoles%2520of%2520DNA%2520topoisomerase%2520II%2520isozymes%2520in%2520chemotherapy%2520and%2520secondary%2520malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D11014%26epage%3D11019%26doi%3D10.1073%2Fpnas.0704002104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabary, X.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1955</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1128/AAC.34.10.1955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.34.10.1955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1990&pages=1955-1960&author=N.+J.+Moreauauthor=H.+Robauxauthor=L.+Baronauthor=X.+Tabary&title=Inhibitory+effects+of+quinolones+on+pro-+and+eucaryotic+DNA+topoisomerases+I+and+II&doi=10.1128%2FAAC.34.10.1955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FAAC.34.10.1955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.34.10.1955%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DN.%2BJ.%26aulast%3DRobaux%26aufirst%3DH.%26aulast%3DBaron%26aufirst%3DL.%26aulast%3DTabary%26aufirst%3DX.%26atitle%3DInhibitory%2520effects%2520of%2520quinolones%2520on%2520pro-%2520and%2520eucaryotic%2520DNA%2520topoisomerases%2520I%2520and%2520II%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1990%26volume%3D34%26spage%3D1955%26epage%3D1960%26doi%3D10.1128%2FAAC.34.10.1955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaever, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanberg, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1126/science.3014661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1126%2Fscience.3014661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=3014661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADyaL28Xlt1yltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=1986&pages=647-649&author=R.+Lynnauthor=G.+Giaeverauthor=S.+L.+Swanbergauthor=J.+C.+Wang&title=Tandem+regions+of+yeast+DNA+topoisomerase+II+share+homology+with+different+subunits+of+bacterial+gyrase&doi=10.1126%2Fscience.3014661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase</span></div><div class="casAuthors">Lynn, Richard; Giaever, Guri; Swanberg, Stephen L.; Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">4764</span>),
    <span class="NLM_cas:pages">647-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The nucleotide sequence for the Saccharomyces cerevisiae gene TOP2, which encodes DNA topoisomerase  [80449-01-0] type II, was compared with the sequence for bacterial DNA gyrase.  The amino and carboxyl terminal halves of the single-subunit yeast enzyme showed homologies with the B and A subunits of bacterial gyrase, resp., at corresponding positions along the polypeptide chains.  Although the 2 enzymes differ in both quaternary structure and activity, the homol. between the 2 proteins indicates mechanistic as well as structural similarities, and a probable evolutionary relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob32rXdTBu47Vg90H21EOLACvtfcHk0liJnldVvuoPKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xlt1yltLk%253D&md5=b5231a7ef2e08a09e4618af73a87631b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1126%2Fscience.3014661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3014661%26sid%3Dliteratum%253Aachs%26aulast%3DLynn%26aufirst%3DR.%26aulast%3DGiaever%26aufirst%3DG.%26aulast%3DSwanberg%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DTandem%2520regions%2520of%2520yeast%2520DNA%2520topoisomerase%2520II%2520share%2520homology%2520with%2520different%2520subunits%2520of%2520bacterial%2520gyrase%26jtitle%3DScience%26date%3D1986%26volume%3D233%26spage%3D647%26epage%3D649%26doi%3D10.1126%2Fscience.3014661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopper, H.</span></span> <span> </span><span class="NLM_article-title">Genotoxicity of several clinically used topoisomerase II inhibitors</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/S0378-4274(00)00192-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1016%2FS0378-4274%2800%2900192-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10906417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2000&pages=7-16&author=G.+Boosauthor=H.+Stopper&title=Genotoxicity+of+several+clinically+used+topoisomerase+II+inhibitors&doi=10.1016%2FS0378-4274%2800%2900192-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of several clinically used topoisomerase II inhibitors</span></div><div class="casAuthors">Boos, G.; Stopper, H.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">7-16</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">DNA topoisomerase II is an essential nuclear enzyme that modulates DNA topol. during multiple cellular processes such as DNA replication and chromosome segregation.  Several important clin. antitumor drugs and antibiotics act through inhibition of topoisomerase II.  There are a no. of different steps in the action of topoisomerase II, all of which are potential targets for inhibition through drugs and also for cellular and genetic toxicity as well as for mutagenesis.  We have investigated and compared the genotoxicity and mutagenicity of the mechanistically different topoisomerase II inhibitors m-amsacrine, mitoxantrone, etoposide, genistein, ICRF 193, and berenil using the in vitro micronucleus test, single cell elelectrophoresis (comet assay) and the mutation assay (tk-locus) in L5178Y mouse lymphoma cells.  All six compds. induced micronuclei and all except berenil were mutagenic.  M-amsacrine, mitoxantrone, etoposide and genistein induced DNA migration in the comet assay, whereas ICRF 193 was only weakly pos. and berenil was neg. in this test.  Our results are in good agreement with the compds.' proposed mechanisms of interaction with topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0kiIlE6JkNbVg90H21EOLACvtfcHk0ljVk8381f7LwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvVyqtrw%253D&md5=2d4d2ab9d9deb23b535c9312c67b5611</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0378-4274%2800%2900192-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-4274%252800%252900192-2%26sid%3Dliteratum%253Aachs%26aulast%3DBoos%26aufirst%3DG.%26aulast%3DStopper%26aufirst%3DH.%26atitle%3DGenotoxicity%2520of%2520several%2520clinically%2520used%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DToxicol.%2520Lett.%26date%3D2000%26volume%3D116%26spage%3D7%26epage%3D16%26doi%3D10.1016%2FS0378-4274%2800%2900192-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Computer-aided drug design in epigenetics</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.3389%2Ffchem.2018.00057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=29594101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=57&author=W.+Luauthor=R.+Zhangauthor=H.+Jiangauthor=H.+Zhangauthor=C.+Luo&title=Computer-aided+drug+design+in+epigenetics&doi=10.3389%2Ffchem.2018.00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-aided drug design in epigenetics</span></div><div class="casAuthors">Lu, Wenchao; Zhang, Rukang; Jiang, Hao; Zhang, Huimin; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57/1-57/23</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Epigenetic dysfunction has been widely implicated in several diseases esp. cancers thus highlights the therapeutic potential for chem. interventions in this field.  With rapid development of computational methodologies and high-performance computational resources, computer-aided drug design has emerged as a promising strategy to speed up epigenetic drug discovery.  Herein, we make a brief overview of major computational methods reported in the literature including druggability prediction, virtual screening, homol. modeling, scaffold hopping, pharmacophore modeling, mol. dynamics simulations, quantum chem. calcn., and 3D quant. structure activity relationship that have been successfully applied in the design and discovery of epi-drugs and epi-probes.  Finally, we discuss about major limitations of current virtual drug design strategies in epigenetics drug discovery and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSWvtrXR3I5LVg90H21EOLACvtfcHk0lhgJ3hdaZ9gKw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKns7bI&md5=5fc80a74098fb5c20c53d94b1ff1a3f2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00057%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DComputer-aided%2520drug%2520design%2520in%2520epigenetics%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D57%26doi%3D10.3389%2Ffchem.2018.00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4772</span>– <span class="NLM_lpage">4795</span>, <span class="refDoi"> DOI: 10.1021/jm500312x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500312x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4772-4795&author=C.+Lingauthor=L.+Fuauthor=S.+Gaoauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+novel+thioether+pleuromutilin+derivatives+as+potent+antibacterial+agents&doi=10.1021%2Fjm500312x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm500312x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500312x%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520novel%2520thioether%2520pleuromutilin%2520derivatives%2520as%2520potent%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4772%26epage%3D4795%26doi%3D10.1021%2Fjm500312x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5397</span>– <span class="NLM_lpage">5407</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1016%2Fj.bmc.2018.07.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=30297119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKktbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=5397-5407&author=W.+C.+Luauthor=H.+Xiongauthor=Y.+Chenauthor=C.+Wangauthor=H.+Zhangauthor=P.+Xuauthor=J.+Hanauthor=S.+H.+Xiaoauthor=H.+Dingauthor=Z.+F.+Chenauthor=T.+Luauthor=J.+Wangauthor=Y.+Y.+Zhangauthor=L.+Y.+Yueauthor=Y.+C.+Liuauthor=C.+H.+Zhangauthor=Y.+X.+Yangauthor=H.+L.+Jiangauthor=K.+X.+Chenauthor=B.+Zhouauthor=C.+Luo&title=Discovery+and+biological+evaluation+of+thiobarbituric+derivatives+as+potent+p300%2FCBP+inhibitors&doi=10.1016%2Fj.bmc.2018.07.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors</span></div><div class="casAuthors">Lu, Wenchao; Xiong, Huan; Chen, Yu; Wang, Chen; Zhang, Hao; Xu, Pan; Han, Jie; Xiao, Senhao; Ding, Hong; Chen, Zhifeng; Lu, Tian; Wang, Jun; Zhang, Yuanyuan; Yue, Liyan; Liu, Yu-Chih; Zhang, Chenhua; Yang, Yaxi; Jiang, Hualiang; Chen, Kaixian; Zhou, Bing; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5397-5407</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone acetyltransferases (HATs) relieve transcriptional repression by preferentially acetylation of ε-amino group of lysine residues on histones.  Dysregulation of HATs is strongly correlated with etiol. of several diseases esp. cancer, thus highlighting the utmost significance of the development of small mol. inhibitors against this potential therapeutic target.  In the present study, through virtual screening and iterative optimization, we identified DCH36_06 as a bona fide, potent p300/CBP inhibitor.  DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells.  The suppression of p300/CBP activity retarded cell proliferation in several leukemic cell lines.  In addn., DCH36_06 arrested cell cycle at G1 phase and induced apoptosis via activation of caspase-3, caspase-9 and PARP that elucidated the mol. mechanism of its anti-proliferation activity.  In transcriptome anal., DCH36_06 altered downstream gene expression and apoptotic pathways-related genes verified by real-time PCR.  Importantly, DCH36_06 blocked the leukemic xenograft growth in mice supporting its potential for in vivo use that underlies the therapeutic potential for p300/CBP inhibitors in clin. translation.  Taken together, our findings suggest that DCH36_06 may serve as a qualified chem. tool to decode the acetylome code and open up new opportunities for clin. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLk30U1TP37Vg90H21EOLACvtfcHk0ljAO7PTjeyH3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKktbnE&md5=6ff2001a48cd5da2e46dcfd841a3fc42</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%2BC.%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DS.%2BH.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%2BF.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DYue%26aufirst%3DL.%2BY.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BX.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520biological%2520evaluation%2520of%2520thiobarbituric%2520derivatives%2520as%2520potent%2520p300%252FCBP%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D5397%26epage%3D5407%26doi%3D10.1016%2Fj.bmc.2018.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 16 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Shuimu Lin, Hongxia Li, Yiwen Tao, Jiayong Liu, Wenchang Yuan, Yongzhi Chen, Ying Liu, <span class="NLM_string-name hlFld-ContribAuthor">Shouping Liu</span>. </span><span class="cited-content_cbyCitation_article-title">In Vitro and in Vivo Evaluation of Membrane-Active Flavone Amphiphiles: Semisynthetic Kaempferol-Derived Antimicrobials against Drug-Resistant Gram-Positive Bacteria. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (11)
                                     , 5797-5815. <a href="https://doi.org/10.1021/acs.jmedchem.0c00053" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00053%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIn%252BVitro%252Band%252Bin%252BVivo%252BEvaluation%252Bof%252BMembrane-Active%252BFlavone%252BAmphiphiles%25253A%252BSemisynthetic%252BKaempferol-Derived%252BAntimicrobials%252Bagainst%252BDrug-Resistant%252BGram-Positive%252BBacteria%26aulast%3DLin%26aufirst%3DShuimu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D10012020%26date%3D26052020%26date%3D13052020%26volume%3D63%26issue%3D11%26spage%3D5797%26epage%3D5815" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Lin Chen, <span class="NLM_string-name hlFld-ContribAuthor">Jin He</span>. </span><span class="cited-content_cbyCitation_article-title">DABCO-Catalyzed Michael/Alkylation Cascade Reactions Involving α-Substituted Ammonium Ylides for the Construction of Spirocyclopropyl Oxindoles: Access to the Powerful Chemical Leads against HIV-1. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>85 </em>
                                    (8)
                                     , 5203-5219. <a href="https://doi.org/10.1021/acs.joc.9b03164" title="DOI URL">https://doi.org/10.1021/acs.joc.9b03164</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.9b03164&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.9b03164%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DDABCO-Catalyzed%252BMichael%25252FAlkylation%252BCascade%252BReactions%252BInvolving%252B%2525CE%2525B1-Substituted%252BAmmonium%252BYlides%252Bfor%252Bthe%252BConstruction%252Bof%252BSpirocyclopropyl%252BOxindoles%25253A%252BAccess%252Bto%252Bthe%252BPowerful%252BChemical%252BLeads%252Bagainst%252BHIV-1%26aulast%3DChen%26aufirst%3DLin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D03122019%26date%3D03042020%26date%3D23032020%26volume%3D85%26issue%3D8%26spage%3D5203%26epage%3D5219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rammohan R. Yadav  Bheemanaboina</span>, <span class="hlFld-ContribAuthor ">Juan  Wang</span>, <span class="hlFld-ContribAuthor ">Yuan-Yuan  Hu</span>, <span class="hlFld-ContribAuthor ">Jiang-Ping  Meng</span>, <span class="hlFld-ContribAuthor ">Zhi  Guan</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">A facile reaction to access novel structural sulfonyl-hybridized imidazolyl ethanols as potential DNA-targeting antibacterial agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>47 </em>, 128198. <a href="https://doi.org/10.1016/j.bmcl.2021.128198" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.128198</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.128198&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.128198%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DA%252Bfacile%252Breaction%252Bto%252Baccess%252Bnovel%252Bstructural%252Bsulfonyl-hybridized%252Bimidazolyl%252Bethanols%252Bas%252Bpotential%252BDNA-targeting%252Bantibacterial%252Bagents%26aulast%3DBheemanaboina%26aufirst%3DRammohan%2BR.%2BYadav%26date%3D2021%26volume%3D47%26spage%3D128198" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yinhui  Qin</span>, <span class="hlFld-ContribAuthor ">Linlin  Xu</span>, <span class="hlFld-ContribAuthor ">Yuetai  Teng</span>, <span class="hlFld-ContribAuthor ">Yinhu  Wang</span>, <span class="hlFld-ContribAuthor ">Peizhi  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel antibacterial agents: Recent developments in D‐alanyl‐D‐alanine ligase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2021,</strong> <em>282 </em><a href="https://doi.org/10.1111/cbdd.13899" title="DOI URL">https://doi.org/10.1111/cbdd.13899</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13899&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13899%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DDiscovery%252Bof%252Bnovel%252Bantibacterial%252Bagents%25253A%252BRecent%252Bdevelopments%252Bin%252BD%2525E2%252580%252590alanyl%2525E2%252580%252590D%2525E2%252580%252590alanine%252Bligase%252Binhibitors%26aulast%3DQin%26aufirst%3DYinhui%26date%3D2021%26date%3D2021%26volume%3D282" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mahboobeh  Salehpour</span>, <span class="hlFld-ContribAuthor ">Javad  Azizian</span>. </span><span class="cited-content_cbyCitation_article-title">Exploration of interaction behavior between spiro[indene-2,2'-[1,3,5]oxathiazine]-1,3-diones and DNA with the help of DFT, molecular docking, and MD simulations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2021,</strong> <em>8 </em>, 1-21. <a href="https://doi.org/10.1080/07391102.2021.1924266" title="DOI URL">https://doi.org/10.1080/07391102.2021.1924266</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2021.1924266&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2021.1924266%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DExploration%252Bof%252Binteraction%252Bbehavior%252Bbetween%252Bspiro%25255Bindene-2%25252C2%252527-%25255B1%25252C3%25252C5%25255Doxathiazine%25255D-1%25252C3-diones%252Band%252BDNA%252Bwith%252Bthe%252Bhelp%252Bof%252BDFT%25252C%252Bmolecular%252Bdocking%25252C%252Band%252BMD%252Bsimulations%26aulast%3DSalehpour%26aufirst%3DMahboobeh%26date%3D2021%26date%3D2021%26volume%3D8%26spage%3D1%26epage%3D21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Yuan  Liang</span>, <span class="hlFld-ContribAuthor ">Narsaiah  Battini</span>, <span class="hlFld-ContribAuthor ">Yan-Fei  Sui</span>, <span class="hlFld-ContribAuthor ">Mohammad Fawad  Ansari</span>, <span class="hlFld-ContribAuthor ">Lin-Ling  Gan</span>, <span class="hlFld-ContribAuthor ">Cheng-He  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Aloe-emodin derived azoles as a new structural type of potential antibacterial agents: design, synthesis, and evaluation of the action on membrane, DNA, and MRSA DNA isomerase. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2021,</strong> <em>12 </em>
                                    (4)
                                     , 602-608. <a href="https://doi.org/10.1039/D0MD00429D" title="DOI URL">https://doi.org/10.1039/D0MD00429D</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00429D&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00429D%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DAloe-emodin%252Bderived%252Bazoles%252Bas%252Ba%252Bnew%252Bstructural%252Btype%252Bof%252Bpotential%252Bantibacterial%252Bagents%25253A%252Bdesign%25252C%252Bsynthesis%25252C%252Band%252Bevaluation%252Bof%252Bthe%252Baction%252Bon%252Bmembrane%25252C%252BDNA%25252C%252Band%252BMRSA%252BDNA%252Bisomerase%26aulast%3DLiang%26aufirst%3DXin-Yuan%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D4%26spage%3D602%26epage%3D608" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romain  Melot</span>, <span class="hlFld-ContribAuthor ">Marco  Zuccarello</span>, <span class="hlFld-ContribAuthor ">Diana  Cavalli</span>, <span class="hlFld-ContribAuthor ">Nadja  Niggli</span>, <span class="hlFld-ContribAuthor ">Michael  Devereux</span>, <span class="hlFld-ContribAuthor ">Thomas  Bürgi</span>, <span class="hlFld-ContribAuthor ">Olivier  Baudoin</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium(0)‐Catalyzed Enantioselective Intramolecular Arylation of Enantiotopic Secondary C−H Bonds. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2021,</strong> <em>133 </em>
                                    (13)
                                     , 7321-7326. <a href="https://doi.org/10.1002/ange.202014605" title="DOI URL">https://doi.org/10.1002/ange.202014605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.202014605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.202014605%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DPalladium%2525280%252529%2525E2%252580%252590Catalyzed%252BEnantioselective%252BIntramolecular%252BArylation%252Bof%252BEnantiotopic%252BSecondary%252BC%2525E2%252588%252592H%252BBonds%26aulast%3DMelot%26aufirst%3DRomain%26date%3D2021%26date%3D2021%26volume%3D133%26issue%3D13%26spage%3D7321%26epage%3D7326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Romain  Melot</span>, <span class="hlFld-ContribAuthor ">Marco  Zuccarello</span>, <span class="hlFld-ContribAuthor ">Diana  Cavalli</span>, <span class="hlFld-ContribAuthor ">Nadja  Niggli</span>, <span class="hlFld-ContribAuthor ">Michael  Devereux</span>, <span class="hlFld-ContribAuthor ">Thomas  Bürgi</span>, <span class="hlFld-ContribAuthor ">Olivier  Baudoin</span>. </span><span class="cited-content_cbyCitation_article-title">Palladium(0)‐Catalyzed Enantioselective Intramolecular Arylation of Enantiotopic Secondary C−H Bonds. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2021,</strong> <em>60 </em>
                                    (13)
                                     , 7245-7250. <a href="https://doi.org/10.1002/anie.202014605" title="DOI URL">https://doi.org/10.1002/anie.202014605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.202014605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.202014605%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DPalladium%2525280%252529%2525E2%252580%252590Catalyzed%252BEnantioselective%252BIntramolecular%252BArylation%252Bof%252BEnantiotopic%252BSecondary%252BC%2525E2%252588%252592H%252BBonds%26aulast%3DMelot%26aufirst%3DRomain%26date%3D2021%26date%3D2021%26volume%3D60%26issue%3D13%26spage%3D7245%26epage%3D7250" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qidi  Kong</span>, <span class="hlFld-ContribAuthor ">Yushe  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in antibacterial agents. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2021,</strong> <em>35 </em>, 127799. <a href="https://doi.org/10.1016/j.bmcl.2021.127799" title="DOI URL">https://doi.org/10.1016/j.bmcl.2021.127799</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2021.127799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2021.127799%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DRecent%252Badvances%252Bin%252Bantibacterial%252Bagents%26aulast%3DKong%26aufirst%3DQidi%26date%3D2021%26volume%3D35%26spage%3D127799" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elvira R.  Zaitseva</span>, <span class="hlFld-ContribAuthor ">Alexander Yu.  Smirnov</span>, <span class="hlFld-ContribAuthor ">Ivan N.  Myasnyanko</span>, <span class="hlFld-ContribAuthor ">Konstantin S.  Mineev</span>, <span class="hlFld-ContribAuthor ">Anatolii I.  Sokolov</span>, <span class="hlFld-ContribAuthor ">Tatyana N.  Volkhina</span>, <span class="hlFld-ContribAuthor ">Andrey A.  Mikhaylov</span>, <span class="hlFld-ContribAuthor ">Nadezhda S.  Baleeva</span>, <span class="hlFld-ContribAuthor ">Mikhail S.  Baranov</span>. </span><span class="cited-content_cbyCitation_article-title">Imidazol-5-ones as a substrate for [1,5]-hydride shift triggered cyclization. </span><span class="cited-content_cbyCitation_journal-name">New Journal of Chemistry</span><span> <strong>2021,</strong> <em>45 </em>
                                    (4)
                                     , 1805-1808. <a href="https://doi.org/10.1039/D0NJ05738J" title="DOI URL">https://doi.org/10.1039/D0NJ05738J</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0NJ05738J&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0NJ05738J%26sid%3Dliteratum%253Aachs%26jtitle%3DNew%2520Journal%2520of%2520Chemistry%26atitle%3DImidazol-5-ones%252Bas%252Ba%252Bsubstrate%252Bfor%252B%25255B1%25252C5%25255D-hydride%252Bshift%252Btriggered%252Bcyclization%26aulast%3DZaitseva%26aufirst%3DElvira%2BR.%26date%3D2021%26date%3D2021%26volume%3D45%26issue%3D4%26spage%3D1805%26epage%3D1808" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Satish N.  Dighe</span>, <span class="hlFld-ContribAuthor ">Trudi A.  Collet</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in DNA gyrase-targeted antimicrobial agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>199 </em>, 112326. <a href="https://doi.org/10.1016/j.ejmech.2020.112326" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112326</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112326&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112326%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Badvances%252Bin%252BDNA%252Bgyrase-targeted%252Bantimicrobial%252Bagents%26aulast%3DDighe%26aufirst%3DSatish%2BN.%26date%3D2020%26volume%3D199%26spage%3D112326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Minghui  Wang</span>, <span class="hlFld-ContribAuthor ">Ruixuan  Gao</span>, <span class="hlFld-ContribAuthor ">Peng  Sang</span>, <span class="hlFld-ContribAuthor ">Timothy  Odom</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Zheng</span>, <span class="hlFld-ContribAuthor ">Yan  Shi</span>, <span class="hlFld-ContribAuthor ">Hai  Xu</span>, <span class="hlFld-ContribAuthor ">Chuanhai  Cao</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Cai</span>. </span><span class="cited-content_cbyCitation_article-title">Dimeric γ-AApeptides With Potent and Selective Antibacterial Activity. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>8 </em><a href="https://doi.org/10.3389/fchem.2020.00441" title="DOI URL">https://doi.org/10.3389/fchem.2020.00441</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2020.00441&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2020.00441%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DDimeric%252B%2525CE%2525B3-AApeptides%252BWith%252BPotent%252Band%252BSelective%252BAntibacterial%252BActivity%26aulast%3DWang%26aufirst%3DMinghui%26date%3D2020%26date%3D2020%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hao  Liu</span>, <span class="hlFld-ContribAuthor ">Zhi-Wen  Chu</span>, <span class="hlFld-ContribAuthor ">Dong-Guo  Xia</span>, <span class="hlFld-ContribAuthor ">Hai-Qun  Cao</span>, <span class="hlFld-ContribAuthor ">Xian-Hai  Lv</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel multi-substituted benzo-indole pyrazole schiff base derivatives with antibacterial activity targeting DNA gyrase. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103807. <a href="https://doi.org/10.1016/j.bioorg.2020.103807" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103807</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103807&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103807%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252Bmulti-substituted%252Bbenzo-indole%252Bpyrazole%252Bschiff%252Bbase%252Bderivatives%252Bwith%252Bantibacterial%252Bactivity%252Btargeting%252BDNA%252Bgyrase%26aulast%3DLiu%26aufirst%3DHao%26date%3D2020%26volume%3D99%26spage%3D103807" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Grace  Obi</span>, <span class="hlFld-ContribAuthor ">Jude C.  Chukwujekwu</span>, <span class="hlFld-ContribAuthor ">Fanie R.  van Heerden</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antimicrobial activity of new prenylated 2-pyrone derivatives. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2020,</strong> <em>50 </em>
                                    (5)
                                     , 726-734. <a href="https://doi.org/10.1080/00397911.2020.1718710" title="DOI URL">https://doi.org/10.1080/00397911.2020.1718710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2020.1718710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2020.1718710%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3DSynthesis%252Band%252Bantimicrobial%252Bactivity%252Bof%252Bnew%252Bprenylated%252B2-pyrone%252Bderivatives%26aulast%3DObi%26aufirst%3DGrace%26date%3D2020%26date%3D2020%26volume%3D50%26issue%3D5%26spage%3D726%26epage%3D734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenjie  Xue</span>, <span class="hlFld-ContribAuthor ">Xueyao  Li</span>, <span class="hlFld-ContribAuthor ">Guixing  Ma</span>, <span class="hlFld-ContribAuthor ">Hongmin  Zhang</span>, <span class="hlFld-ContribAuthor ">Ya  Chen</span>, <span class="hlFld-ContribAuthor ">Johannes  Kirchmair</span>, <span class="hlFld-ContribAuthor ">Jie  Xia</span>, <span class="hlFld-ContribAuthor ">Song  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">N-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides bearing heteroaromatic rings as novel antibacterial agents: Design, synthesis, biological evaluation and target identification. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>188 </em>, 112022. <a href="https://doi.org/10.1016/j.ejmech.2019.112022" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.112022</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.112022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.112022%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DN-thiadiazole-4-hydroxy-2-quinolone-3-carboxamides%252Bbearing%252Bheteroaromatic%252Brings%252Bas%252Bnovel%252Bantibacterial%252Bagents%25253A%252BDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Btarget%252Bidentification%26aulast%3DXue%26aufirst%3DWenjie%26date%3D2020%26volume%3D188%26spage%3D112022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Md Ataul  Islam</span>, <span class="hlFld-ContribAuthor ">Tahir S.  Pillay</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of promising anti-DNA gyrase antibacterial compounds using
              de novo
              design, molecular docking and molecular dynamics studies. </span><span class="cited-content_cbyCitation_journal-name">Journal of Biomolecular Structure and Dynamics</span><span> <strong>2019,</strong> <em> </em>, 1-12. <a href="https://doi.org/10.1080/07391102.2019.1617785" title="DOI URL">https://doi.org/10.1080/07391102.2019.1617785</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/07391102.2019.1617785&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F07391102.2019.1617785%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Biomolecular%2520Structure%2520and%2520Dynamics%26atitle%3DIdentification%252Bof%252Bpromising%252Banti-DNA%252Bgyrase%252Bantibacterial%252Bcompounds%252Busing%252Bde%252Bnovo%252Bdesign%25252C%252Bmolecular%252Bdocking%252Band%252Bmolecular%252Bdynamics%252Bstudies%26aulast%3DIslam%26aufirst%3DMd%2BAtaul%26date%3D2019%26date%3D2019%26spage%3D1%26epage%3D12" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0021.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0001.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. SPTs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0002.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. T-reaction for the synthesis of SPTs.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0003.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Single<b>-</b>crystal X-ray structure of <b>39e</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Compounds (±)-<b>16a</b>–<b>d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LDA, DMF, tetrahydrofuran (THF), −78 °C, 77%; (b) CH<sub>3</sub>I, K<sub>2</sub>CO<sub>3</sub>, DMF, room temperature (rt), 59%; (c) ethylene glycol, <i>p</i>-toluenesulfonic acid, toluene, 140 °C, 80%; (d) 7 M NH<sub>3</sub> in MeOH, sealed tube, 90 °C, 42%; (e) 2 M NaOH aqueous solution, EtOH, 40 °C; (f) 2 M HCl aqueous solution, EtOH, rt, 90% (for two steps); (g) <i>cis</i>-2,6-dimethylmorpholine, <i>N</i>,<i>N</i>-diisopropylethylamine (DIPEA), CH<sub>3</sub>CN, 90 °C, 85%; (h) methoxyammonium chloride, Et<sub>3</sub>N, MeOH, rt, 87%; (i) formamidine acetate, 1,4-dioxane, MeOH, microwave at 90 °C, 70%; (j) POCl<sub>3</sub>, Et<sub>3</sub>N, toluene, 105 °C, 84%; (k) for <b>14a</b>: CH<sub>3</sub>MgBr, THF, Ar, 0 °C to rt, 64%; for <b>14b</b>: morpholine, THF, rt, 78%; for <b>14c</b>: thiomorpholine, THF, rt; for <b>14d</b>: 3-ketomorpholine, dimethylbisdiphenylphosphinoxanthene, Pd<sub>2</sub>(dba)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 100 °C, 45%; (l) 2 M HCl aqueous solution, formaldehyde, CH<sub>3</sub>COOH, acetone, rt, 79% for <b>15a</b>, 80% for <b>15b</b>, 66% for <b>15c</b> (for two steps), 46% for <b>15d</b>; (m) barbituric acid, CH<sub>3</sub>COOH, toluene, 100 °C, 50–87%.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Compound (±)-<b>20</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 2 M HCl aqueous solution, formaldehyde, CH<sub>3</sub>COOH, acetone, rt, 90%; (b) POCl<sub>3</sub>, Et<sub>3</sub>N, toluene, reflux, 33%; (c) 1,2,4-triazole, THF, 80 °C, 89%; (d) barbituric acid, CH<sub>3</sub>COOH, toluene, 100 °C, 51%.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compound (±)-<b>24</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethanolamine, THF, rt, 93%; (b) CDI, DMF, 105 °C, 66%; (c) HCl aqueous solution, formaldehyde, CH<sub>3</sub>COOH, acetone, rt, 48%; (d) barbituric acid, CH<sub>3</sub>COOH, toluene, 100 °C, 73%.</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>26a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 1,2,6-thiadiazinane-3,5-dione 1,1-dioxide, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 74%; (b) 2-thioxodihydropyrimidine-4,6(1<i>H</i>,5<i>H</i>)-dione, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 55%; (c) 1,3-dimethylpyrimidine-2,4,6(1<i>H</i>,3<i>H</i>,5<i>H</i>)-trione, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 80%.</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compounds <b>33a–h</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCS, DMF, 40 °C; (b) appropriate amines, DMF, 0 °C to rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt to 40 °C, 53–76% (for three steps); (d) for <b>29a</b>–<b>c</b> and <b>29e</b>–<b>h</b>: CDI, 4-dimethylaminopyridine (DMAP), DMF, 100 °C, 63–91%; for <b>29d</b>: 1,1’-thiocarbonyldiimidazole, DMAP, DMF, 100 °C, 40%; (e) for <b>30a</b>–<b>g</b>: 6 M HCl aqueous solution, 1,4-dioxane, rt, 80–99%; for <b>30h</b>: 4 M H<sub>2</sub>SO<sub>4</sub> aqueous solution, 1,4-dioxane, rt, 75%; (f) <i>cis</i>-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 41–69%; (g) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 41–88%; (h) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 43–86%.</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>39a–o</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCS, DMF, 40 °C; (b) corresponding amine, DMF, 0 °C to rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt to 40 °C, 46–88% (for three steps); (d) PPh<sub>3</sub>, diisopropyl azodicarboxylate (DIAD), thioacetic acid, THF, 0 °C, 49–99%; (e) 2 M NaOH aqueous solution, <span class="smallcaps smallerCapital">dl</span>-1,4-dithiothreitol (DTT), MeOH, rt; (f) CDI, DMAP, DMF, 100 °C, 26–93% (for two steps); (g) 6 M HCl aqueous solution, 1,4-dioxane, rt, 56–100%; (h) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 39–87%; (i) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 59–84%.</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>50</b>–<b>52</b> and <b>69</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) NCS, DMF, 40 °C; (b) (<i>S</i>)-3-aminopropane-1,2-diol, DMF, 0 °C to rt; (c) Cs<sub>2</sub>CO<sub>3</sub>, DMF, rt to 40 °C, 77% (for three steps); (d) TBSCl, imidazole, DMF, rt, 74%; (e) PPh<sub>3</sub>, DIAD, thioacetic acid, THF, 0 °C, 86%; (f) 2 M NaOH, <span class="smallcaps smallerCapital">dl</span>-1,4-dithiothreitol, MeOH, rt; (g) CDI, DMAP, DMF, 100 °C, 73% (for two steps); (h) 6 M HCl aqueous solution, 1,4-dioxane, rt, 74%; (i) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 49–66%; (j) barbituric acid, EtOH, 6 M HCl aqueous solution, 100 °C, 87%; (k) trimethyloxonium tetrafluoroborate, 2,6-bis(1,1-dimethylethyl)pyridine, dichloromethane (DCM), rt, 99%; (l) methanesulfonyl chloride (MsCl), DIPEA, DCM, 0 °C to rt, 87%; (m) NaN<sub>3</sub>, DMF, 70 °C, 90%; (n) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 40–85%; (o) PPh<sub>3</sub>, THF, H<sub>2</sub>O, rt, 62%; (p) acetic anhydride, DIPEA, DCM, EtOAc, rt, 86%.</p></p></figure><figure data-id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compounds <b>57</b>, <b>61</b>, and <b>67</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) tetra-<i>n</i>-butylammonium fluoride, DMF, 0 °C, 72%; (b) diethylaminosulfur trifluoride, THF, 35 °C, 74%; (c) 6 M HCl aqueous solution, 1,4-dioxane, rt, 80–99%; (d) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 90 °C, 59–91%; (e) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 34–65%; (f) AgOTf, Selectfluor, KF, 2-fluoropyridine, (trifluoromethyl)trimethylsilane, EtOAc, rt, 11%; (g) MsCl, DIPEA, DCM, 0 °C, 92%; (h) CH<sub>3</sub>SNa, DIPEA, 0 °C, 43%; (i) H<sub>2</sub>O<sub>2</sub>, Na<sub>2</sub>WO<sub>4</sub>·2H<sub>2</sub>O, MeOH/H<sub>2</sub>O, rt, 41%.</p></p></figure><figure data-id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0014.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compounds <b>79a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) LDA, DMF, THF, −78 °C, 48%; (b) ethylene glycol, <i>p</i>-toluenesulfonic acid, toluene, 140 °C, 76%; (c) LDA, DMF, THF, −78 °C, 64%; (d) hydroxylamine hydrochloride, pyridine, MeOH, rt, 96%; (e) NCS, DMF, 40 °C; (f) the corresponding amine, DMF, 0 °C to rt, 27–77% (for two steps); (g) 6 M HCl aqueous solution, 1,4-dioxane, 35 °C; (h) NaHCO<sub>3</sub>, DMAP, DMF, rt, 18–44% (for two steps); (i) (2<i>R</i>,6<i>R</i>)-2,6-dimethylmorpholine, DIPEA, CH<sub>3</sub>CN, 40 °C, 70–88%; (j) CDI, DMAP, DMF, 100 °C, 50–70%; (k) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 32–54%.</p></p></figure><figure data-id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0015.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Compound <b>82</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) PPh<sub>3</sub>, DIAD, thioacetic acid, THF, 0 °C, 35%; (b) 2 M NaOH aqueous solution, <span class="smallcaps smallerCapital">dl</span>-1,4-dithiothreitol, MeOH, rt; (c) CDI, DMAP, DMF, 90 °C, 62% (for two steps); (d) barbituric acid, CH<sub>3</sub>COOH, H<sub>2</sub>O, 110 °C, 62%.</p></p></figure><figure data-id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0004.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modification of the benzisoxazole scaffold.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/medium/jm-2018-017507_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0005.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Docking results for compounds <b>3</b> and <b>33e</b> within the <i>S. aureus</i> gyrase. (A, B) <b>3</b> and <b>33e</b> in the binding pocket. The pocket was represented as an electrostatic potential surface. QPT-1, <b>3</b>, and <b>33e</b> are shown as white, yellow, and cyan sticks, respectively. The figure is generated with PyMOL version 1.3r1 (Schrodinger, 2010). (C, D) Detailed binding modes of <b>3</b> and <b>33e</b> with <i>S. aureus</i> gyrase. The structural waters are shown in cyan spheres. The figure is generated using LigPlot+ version 1.4.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-6/acs.jmedchem.8b01750/20190321/images/large/jm-2018-017507_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.8b01750&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i90">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_88355" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_88355" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 36 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span> <i>Antimicrobial
Resistance: Global Report on Surveillance</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2014</span>. <a href="http://www.who.int/antimicrobial-resistance/publications/surveillancereport/en/" class="extLink">http://www.who.int/antimicrobial-resistance/publications/surveillancereport/en/</a> (accessed Nov 11, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Antimicrobial%0AResistance%3A+Global+Report+on+Surveillance%3B+World+Health+Organization%3A+Geneva%2C+2014.+http%3A%2F%2Fwww.who.int%2Fantimicrobial-resistance%2Fpublications%2Fsurveillancereport%2Fen%2F+%28accessed+Nov+11%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DAntimicrobial%250AResistance%253A%2520Global%2520Report%2520on%2520Surveillance%26pub%3DWorld%2520Health%2520Organization%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Spellberg, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guidos, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilbert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucher, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheld, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartlett, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edwards, J.</span></span> <span> </span><span class="NLM_article-title">The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America</span>. <i>Clin. Infect. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">164</span>, <span class="refDoi"> DOI: 10.1086/524891</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1086%2F524891" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18171244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FgslGitw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2008&pages=155-164&author=B.+Spellbergauthor=R.+Guidosauthor=D.+Gilbertauthor=J.+Bradleyauthor=H.+W.+Boucherauthor=W.+M.+Scheldauthor=J.+G.+Bartlettauthor=J.+Edwards&title=The+epidemic+of+antibiotic-resistant+infections%3A+a+call+to+action+for+the+medical+community+from+the+Infectious+Diseases+Society+of+America&doi=10.1086%2F524891"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America</span></div><div class="casAuthors">Spellberg Brad; Guidos Robert; Gilbert David; Bradley John; Boucher Helen W; Scheld W Michael; Bartlett John G; Edwards John Jr</div><div class="citationInfo"><span class="NLM_cas:title">Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">155-64</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The ongoing explosion of antibiotic-resistant infections continues to plague global and US health care.  Meanwhile, an equally alarming decline has occurred in the research and development of new antibiotics to deal with the threat.  In response to this microbial "perfect storm," in 2001, the federal Interagency Task Force on Antimicrobial Resistance released the "Action Plan to Combat Antimicrobial Resistance; Part 1: Domestic" to strengthen the response in the United States.  The Infectious Diseases Society of America (IDSA) followed in 2004 with its own report, "Bad Bugs, No Drugs: As Antibiotic Discovery Stagnates, A Public Health Crisis Brews," which proposed incentives to reinvigorate pharmaceutical investment in antibiotic research and development.  The IDSA's subsequent lobbying efforts led to the introduction of promising legislation in the 109 th US Congress (January 2005-December 2006).  Unfortunately, the legislation was not enacted.  During the 110 th Congress, the IDSA has continued to work with congressional leaders on promising legislation to address antibiotic-resistant infection.  Nevertheless, despite intensive public relations and lobbying efforts, it remains unclear whether sufficiently robust legislation will be enacted.  In the meantime, microbes continue to become more resistant, the antibiotic pipeline continues to diminish, and the majority of the public remains unaware of this critical situation.  The result of insufficient federal funding; insufficient surveillance, prevention, and control; insufficient research and development activities; misguided regulation of antibiotics in agriculture and, in particular, for food animals; and insufficient overall coordination of US (and international) efforts could mean a literal return to the preantibiotic era for many types of infections.  If we are to address the antimicrobial resistance crisis, a concerted, grassroots effort led by the medical community will be required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ5IgYdIVkSKVf1XRtfYM0dfW6udTcc2ebRLNFiJnbOObntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FgslGitw%253D%253D&md5=52bb108e9c29dc9da3031f7127cba99f</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1086%2F524891&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1086%252F524891%26sid%3Dliteratum%253Aachs%26aulast%3DSpellberg%26aufirst%3DB.%26aulast%3DGuidos%26aufirst%3DR.%26aulast%3DGilbert%26aufirst%3DD.%26aulast%3DBradley%26aufirst%3DJ.%26aulast%3DBoucher%26aufirst%3DH.%2BW.%26aulast%3DScheld%26aufirst%3DW.%2BM.%26aulast%3DBartlett%26aufirst%3DJ.%2BG.%26aulast%3DEdwards%26aufirst%3DJ.%26atitle%3DThe%2520epidemic%2520of%2520antibiotic-resistant%2520infections%253A%2520a%2520call%2520to%2520action%2520for%2520the%2520medical%2520community%2520from%2520the%2520Infectious%2520Diseases%2520Society%2520of%2520America%26jtitle%3DClin.%2520Infect.%2520Dis.%26date%3D2008%26volume%3D46%26spage%3D155%26epage%3D164%26doi%3D10.1086%2F524891" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wright, G. D.</span></span> <span> </span><span class="NLM_article-title">Antibacterial drug discovery in the resistance era</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>529</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">343</span>, <span class="refDoi"> DOI: 10.1038/nature17042</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2Fnature17042" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=26791724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=529&publication_year=2016&pages=336-343&author=E.+D.+Brownauthor=G.+D.+Wright&title=Antibacterial+drug+discovery+in+the+resistance+era&doi=10.1038%2Fnature17042"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Antibacterial drug discovery in the resistance era</span></div><div class="casAuthors">Brown, Eric D.; Wright, Gerard D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">529</span>
        (<span class="NLM_cas:issue">7586</span>),
    <span class="NLM_cas:pages">336-343</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The looming antibiotic resistance crisis has penetrated the consciousness of clinicians, researchers, policymakers, politicians and the public at large.  The evolution and widespread distribution of antibiotic resistance elements in bacterial pathogens has made diseases that were once easily treatable deadly again.  Unfortunately, accompanying the rise in global resistance is a failure in antibacterial drug discovery.  Lessons from the history of antibiotic discovery and fresh understanding of antibiotic action and the cell biol. of microorganisms have the potential to deliver twenty-first century medicines that are able to control infection in the resistance era.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKJH_K99a5abVg90H21EOLACvtfcHk0ligbj4l-iExZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1Oisro%253D&md5=62e0454601a242db039e60d77be26406</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnature17042&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17042%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DE.%2BD.%26aulast%3DWright%26aufirst%3DG.%2BD.%26atitle%3DAntibacterial%2520drug%2520discovery%2520in%2520the%2520resistance%2520era%26jtitle%3DNature%26date%3D2016%26volume%3D529%26spage%3D336%26epage%3D343%26doi%3D10.1038%2Fnature17042" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chellat, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguž, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riedl, R.</span></span> <span> </span><span class="NLM_article-title">Targeting antibiotic resistance</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6600</span>– <span class="NLM_lpage">6626</span>, <span class="refDoi"> DOI: 10.1002/anie.201506818</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1002%2Fanie.201506818" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2016&pages=6600-6626&author=M.+F.+Chellatauthor=L.+Ragu%C5%BEauthor=R.+Riedl&title=Targeting+antibiotic+resistance&doi=10.1002%2Fanie.201506818"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Antibiotic Resistance</span></div><div class="casAuthors">Chellat, Mathieu F.; Raguz, Luka; Riedl, Rainer</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6600-6626</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Finding strategies against the development of antibiotic resistance is a major global challenge for the life sciences community and for public health.  The past decades have seen a dramatic worldwide increase in human-pathogenic bacteria that are resistant to one or multiple antibiotics.  More and more infections caused by resistant microorganisms fail to respond to conventional treatment, and in some cases, even last-resort antibiotics have lost their power.  In addn., industry pipelines for the development of novel antibiotics have run dry over the past decades.  A recent world health day by the World Health Organization titled "Combat drug resistance: no action today means no cure tomorrow" triggered an increase in research activity, and several promising strategies have been developed to restore treatment options against infections by resistant bacterial pathogens.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRcddMQflU3LVg90H21EOLACvtfcHk0liiLF62QZio4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xks1Cju7k%253D&md5=b8194ac5902fa3ac4da2e36de71f82b4</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1002%2Fanie.201506818&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201506818%26sid%3Dliteratum%253Aachs%26aulast%3DChellat%26aufirst%3DM.%2BF.%26aulast%3DRagu%25C5%25BE%26aufirst%3DL.%26aulast%3DRiedl%26aufirst%3DR.%26atitle%3DTargeting%2520antibiotic%2520resistance%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2016%26volume%3D55%26spage%3D6600%26epage%3D6626%26doi%3D10.1002%2Fanie.201506818" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span> <i>Global
Priority List of Antibiotic-Resistant Bacteria To Guide Research,
Discovery, and Development of New Antibiotics</i>; <span class="NLM_publisher-name">World Health Organization</span>: <span class="NLM_publisher-loc">Geneva</span>, <span class="NLM_year">2017</span>. <a href="http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf" class="extLink">http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf</a> (accessed Nov 11, 2018).</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+Global%0APriority+List+of+Antibiotic-Resistant+Bacteria+To+Guide+Research%2C%0ADiscovery%2C+and+Development+of+New+Antibiotics%3B+World+Health+Organization%3A+Geneva%2C+2017.+http%3A%2F%2Fwww.who.int%2Fmedicines%2Fpublications%2FWHO-PPL-Short_Summary_25Feb-ET_NM_WHO.pdf+%28accessed+Nov+11%2C+2018%29."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26btitle%3DGlobal%250APriority%2520List%2520of%2520Antibiotic-Resistant%2520Bacteria%2520To%2520Guide%2520Research%252C%250ADiscovery%252C%2520and%2520Development%2520of%2520New%2520Antibiotics%26pub%3DWorld%2520Health%2520Organization%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Khan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gould, I. M.</span></span> <span> </span><span class="NLM_article-title">Current and future treatment options for community-associated MRSA infection</span>. <i>Expert Opin. Pharmacother.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">457</span>– <span class="NLM_lpage">470</span>, <span class="refDoi"> DOI: 10.1080/14656566.2018.1442826</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1080%2F14656566.2018.1442826" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=29480032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC1cXltFWrtLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2018&pages=457-470&author=A.+Khanauthor=B.+Wilsonauthor=I.+M.+Gould&title=Current+and+future+treatment+options+for+community-associated+MRSA+infection&doi=10.1080%2F14656566.2018.1442826"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Current and future treatment options for community-associated MRSA infection</span></div><div class="casAuthors">Khan, A.; Wilson, B.; Gould, I. M.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Pharmacotherapy</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">457-470</span>CODEN:
                <span class="NLM_cas:coden">EOPHF7</span>;
        ISSN:<span class="NLM_cas:issn">1465-6566</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">: Community-assocd. MRSA (CA-MRSA) represents a global epidemic which beautifully encapsulates the fascinating ability of bacterial organisms to adapt quickly on an evolutionary basis to the extreme selective pressure of antibiotic exposure.  In stark contrast to Healthcare-assocd. MRSA (HA-MRSA), it has become apparent that CA-MRSA is less straight forward of a challenge in terms of controlling its transmission, and has forced clinicians to adjust empiric management of clin. syndromes such as skin and soft tissue infection (SSTI) as well as pneumonia.: This review details the history and epidemiol. of CA-MRSA, while covering both current and future treatment options that are and may be available to clinicians.  The authors reviewed both historic and more recent literature on this ever-evolving topic.: While development of new anti-MRSA agents should be encouraged, the importance of antimicrobial stewardship in the battle to stay ahead of the curve with regards to the ongoing control of the MRSA epidemic should be emphasized.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreCiRGwopdprVg90H21EOLACvtfcHk0ljPkDHPFC2x8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXltFWrtLg%253D&md5=44b2013a1eb6dd7dc1a0af0d1059e02a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1080%2F14656566.2018.1442826&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14656566.2018.1442826%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DA.%26aulast%3DWilson%26aufirst%3DB.%26aulast%3DGould%26aufirst%3DI.%2BM.%26atitle%3DCurrent%2520and%2520future%2520treatment%2520options%2520for%2520community-associated%2520MRSA%2520infection%26jtitle%3DExpert%2520Opin.%2520Pharmacother.%26date%3D2018%26volume%3D19%26spage%3D457%26epage%3D470%26doi%3D10.1080%2F14656566.2018.1442826" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berger, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gamblin, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrison, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Structure and mechanism of DNA topoisomerase II</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>379</i></span>,  <span class="NLM_fpage">225</span>– <span class="NLM_lpage">232</span>, <span class="refDoi"> DOI: 10.1038/379225a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2F379225a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=8538787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADyaK28Xmtl2gsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=1996&pages=225-232&author=J.+M.+Bergerauthor=S.+J.+Gamblinauthor=S.+C.+Harrisonauthor=J.+C.+Wang&title=Structure+and+mechanism+of+DNA+topoisomerase+II&doi=10.1038%2F379225a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and mechanism of DNA topoisomerase II</span></div><div class="casAuthors">Berger, James M.; Gamblin, Steven J.; Harrison, Stephen C.; Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">379</span>
        (<span class="NLM_cas:issue">6562</span>),
    <span class="NLM_cas:pages">225-32</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">The crystal structure of a large fragment of yeast type II DNA topoisomerase reveals a heart-shaped dimeric protein with a large central hole.  It provides a mol. model of the enzyme as an ATP-modulated clamp with two sets of jaws at opposite ends, connected by multiple joints.  An enzyme with bound DNA can admit a second DNA duplex through one set of jaws, transport it through the cleaved first duplex, and expel it through the other set of jaws.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqx1Jz5DLrCobVg90H21EOLACvtfcHk0lieLcvEsBQdjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xmtl2gsg%253D%253D&md5=5f3522c462cb3af85c6d2230f3a79002</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1038%2F379225a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F379225a0%26sid%3Dliteratum%253Aachs%26aulast%3DBerger%26aufirst%3DJ.%2BM.%26aulast%3DGamblin%26aufirst%3DS.%2BJ.%26aulast%3DHarrison%26aufirst%3DS.%2BC.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DStructure%2520and%2520mechanism%2520of%2520DNA%2520topoisomerase%2520II%26jtitle%3DNature%26date%3D1996%26volume%3D379%26spage%3D225%26epage%3D232%26doi%3D10.1038%2F379225a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gellert, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizuuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Dea, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nash, H. A.</span></span> <span> </span><span class="NLM_article-title">DNA gyrase: an enzyme that introduces superhelical turns into DNA</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">3872</span>– <span class="NLM_lpage">3876</span>, <span class="refDoi"> DOI: 10.1073/pnas.73.11.3872</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1073%2Fpnas.73.11.3872" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=186775" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADyaE2sXjvFWmsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=1976&pages=3872-3876&author=M.+Gellertauthor=K.+Mizuuchiauthor=M.+H.+O%E2%80%99Deaauthor=H.+A.+Nash&title=DNA+gyrase%3A+an+enzyme+that+introduces+superhelical+turns+into+DNA&doi=10.1073%2Fpnas.73.11.3872"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">DNA gyrase:  An enzyme that introduces superhelical turns into DNA</span></div><div class="casAuthors">Gellert, Martin; Mizuuchi, Kiyoshi; O'Dea, Mary H.; Nash, Howard A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1976</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3872-6</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">Relaxed closed-circular DNA was converted to neg. supercoiled DNA by DNA gyrase.  This enzyme was purified from Escherichia coli cells.  The reaction required ATP and Mg2+ and was stimulated by spermidine.  The enzyme acted equally well on relaxed closed-circular colicin E1, bacteriophage λ, and simian virus 40 DNA.  The final superhelix d. of the DNA could be considerably greater than that found in intracellularly supercoiled DNA.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWknjnsm_VqrVg90H21EOLACvtfcHk0lieLcvEsBQdjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXjvFWmsQ%253D%253D&md5=adc7a9bfe9d48cba5143727e982e7b81</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.73.11.3872&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.73.11.3872%26sid%3Dliteratum%253Aachs%26aulast%3DGellert%26aufirst%3DM.%26aulast%3DMizuuchi%26aufirst%3DK.%26aulast%3DO%25E2%2580%2599Dea%26aufirst%3DM.%2BH.%26aulast%3DNash%26aufirst%3DH.%2BA.%26atitle%3DDNA%2520gyrase%253A%2520an%2520enzyme%2520that%2520introduces%2520superhelical%2520turns%2520into%2520DNA%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1976%26volume%3D73%26spage%3D3872%26epage%3D3876%26doi%3D10.1073%2Fpnas.73.11.3872" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sissi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palumbo, M.</span></span> <span> </span><span class="NLM_article-title">In front of and behind the replication fork: bacterial type IIA topoisomerases</span>. <i>Cell. Mol. Life Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">2001</span>– <span class="NLM_lpage">2024</span>, <span class="refDoi"> DOI: 10.1007/s00018-010-0299-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1007%2Fs00018-010-0299-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=20165898" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmsFyrurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2010&pages=2001-2024&author=C.+Sissiauthor=M.+Palumbo&title=In+front+of+and+behind+the+replication+fork%3A+bacterial+type+IIA+topoisomerases&doi=10.1007%2Fs00018-010-0299-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">In front of and behind the replication fork: bacterial type IIA topoisomerases</span></div><div class="casAuthors">Sissi, Claudia; Palumbo, Manlio</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2001-2024</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Verlag</span>)
        </div><div class="casAbstract">A review.  Topoisomerases are vital enzymes specialized in controlling DNA topol., in particular supercoiling and decatenation, to properly handle nucleic acid packing and cell dynamics.  The type IIA enzymes act by cleaving both strands of a double helix and having another strand from the same or another mol. cross the DNA gate before a re-sealing event completes the catalytic cycle.  Here, we will consider the two types of IIA prokaryotic topoisomerases, DNA Gyrase and Topoisomerase IV, as crucial regulators of bacterial cell cycle progression.  Their synergistic action allows control of chromosome packing and grants occurrence of functional transcription and replication processes.  In addn. to displaying a fascinating mol. mechanism of action, which transduces chem. energy into mech. energy by means of large conformational changes, these enzymes represent attractive pharmacol. targets for antibacterial chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1ESOZ27csO7Vg90H21EOLACvtfcHk0ljmzPjJWvbNlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmsFyrurg%253D&md5=beddf7151ca953f43ced56b17baa9f7c</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1007%2Fs00018-010-0299-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-010-0299-5%26sid%3Dliteratum%253Aachs%26aulast%3DSissi%26aufirst%3DC.%26aulast%3DPalumbo%26aufirst%3DM.%26atitle%3DIn%2520front%2520of%2520and%2520behind%2520the%2520replication%2520fork%253A%2520bacterial%2520type%2520IIA%2520topoisomerases%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2010%26volume%3D67%26spage%3D2001%26epage%3D2024%26doi%3D10.1007%2Fs00018-010-0299-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giacobbe, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patey, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnstone, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potter, M. E.</span></span> <span> </span><span class="NLM_article-title">In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1128/AAC.04124-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.04124-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=25385112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXht1ais70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=467-474&author=M.+D.+Hubandauthor=P.+A.+Bradfordauthor=L.+G.+Ottersonauthor=G.+S.+Basarabauthor=A.+C.+Kutschkeauthor=R.+A.+Giacobbeauthor=S.+A.+Pateyauthor=R.+A.+Almauthor=M.+R.+Johnstoneauthor=M.+E.+Potter&title=In+vitro+antibacterial+activity+of+AZD0914%2C+a+new+spiropyrimidinetrione+DNA+gyrase%2Ftopoisomerase+inhibitor+with+potent+activity+against+Gram-positive%2C+fastidious+Gram-negative%2C+and+atypical+bacteria&doi=10.1128%2FAAC.04124-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro antibacterial activity of AZD0914, a new spiropyrimidinetrione DNA gyrase/topoisomerase inhibitor with potent activity against Gram-positive, fastidious Gram-negative, and atypical bacteria</span></div><div class="casAuthors">Huband, Michael D.; Bradford, Patricia A.; Otterson, Linda G.; Basarab, Gregory S.; Kutschke, Amy C.; Giacobbe, Robert A.; Patey, Sara A.; Alm, Richard A.; Johnstone, Michele R.; Potter, Marie E.; Miller, Paul F.; Mueller, John P.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">467-474/1-467-474/8, 8 pp.</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">1098-6596</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">AZD0914 is a new spiropyrimidinetrione bacterial DNA gyrase/topoisomerase inhibitor with potent in vitro antibacterial activity against key Gram-pos. (Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus pyogenes, and Streptococcus agalactiae), fastidious Gram-neg. (Haemophilus influenzae and Neisseria gonorrhoeae), atypical (Legionella pneumophila), and anaerobic (Clostridium difficile) bacterial species, including isolates with known resistance to fluoroquinolones.  AZD0914 works via inhibition of DNA biosynthesis and accumulation of double-strand cleavages; this mechanism of inhibition differs from those of other marketed antibacterial compds.  AZD0914 stabilizes and arrests the cleaved covalent complex of gyrase with double-strand broken DNA under permissive conditions and thus blocks religation of the double-strand cleaved DNA to form fused circular DNA.  Whereas this mechanism is similar to that seen with fluoroquinolones, it is mechanistically distinct.  AZD0914 exhibited low frequencies of spontaneous resistance in S. aureus, and if mutants were obtained, the mutations mapped to gyrB.  Addnl., no cross-resistance was obsd. for AZD0914 against recent bacterial clin. isolates demonstrating resistance to fluoroquinolones or other drug classes, including macrolides, β-lactams, glycopeptides, and oxazolidinones.  AZD0914 was bactericidal in both min. bactericidal concn. and in vitro time-kill studies.  In in vitro checkerboard/synergy testing with 17 comparator antibacterials, only additivity/indifference was obsd.  The potent in vitro antibacterial activity (including activity against fluoroquinolone-resistant isolates), low frequency of resistance, lack of cross-resistance, and bactericidal activity of AZD0914 support its continued development. Staphylococcus Streptococcus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFPxzzSNWQwbVg90H21EOLACvtfcHk0lhOraKLJGQQVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXht1ais70%253D&md5=cdd3b247d62ce74d50a10347d88b0a1b</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1128%2FAAC.04124-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04124-14%26sid%3Dliteratum%253Aachs%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DBradford%26aufirst%3DP.%2BA.%26aulast%3DOtterson%26aufirst%3DL.%2BG.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DKutschke%26aufirst%3DA.%2BC.%26aulast%3DGiacobbe%26aufirst%3DR.%2BA.%26aulast%3DPatey%26aufirst%3DS.%2BA.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DJohnstone%26aufirst%3DM.%2BR.%26aulast%3DPotter%26aufirst%3DM.%2BE.%26atitle%3DIn%2520vitro%2520antibacterial%2520activity%2520of%2520AZD0914%252C%2520a%2520new%2520spiropyrimidinetrione%2520DNA%2520gyrase%252Ftopoisomerase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520Gram-positive%252C%2520fastidious%2520Gram-negative%252C%2520and%2520atypical%2520bacteria%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D467%26epage%3D474%26doi%3D10.1128%2FAAC.04124-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McLaughlin, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span> <span> </span><span class="NLM_article-title">Characterization of the novel DNA gyrase inhibitor AZD0914: low resistance potential and lack of cross-resistance in <i>Neisseria gonorrhoeae</i></span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">1478</span>– <span class="NLM_lpage">1486</span>, <span class="refDoi"> DOI: 10.1128/AAC.04456-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.04456-14" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=1478-1486&author=R.+A.+Almauthor=S.+D.+Lahiriauthor=A.+Kutschkeauthor=L.+G.+Ottersonauthor=R.+E.+McLaughlinauthor=J.+D.+Whiteakerauthor=L.+A.+Lewisauthor=X.+Suauthor=M.+D.+Hubandauthor=H.+Gardnerauthor=J.+P.+Mueller&title=Characterization+of+the+novel+DNA+gyrase+inhibitor+AZD0914%3A+low+resistance+potential+and+lack+of+cross-resistance+in+Neisseria+gonorrhoeae&doi=10.1128%2FAAC.04456-14"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1128%2FAAC.04456-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04456-14%26sid%3Dliteratum%253Aachs%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DOtterson%26aufirst%3DL.%2BG.%26aulast%3DMcLaughlin%26aufirst%3DR.%2BE.%26aulast%3DWhiteaker%26aufirst%3DJ.%2BD.%26aulast%3DLewis%26aufirst%3DL.%2BA.%26aulast%3DSu%26aufirst%3DX.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26atitle%3DCharacterization%2520of%2520the%2520novel%2520DNA%2520gyrase%2520inhibitor%2520AZD0914%253A%2520low%2520resistance%2520potential%2520and%2520lack%2520of%2520cross-resistance%2520in%2520Neisseria%2520gonorrhoeae%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D1478%26epage%3D1486%26doi%3D10.1128%2FAAC.04456-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Biedenbach, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackel, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jonge, B. L. M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sahm, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradford, P. A.</span></span> <span> </span><span class="NLM_article-title">In vitro activity of AZD0914, a novel bacterial DNA gyrase/topoisomerase IV inhibitor, against clinically relevant Gram-positive and fastidious Gram-negative pathogens</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">6053</span>– <span class="NLM_lpage">6063</span>, <span class="refDoi"> DOI: 10.1128/AAC.01016-15</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.01016-15" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=6053-6063&author=D.+J.+Biedenbachauthor=M.+D.+Hubandauthor=M.+Hackelauthor=B.+L.+M.+D.+Jongeauthor=D.+F.+Sahmauthor=P.+A.+Bradford&title=In+vitro+activity+of+AZD0914%2C+a+novel+bacterial+DNA+gyrase%2Ftopoisomerase+IV+inhibitor%2C+against+clinically+relevant+Gram-positive+and+fastidious+Gram-negative+pathogens&doi=10.1128%2FAAC.01016-15"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1128%2FAAC.01016-15&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.01016-15%26sid%3Dliteratum%253Aachs%26aulast%3DBiedenbach%26aufirst%3DD.%2BJ.%26aulast%3DHuband%26aufirst%3DM.%2BD.%26aulast%3DHackel%26aufirst%3DM.%26aulast%3DJonge%26aufirst%3DB.%2BL.%2BM.%2BD.%26aulast%3DSahm%26aufirst%3DD.%2BF.%26aulast%3DBradford%26aufirst%3DP.%2BA.%26atitle%3DIn%2520vitro%2520activity%2520of%2520AZD0914%252C%2520a%2520novel%2520bacterial%2520DNA%2520gyrase%252Ftopoisomerase%2520IV%2520inhibitor%252C%2520against%2520clinically%2520relevant%2520Gram-positive%2520and%2520fastidious%2520Gram-negative%2520pathogens%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26spage%3D6053%26epage%3D6063%26doi%3D10.1128%2FAAC.01016-15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miller, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mott, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skepner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hromockyj, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marotti, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zurenko, G. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Munzner, J. B.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">2806</span>– <span class="NLM_lpage">2812</span>, <span class="refDoi"> DOI: 10.1128/AAC.00247-08</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.00247-08" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18519725" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2008&pages=2806-2812&author=A.+A.+Millerauthor=G.+L.+Bundyauthor=J.+E.+Mottauthor=J.+E.+Skepnerauthor=T.+P.+Boyleauthor=D.+W.+Harrisauthor=A.+E.+Hromockyjauthor=K.+R.+Marottiauthor=G.+E.+Zurenkoauthor=J.+B.+Munzner&title=Discovery+and+characterization+of+QPT-1%2C+the+progenitor+of+a+new+class+of+bacterial+topoisomerase+inhibitors&doi=10.1128%2FAAC.00247-08"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and characterization of QPT-1, the progenitor of a new class of bacterial topoisomerase inhibitors</span></div><div class="casAuthors">Miller, Alita A.; Bundy, Gordon L.; Mott, John E.; Skepner, Jill E.; Boyle, Timothy P.; Harris, Douglas W.; Hromockyj, Alexander E.; Marotti, Keith R.; Zurenko, Gary E.; Munzner, Jennifer B.; Sweeney, Michael T.; Bammert, Gary F.; Hamel, Judith C.; Ford, Charles W.; Zhong, Wei-Zhu; Graber, David R.; Martin, Gary E.; Han, Fusen; Dolak, Lester A.; Seest, Eric P.; Ruble, J. Craig; Kamilar, Gregg M.; Palmer, John R.; Banitt, Lee S.; Hurd, Alexander R.; Barbachyn, Michael R.</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial Agents and Chemotherapy</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2806-2812</span>CODEN:
                <span class="NLM_cas:coden">AMACCQ</span>;
        ISSN:<span class="NLM_cas:issn">0066-4804</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">QPT-1 was discovered in a compd. library by high-throughput screening and triage for substances with whole-cell antibacterial activity.  This totally synthetic compd. is an unusual barbituric acid deriv. whose activity resides in the (-)-enantiomer.  QPT-1 had activity against a broad spectrum of pathogenic, antibiotic-resistant bacteria, was nontoxic to eukaryotic cells, and showed oral efficacy in a murine infection model, all before any medicinal chem. optimization.  Biochem. and genetic characterization showed that the QPT-1 targets the β subunit of bacterial type II topoisomerases via a mechanism of inhibition distinct from the mechanisms of fluoroquinolones and novobiocin.  Given these attributes, this compd. represents a promising new class of antibacterial agents.  The success of this reverse genomics effort demonstrates the utility of exploring strategies that are alternatives to target-based screens in antibacterial drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpoPSHAUxaaj7Vg90H21EOLACvtfcHk0liATxNRHQcyRQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Ogt7c%253D&md5=c459d15b895768ec27648222ad03d20d</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1128%2FAAC.00247-08&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.00247-08%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DA.%2BA.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DMott%26aufirst%3DJ.%2BE.%26aulast%3DSkepner%26aufirst%3DJ.%2BE.%26aulast%3DBoyle%26aufirst%3DT.%2BP.%26aulast%3DHarris%26aufirst%3DD.%2BW.%26aulast%3DHromockyj%26aufirst%3DA.%2BE.%26aulast%3DMarotti%26aufirst%3DK.%2BR.%26aulast%3DZurenko%26aufirst%3DG.%2BE.%26aulast%3DMunzner%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520QPT-1%252C%2520the%2520progenitor%2520of%2520a%2520new%2520class%2520of%2520bacterial%2520topoisomerase%2520inhibitors%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2008%26volume%3D52%26spage%3D2806%26epage%3D2812%26doi%3D10.1128%2FAAC.00247-08" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span>; <span class="NLM_string-name">Dobrowolski, P. J.</span>; <span class="NLM_string-name">Hagen, S. E.</span>; <span class="NLM_string-name">Heimbach, T. H.</span>; <span class="NLM_string-name">Hurd, A. R.</span>; <span class="NLM_string-name">Johnson, T. A.</span>; <span class="NLM_string-name">McNamara, D. J.</span>; <span class="NLM_string-name">Ruble, J. C.</span>; <span class="NLM_string-name">Sherry, D. A.</span>; <span class="NLM_string-name">Thomasco, L. M.</span>; <span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">Antibacterials Agent</span>. PCT Patent <span class="NLM_patent">WO2006120563A2</span><span class="NLM_year">2006</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2006&author=M.+R.+Barbachyn&author=P.+J.+Dobrowolski&author=S.+E.+Hagen&author=T.+H.+Heimbach&author=A.+R.+Hurd&author=T.+A.+Johnson&author=D.+J.+McNamara&author=J.+C.+Ruble&author=D.+A.+Sherry&author=L.+M.+Thomasco&author=P.+L.+Toogood&title=Antibacterials+Agent"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26atitle%3DAntibacterials%2520Agent%26date%3D2006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span>; <span class="NLM_string-name">Sherry, D. A.</span>; <span class="NLM_string-name">McNamara, D. J.</span>; <span class="NLM_string-name">Toogood, P. L.</span></span> <span> </span><span class="NLM_article-title">8-Pyrazinyl-5-Spiropyrimidinetrione-Oxazinoquinoline Derivatives as Antibacterial Agents</span>. PCT Patent <span class="NLM_patent">WO2007072151A1</span><span class="NLM_year">2007</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2007&author=T.+A.+Johnson&author=D.+A.+Sherry&author=D.+J.+McNamara&author=P.+L.+Toogood&title=8-Pyrazinyl-5-Spiropyrimidinetrione-Oxazinoquinoline+Derivatives+as+Antibacterial+Agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26atitle%3D8-Pyrazinyl-5-Spiropyrimidinetrione-Oxazinoquinoline%2520Derivatives%2520as%2520Antibacterial%2520Agents%26date%3D2007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brassil, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haimes, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Novel DNA gyrase inhibiting spiropyrimidinetriones with a benzisoxazole scaffold: SAR and in vivo characterization</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">9078</span>– <span class="NLM_lpage">9095</span>, <span class="refDoi"> DOI: 10.1021/jm501174m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501174m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=9078-9095&author=G.%0AS.+Basarabauthor=P.+Brassilauthor=P.+Doigauthor=V.+Galulloauthor=H.+B.+Haimesauthor=G.+Kernauthor=A.+Kutschkeauthor=J.+McNultyauthor=V.+J.+Schuckauthor=G.+Stoneauthor=M.+Gowravaram&title=Novel+DNA+gyrase+inhibiting+spiropyrimidinetriones+with+a+benzisoxazole+scaffold%3A+SAR+and+in+vivo+characterization&doi=10.1021%2Fjm501174m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Novel DNA Gyrase Inhibiting Spiropyrimidinetriones with a Benzisoxazole Scaffold: SAR and in Vivo Characterization</span></div><div class="casAuthors">Basarab, Gregory S.; Brassil, Patrick; Doig, Peter; Galullo, Vincent; Haimes, Howard B.; Kern, Gunther; Kutschke, Amy; McNulty, John; Schuck, Virna J. A.; Stone, Gregory; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">9078-9095</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The compds. described herein with a spirocyclic architecture fused to a benzisoxazole ring represent a new class of antibacterial agents that operate by inhibition of DNA gyrase as corroborated in an enzyme assay and by the inhibition of precursor thymidine into DNA during cell growth.  Activity resided in the configurationally lowest energy (2S,4R,4aR) diastereomer.  Highly active compds. against Staphylococcus aureus had sufficiently high soly., high plasma protein free fraction, and favorable pharmacokinetics to suggest that in vivo efficacy could be demonstrated, which was realized with compd. I in S. aureus mouse infection models.  A high drug exposure NOEL on oral dosing in the rat suggested that a high therapeutic margin could be achieved.  Importantly, I was not cross-resistant with other DNA gyrase inhibitors such as fluoroquinolone and aminocoumarin antibacterials.  Hence, this class shows considerable promise for the treatment of infections caused by multidrug resistant bacteria, including S. aureus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpvqD0DFpAALVg90H21EOLACvtfcHk0lhiX6YdvrgpNA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1yju7bE&md5=7eccef41b07e14842d79665591364050</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm501174m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501174m%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DBrassil%26aufirst%3DP.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DHaimes%26aufirst%3DH.%2BB.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%26aulast%3DStone%26aufirst%3DG.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DNovel%2520DNA%2520gyrase%2520inhibiting%2520spiropyrimidinetriones%2520with%2520a%2520benzisoxazole%2520scaffold%253A%2520SAR%2520and%2520in%2520vivo%2520characterization%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D9078%26epage%3D9095%26doi%3D10.1021%2Fjm501174m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G.
S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otterson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span> <span> </span><span class="NLM_article-title">Discovery of novel DNA gyrase inhibiting spiropyrimidinetriones: benzisoxazole fusion with N-linked oxazolidinone substituents leading to a clinical candidate (ETX0914)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">6264</span>– <span class="NLM_lpage">6282</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b00863</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b00863" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=6264-6282&author=G.%0AS.+Basarabauthor=P.+Doigauthor=V.+Galulloauthor=G.+Kernauthor=A.+Kimzeyauthor=A.+Kutschkeauthor=J.+P.+Newmanauthor=M.+Morningstarauthor=J.+Muellerauthor=L.+Ottersonauthor=K.+Vishwanathanauthor=F.+Zhouauthor=M.+Gowravaram&title=Discovery+of+novel+DNA+gyrase+inhibiting+spiropyrimidinetriones%3A+benzisoxazole+fusion+with+N-linked+oxazolidinone+substituents+leading+to+a+clinical+candidate+%28ETX0914%29&doi=10.1021%2Facs.jmedchem.5b00863"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Novel DNA Gyrase Inhibiting Spiropyrimidinetriones: Benzisoxazole Fusion with N-Linked Oxazolidinone Substituents Leading to a Clinical Candidate (ETX0914)</span></div><div class="casAuthors">Basarab, Gregory S.; Doig, Peter; Galullo, Vincent; Kern, Gunther; Kimzey, Amy; Kutschke, Amy; Newman, Joseph P.; Morningstar, Marshall; Mueller, John; Otterson, Linda; Vishwanathan, Karthick; Zhou, Fei; Gowravaram, Madhusudhan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6264-6282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel class of bacterial type-II topoisomerase inhibitor displaying a spiropyrimidinetrione architecture fused to a benzisoxazole scaffold shows potent activity against Gram-pos. and fastidious Gram-neg. bacteria.  Here, the authors describe a series of N-linked oxazolidinone substituents on the benzisoxazole that improve upon the antibacterial activity of initially described compds. of the class, show favorable PK properties, and demonstrate efficacy in an in vivo Staphylococcus aureus infection model.  Inhibition of the topoisomerases DNA gyrase and topoisomerase IV from both Gram-pos. and a Gram-neg. organisms was demonstrated.  Compds. showed a clean in vitro toxicity profile, including no genotoxicity and no bone marrow toxicity at the highest evaluated concns. or other issues that have been problematic for some fluoroquinolones.  Compd. I was identified for advancement into human clin. trials for treatment of uncomplicated gonorrhea based on a variety of beneficial attributes including the potent activity and the favorable safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoo8zOqBRUJg7Vg90H21EOLACvtfcHk0lhd2umHVvDPmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFCrurvL&md5=67b21b269a0dfdf74b7e93196d8dfc4e</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b00863&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b00863%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DKern%26aufirst%3DG.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DNewman%26aufirst%3DJ.%2BP.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DMueller%26aufirst%3DJ.%26aulast%3DOtterson%26aufirst%3DL.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DGowravaram%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%2520DNA%2520gyrase%2520inhibiting%2520spiropyrimidinetriones%253A%2520benzisoxazole%2520fusion%2520with%2520N-linked%2520oxazolidinone%2520substituents%2520leading%2520to%2520a%2520clinical%2520candidate%2520%2528ETX0914%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26spage%3D6264%26epage%3D6282%26doi%3D10.1021%2Facs.jmedchem.5b00863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kern, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNulty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mueller, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lawrence, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alm, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barvian, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doig, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galullo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardner, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gowravaram, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huband, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kimzey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morningstar, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kutschke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perros, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuck, V. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tommasi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walkup, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newman, J. V.</span></span> <span> </span><span class="NLM_article-title">Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial type II topoisomerases</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>5</i></span>, <span class="NLM_elocation-id">11827</span> <span class="refDoi"> DOI: 10.1038/srep11827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2Fsrep11827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=26168713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2015&author=G.+S.+Basarabauthor=G.+H.+Kernauthor=J.+McNultyauthor=J.+P.+Muellerauthor=K.+Lawrenceauthor=K.+Vishwanathanauthor=R.+A.+Almauthor=K.+Barvianauthor=P.+Doigauthor=V.+Galulloauthor=H.+Gardnerauthor=M.+Gowravaramauthor=M.+Hubandauthor=A.+Kimzeyauthor=M.+Morningstarauthor=A.+Kutschkeauthor=S.+D.+Lahiriauthor=M.+Perrosauthor=R.+Singhauthor=V.+J.+Schuckauthor=R.+Tommasiauthor=G.+Walkupauthor=J.+V.+Newman&title=Responding+to+the+challenge+of+untreatable+gonorrhea%3A+ETX0914%2C+a+first-in-class+agent+with+a+distinct+mechanism-of-action+against+bacterial+type+II+topoisomerases&doi=10.1038%2Fsrep11827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases</span></div><div class="casAuthors">Basarab, Gregory S.; Kern, Gunther H.; McNulty, John; Mueller, John P.; Lawrence, Kenneth; Vishwanathan, Karthick; Alm, Richard A.; Barvian, Kevin; Doig, Peter; Galullo, Vincent; Gardner, Humphrey; Gowravaram, Madhusudhan; Huband, Michael; Kimzey, Amy; Morningstar, Marshall; Kutschke, Amy; Lahiri, Sushmita D.; Perros, Manos; Singh, Renu; Schuck, Virna J. A.; Tommasi, Ruben; Walkup, Grant; Newman, Joseph V.</div><div class="citationInfo"><span class="NLM_cas:title">Scientific Reports</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">11827</span>CODEN:
                <span class="NLM_cas:coden">SRCEC3</span>;
        ISSN:<span class="NLM_cas:issn">2045-2322</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">With the diminishing effectiveness of current antibacterial therapies, it is critically important to discover agents that operate by a mechanism that circumvents existing resistance.  ETX0914, the first of a new class of antibacterial agent targeted for the treatment of gonorrhea, operates by a novel mode-of-inhibition against bacterial type II topoisomerases.  Incorporating an oxazolidinone on the scaffold mitigated toxicol. issues often seen with topoisomerase inhibitors.  Organisms resistant to other topoisomerase inhibitors were not cross-resistant with ETX0914 nor were spontaneous resistant mutants to ETX0914 cross-resistant with other topoisomerase inhibitor classes, including the widely used fluoroquinolone class.  Preclin. evaluation of ETX0914 pharmacokinetics and pharmacodynamics showed distribution into vascular tissues and efficacy in a murine Staphylococcus aureus infection model that served as a surrogate for predicting efficacious exposures for the treatment of Neisseria gonorrhoeae infections.  A wide safety margin to the efficacious exposure in toxicol. evaluations supported progression to Phase 1.  Dosing ETX0914 in human volunteers showed sufficient exposure and minimal adverse effects to expect a highly efficacious anti-gonorrhea therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpiUrCSFU1rVg90H21EOLACvtfcHk0ljtjUa6uH6-lA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlCjsLvE&md5=0a681c2bd92414d798b03a9c712e138e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsrep11827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep11827%26sid%3Dliteratum%253Aachs%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DKern%26aufirst%3DG.%2BH.%26aulast%3DMcNulty%26aufirst%3DJ.%26aulast%3DMueller%26aufirst%3DJ.%2BP.%26aulast%3DLawrence%26aufirst%3DK.%26aulast%3DVishwanathan%26aufirst%3DK.%26aulast%3DAlm%26aufirst%3DR.%2BA.%26aulast%3DBarvian%26aufirst%3DK.%26aulast%3DDoig%26aufirst%3DP.%26aulast%3DGalullo%26aufirst%3DV.%26aulast%3DGardner%26aufirst%3DH.%26aulast%3DGowravaram%26aufirst%3DM.%26aulast%3DHuband%26aufirst%3DM.%26aulast%3DKimzey%26aufirst%3DA.%26aulast%3DMorningstar%26aufirst%3DM.%26aulast%3DKutschke%26aufirst%3DA.%26aulast%3DLahiri%26aufirst%3DS.%2BD.%26aulast%3DPerros%26aufirst%3DM.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DSchuck%26aufirst%3DV.%2BJ.%26aulast%3DTommasi%26aufirst%3DR.%26aulast%3DWalkup%26aufirst%3DG.%26aulast%3DNewman%26aufirst%3DJ.%2BV.%26atitle%3DResponding%2520to%2520the%2520challenge%2520of%2520untreatable%2520gonorrhea%253A%2520ETX0914%252C%2520a%2520first-in-class%2520agent%2520with%2520a%2520distinct%2520mechanism-of-action%2520against%2520bacterial%2520type%2520II%2520topoisomerases%26jtitle%3DSci.%2520Rep.%26date%3D2015%26volume%3D5%26doi%3D10.1038%2Fsrep11827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stepan, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baillie, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kalgutkar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aleo, M. D.</span></span> <span> </span><span class="NLM_article-title">Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States</span>. <i>Chem. Res. Toxicol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1345</span>– <span class="NLM_lpage">1410</span>, <span class="refDoi"> DOI: 10.1021/tx200168d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/tx200168d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2011&pages=1345-1410&author=A.+F.+Stepanauthor=D.+P.+Walkerauthor=J.+Baumanauthor=D.+A.+Priceauthor=T.+A.+Baillieauthor=A.+S.+Kalgutkarauthor=M.+D.+Aleo&title=Structural+alert%2Freactive+metabolite+concept+as+applied+in+medicinal+chemistry+to+mitigate+the+risk+of+idiosyncratic+drug+toxicity%3A+a+perspective+based+on+the+critical+examination+of+trends+in+the+top+200+drugs+marketed+in+the+United+States&doi=10.1021%2Ftx200168d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Alert/Reactive Metabolite Concept as Applied in Medicinal Chemistry to Mitigate the Risk of Idiosyncratic Drug Toxicity: A Perspective Based on the Critical Examination of Trends in the Top 200 Drugs Marketed in the United States</span></div><div class="casAuthors">Stepan, Antonia F.; Walker, Daniel P.; Bauman, Jonathan; Price, David A.; Baillie, Thomas A.; Kalgutkar, Amit S.; Aleo, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Research in Toxicology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1345-1410</span>CODEN:
                <span class="NLM_cas:coden">CRTOEC</span>;
        ISSN:<span class="NLM_cas:issn">0893-228X</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Because of a preconceived notion that eliminating reactive metabolite (RM) formation with new drug candidates could mitigate the risk of idiosyncratic drug toxicity, the potential for RM formation is routinely examd. as part of lead optimization efforts in drug discovery.  Likewise, avoidance of "structural alerts" is almost a norm in drug design.  However, there is a growing concern that the perceived safety hazards assocd. with structural alerts and/or RM screening tools as standalone predictors of toxicity risks may be over exaggerated.  In addn., the multifactorial nature of idiosyncratic toxicity is now well recognized based upon observations that mechanisms other than RM formation (e.g., mitochondrial toxicity and inhibition of bile salt export pump (BSEP)) also can account for certain target organ toxicities.  Hence, fundamental questions arise such as: When is a mol. that contains a structural alert (RM pos. or neg.) a cause for concern.  Could the mol. in its parent form exert toxicity.  Can a low dose drug candidate truly mitigate metab.-dependent and -independent idiosyncratic toxicity risks.  In an effort to address these questions, we have retrospectively examd. 68 drugs (recalled or assocd. with a black box warning due to idiosyncratic toxicity) and the top 200 drugs (prescription and sales) in the United States in 2009 for trends in physiochem. characteristics, daily doses, presence of structural alerts, evidence for RM formation as well as toxicity mechanism(s) potentially mediated by parent drugs.  Collectively, our anal. revealed that a significant proportion (∼78-86%) of drugs assocd. with toxicity contained structural alerts and evidence indicating that RM formation as a causative factor for toxicity has been presented in 62-69% of these mols.  In several cases, mitochondrial toxicity and BSEP inhibition mediated by parent drugs were also noted as potential causative factors.  Most drugs were administered at daily doses exceeding several hundred milligrams.  There was no obvious link between idiosyncratic toxicity and physicochem. properties such as mol. wt., lipophilicity, etc.  Approx. half of the top 200 drugs for 2009 (prescription and sales) also contained one or more alerts in their chem. architecture, and many were found to be RM-pos.  Several instances of BSEP and mitochondrial liabilities were also noted with agents in the top 200 category.  However, with relatively few exceptions, the vast majority of these drugs are rarely assocd. with idiosyncratic toxicity, despite years of patient use.  The major differentiating factor appeared to be the daily dose; most of the drugs in the top 200 list are administered at low daily doses.  In addn., competing detoxication pathways and/or alternate nonmetabolic clearance routes provided suitable justifications for the safety records of RM-pos. drugs in the top 200 category.  Thus, while RM elimination may be a useful and pragmatic starting point in mitigating idiosyncratic toxicity risks, our anal. suggests a need for a more integrated screening paradigm for chem. hazard identification in drug discovery.  Thus, in addn. to a detailed assessment of RM formation potential (in relationship to the overall elimination mechanisms of the compd.(s)) for lead compds., effects on cellular health (e.g., cytotoxicity assays), BSEP inhibition, and mitochondrial toxicity are the recommended suite of assays to characterize compd. liabilities.  However, the prospective use of such data in compd. selection will require further validation of the cellular assays using marketed agents.  Until we gain a better understanding of the pathophysiol. mechanisms assocd. with idiosyncratic toxicities, improving pharmacokinetics and intrinsic potency as means of decreasing the dose size and the assocd. "body burden" of the parent drug and its metabolites will remain an overarching goal in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3IhczIcvVDLVg90H21EOLACvtfcHk0ljOOreQQ3bxOg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXos1Whtbo%253D&md5=632b73f755738e49eb233bc8dca1fbcc</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Ftx200168d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx200168d%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DWalker%26aufirst%3DD.%2BP.%26aulast%3DBauman%26aufirst%3DJ.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DKalgutkar%26aufirst%3DA.%2BS.%26aulast%3DAleo%26aufirst%3DM.%2BD.%26atitle%3DStructural%2520alert%252Freactive%2520metabolite%2520concept%2520as%2520applied%2520in%2520medicinal%2520chemistry%2520to%2520mitigate%2520the%2520risk%2520of%2520idiosyncratic%2520drug%2520toxicity%253A%2520a%2520perspective%2520based%2520on%2520the%2520critical%2520examination%2520of%2520trends%2520in%2520the%2520top%2520200%2520drugs%2520marketed%2520in%2520the%2520United%2520States%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2011%26volume%3D24%26spage%3D1345%26epage%3D1410%26doi%3D10.1021%2Ftx200168d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srikannathasan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fosberry, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hann, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hibbs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Homes, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingraham, K.</span></span><span class="NLM_etal"></span> <span> </span><span class="NLM_article-title">Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>6</i></span>, <span class="NLM_elocation-id">10048</span> <span class="refDoi"> DOI: 10.1038/ncomms10048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1038%2Fncomms10048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=26640131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2015&author=P.+F.+Chanauthor=V.+Srikannathasanauthor=J.+Huangauthor=H.+Cuiauthor=A.+P.+Fosberryauthor=M.+Guauthor=M.+M.+Hannauthor=M.+Hibbsauthor=P.+Homesauthor=K.+Ingraham&title=Structural+basis+of+DNA+gyrase+inhibition+by+antibacterial+QPT-1%2C+anticancer+drug+etoposide+and+moxifloxacin&doi=10.1038%2Fncomms10048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin</span></div><div class="casAuthors">Chan, Pan F.; Srikannathasan, Velupillai; Huang, Jianzhong; Cui, Haifeng; Fosberry, Andrew P.; Gu, Minghua; Hann, Michael M.; Hibbs, Martin; Homes, Paul; Ingraham, Karen; Pizzollo, Jason; Shen, Carol; Shillings, Anthony J.; Spitzfaden, Claus E.; Tanner, Robert; Theobald, Andrew J.; Stavenger, Robert A.; Bax, Benjamin D.; Gwynn, Michael N.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">10048</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">New antibacterials are needed to tackle antibiotic-resistant bacteria.  Type IIA topoisomerases (topo2As), the targets of fluoroquinolones, regulate DNA topol. by creating transient double-strand DNA breaks.  Here we report the first co-crystal structures of the antibacterial QPT-1 and the anticancer drug etoposide with Staphylococcus aureus DNA gyrase, showing binding at the same sites in the cleaved DNA as the fluoroquinolone moxifloxacin.  Unlike moxifloxacin, QPT-1 and etoposide interact with conserved GyrB TOPRIM residues rationalizing why QPT-1 can overcome fluoroquinolone resistance.  Our data show etoposide's antibacterial activity is due to DNA gyrase inhibition and suggests other anticancer agents act similarly.  Anal. of multiple DNA gyrase co-crystal structures, including asym. cleavage complexes, led to a 'pair of swing-doors' hypothesis in which the movement of one DNA segment regulates cleavage and religation of the second DNA duplex.  This mechanism can explain QPT-1's bacterial specificity.  Structure-based strategies for developing topo2A antibacterials are suggested.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoY_mF0ShDkkbVg90H21EOLACvtfcHk0lgCHdyMlIBlcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFyks7jL&md5=1e358e6e0e9454967cf2aa2e01a0306b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Fncomms10048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms10048%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DP.%2BF.%26aulast%3DSrikannathasan%26aufirst%3DV.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DCui%26aufirst%3DH.%26aulast%3DFosberry%26aufirst%3DA.%2BP.%26aulast%3DGu%26aufirst%3DM.%26aulast%3DHann%26aufirst%3DM.%2BM.%26aulast%3DHibbs%26aufirst%3DM.%26aulast%3DHomes%26aufirst%3DP.%26aulast%3DIngraham%26aufirst%3DK.%26atitle%3DStructural%2520basis%2520of%2520DNA%2520gyrase%2520inhibition%2520by%2520antibacterial%2520QPT-1%252C%2520anticancer%2520drug%2520etoposide%2520and%2520moxifloxacin%26jtitle%3DNat.%2520Commun.%26date%3D2015%26volume%3D6%26doi%3D10.1038%2Fncomms10048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mátyus, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Éliás, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tapolcsányi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polonka-Bálint, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Halász-Dajka, B.</span></span> <span> </span><span class="NLM_article-title">Ring-closure reactions of <i>ortho</i>-vinyl-<i>tert</i>-anilines and (Di)aza-heterocyclic analogues via the <i>tert</i>-amino effect: recent developments</span>. <i>Synthesis</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>2006</i></span>,  <span class="NLM_fpage">2625</span>– <span class="NLM_lpage">2639</span>, <span class="refDoi"> DOI: 10.1055/s-2006-942490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1055%2Fs-2006-942490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2006&publication_year=2006&pages=2625-2639&author=P.+M%C3%A1tyusauthor=O.+%C3%89li%C3%A1sauthor=P.+Tapolcs%C3%A1nyiauthor=A.+Polonka-B%C3%A1lintauthor=B.+Hal%C3%A1sz-Dajka&title=Ring-closure+reactions+of+ortho-vinyl-tert-anilines+and+%28Di%29aza-heterocyclic+analogues+via+the+tert-amino+effect%3A+recent+developments&doi=10.1055%2Fs-2006-942490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1055%2Fs-2006-942490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1055%252Fs-2006-942490%26sid%3Dliteratum%253Aachs%26aulast%3DM%25C3%25A1tyus%26aufirst%3DP.%26aulast%3D%25C3%2589li%25C3%25A1s%26aufirst%3DO.%26aulast%3DTapolcs%25C3%25A1nyi%26aufirst%3DP.%26aulast%3DPolonka-B%25C3%25A1lint%26aufirst%3DA.%26aulast%3DHal%25C3%25A1sz-Dajka%26aufirst%3DB.%26atitle%3DRing-closure%2520reactions%2520of%2520ortho-vinyl-tert-anilines%2520and%2520%2528Di%2529aza-heterocyclic%2520analogues%2520via%2520the%2520tert-amino%2520effect%253A%2520recent%2520developments%26jtitle%3DSynthesis%26date%3D2006%26volume%3D2006%26spage%3D2625%26epage%3D2639%26doi%3D10.1055%2Fs-2006-942490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">D’Yachenko, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glukhareva, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dyudya, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eltsov, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morzherin, Y.</span></span> <span> </span><span class="NLM_article-title">The <i>tert</i>-amino effect in heterocyclic chemistry. Synthesis of spiro heterocycles</span>. <i>Molecules</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1108</span>, <span class="refDoi"> DOI: 10.3390/10091101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.3390%2F10091101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18007375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1WmsrfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2005&pages=1101-1108&author=E.+D%E2%80%99Yachenkoauthor=T.+Glukharevaauthor=L.+Dyudyaauthor=O.+Eltsovauthor=Y.+Morzherin&title=The+tert-amino+effect+in+heterocyclic+chemistry.+Synthesis+of+spiro+heterocycles&doi=10.3390%2F10091101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">The tert-amino effect in heterocyclic chemistry. Synthesis of spiro heterocycles</span></div><div class="casAuthors">D'yachenko, Elisaveta V.; Glukhareva, Tatiana V.; Dyudya, Lyudmila V.; Eltsov, Oleg V.; Morzherin, Yury Yu.</div><div class="citationInfo"><span class="NLM_cas:title">Molecules</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1101-1108</span>CODEN:
                <span class="NLM_cas:coden">MOLEFW</span>;
        ISSN:<span class="NLM_cas:issn">1420-3049</span>.
    
            (<span class="NLM_cas:orgname">Molecular Diversity Preservation International</span>)
        </div><div class="casAbstract">A review.  The tert-amino reaction effect was examd.  A new method to synthesize spiro heterocycles is presented.  The tert-amino effect could be applied to the formation of spiro-fused heterocycles.  The formation of spiro compds. proceeds in most cases in good yields in a 1-pot reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4waXqp_8qa7Vg90H21EOLACvtfcHk0lhzlUucl45DOA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1WmsrfN&md5=45dace56623d8dee541849f93f5a5b2f</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.3390%2F10091101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252F10091101%26sid%3Dliteratum%253Aachs%26aulast%3DD%25E2%2580%2599Yachenko%26aufirst%3DE.%26aulast%3DGlukhareva%26aufirst%3DT.%26aulast%3DDyudya%26aufirst%3DL.%26aulast%3DEltsov%26aufirst%3DO.%26aulast%3DMorzherin%26aufirst%3DY.%26atitle%3DThe%2520tert-amino%2520effect%2520in%2520heterocyclic%2520chemistry.%2520Synthesis%2520of%2520spiro%2520heterocycles%26jtitle%3DMolecules%26date%3D2005%26volume%3D10%26spage%3D1101%26epage%3D1108%26doi%3D10.3390%2F10091101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ruble, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurd, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherry, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachyn, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toogood, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bundy, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Graber, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamilar, G. M.</span></span> <span> </span><span class="NLM_article-title">Synthesis of (−)-PNU-286607 by asymmetric cyclization of alkylidene barbiturates</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>131</i></span>,  <span class="NLM_fpage">3991</span>– <span class="NLM_lpage">3997</span>, <span class="refDoi"> DOI: 10.1021/ja808014h</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja808014h" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2009&pages=3991-3997&author=J.+C.+Rubleauthor=A.+R.+Hurdauthor=T.+A.+Johnsonauthor=D.+A.+Sherryauthor=M.+R.+Barbachynauthor=P.+L.+Toogoodauthor=G.+L.+Bundyauthor=D.+R.+Graberauthor=G.+M.+Kamilar&title=Synthesis+of+%28%E2%88%92%29-PNU-286607+by+asymmetric+cyclization+of+alkylidene+barbiturates&doi=10.1021%2Fja808014h"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis of (-)-PNU-286607 by Asymmetric Cyclization of Alkylidene Barbiturates</span></div><div class="casAuthors">Ruble, J. Craig; Hurd, Alexander R.; Johnson, Timothy A.; Sherry, Debra A.; Barbachyn, Michael R.; Toogood, Peter L.; Bundy, Gordon L.; Graber, David R.; Kamilar, Gregg M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3991-3997</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">PNU 286607 I, a oxazinoquinolinespiropyrimidinetrione inhibitor of bacterial DNA gyrase for potential use as an antibacterial agent against antibiotic-resistant bacterial strains, is prepd. in two steps from 2-fluoro-5-nitrobenzaldehyde and (R,R)-2,6-dimethylmorpholine by nucleophilic arom. substitution followed by condensation with barbituric acid and a concomitant stereoselective cyclization of the benzylidenepyrimidinetrione.  The stereoselectivities and mechanism of the condensation and cyclization reactions (based on the rearrangements of vinyl anilines, known in the literature as the "tert-amino effect") are investigated using the NMR spectroscopic anal. of the reactions of racemic substrates and the reactions of racemic and nonracemic deuterated substrates; based on the data obtained, the asym. synthesis of I is developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYwZZhoPHBHrVg90H21EOLACvtfcHk0lgB1PZZA1Q7wg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVeisL4%253D&md5=f837986da667a40ce19753baa9d58125</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fja808014h&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja808014h%26sid%3Dliteratum%253Aachs%26aulast%3DRuble%26aufirst%3DJ.%2BC.%26aulast%3DHurd%26aufirst%3DA.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BA.%26aulast%3DSherry%26aufirst%3DD.%2BA.%26aulast%3DBarbachyn%26aufirst%3DM.%2BR.%26aulast%3DToogood%26aufirst%3DP.%2BL.%26aulast%3DBundy%26aufirst%3DG.%2BL.%26aulast%3DGraber%26aufirst%3DD.%2BR.%26aulast%3DKamilar%26aufirst%3DG.%2BM.%26atitle%3DSynthesis%2520of%2520%2528%25E2%2588%2592%2529-PNU-286607%2520by%2520asymmetric%2520cyclization%2520of%2520alkylidene%2520barbiturates%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2009%26volume%3D131%26spage%3D3991%26epage%3D3997%26doi%3D10.1021%2Fja808014h" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X. L.</span></span> <span> </span><span class="NLM_article-title">Synthesis and antibacterial activities of novel spiropyrimidinetrione compounds</span>. <i>Chin. J. Synth. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">653</span>– <span class="NLM_lpage">652</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=653-652&author=Y.+Y.+Zhangauthor=C.+H.+Shiauthor=X.+L.+Zhou&title=Synthesis+and+antibacterial+activities+of+novel+spiropyrimidinetrione+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DShi%26aufirst%3DC.%2BH.%26aulast%3DZhou%26aufirst%3DX.%2BL.%26atitle%3DSynthesis%2520and%2520antibacterial%2520activities%2520of%2520novel%2520spiropyrimidinetrione%2520compounds%26jtitle%3DChin.%2520J.%2520Synth.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D653%26epage%3D652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joubran, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luzietti, R. A.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Basarab, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grimm, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vishwanathan, K.</span></span> <span> </span><span class="NLM_article-title">Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents</span>. <i>Xenobiotica</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>47</i></span>,  <span class="NLM_fpage">31</span>– <span class="NLM_lpage">49</span>, <span class="refDoi"> DOI: 10.3109/00498254.2016.1156186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.3109%2F00498254.2016.1156186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=27122100" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC28XmvFegt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2017&pages=31-49&author=J.+Guoauthor=C.+Joubranauthor=R.+A.+Luziettiauthor=G.+S.+Basarabauthor=S.+W.+Grimmauthor=K.+Vishwanathan&title=Absorption%2C+distribution%2C+metabolism+and+elimination+of+14C-ETX0914%2C+a+novel+inhibitor+of+bacterial+type-II+topoisomerases+in+rodents&doi=10.3109%2F00498254.2016.1156186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents</span></div><div class="casAuthors">Guo, Jian; Joubran, Camil; Luzietti, Ricardo A., Jr.; Basarab, Gregory S.; Grimm, Scott W.; Vishwanathan, Karthick</div><div class="citationInfo"><span class="NLM_cas:title">Xenobiotica</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">31-49</span>CODEN:
                <span class="NLM_cas:coden">XENOBH</span>;
        ISSN:<span class="NLM_cas:issn">0049-8254</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">1. ETX0914 is a novel bacterial topoisomerase inhibitor that has a novel mode-of-inhibition and is in clin. development for the treatment of infections caused by Neisseria gonorrhoeae.2.  The in vitro biotransformation studies of ETX0914 using mouse, rat, dog and human hepatocytes showed moderate intrinsic clearance in mouse and rat and low intrinsic clearance in dog and human.3.  Following i.v. administration of [14C]-ETX0914 in rats, the mean recovery of administered dose in urine, bile and feces was approx. 15%, 55% and 24%, resp.  Unchanged ETX0914 recovered in urine and bile was less than 5% of the dose, indicating that ETX0914 underwent extensive metab. in rats.  Metabolites M1, M2, M4, M6 and M12 detected in both rat and mouse urine samples were not detected in mouse urine when predosed with 1-aminobenzotriazole, indicating that these metabolites were cytochrome P 450 mediated products.  The major fecal metabolites obsd. in rats were not formed when ETX0914 was incubated with fresh feces from germ free rats under sterile condition or in incubations with rat intestinal microsome and cytosol, suggesting that most likely ETX0914 was directly excreted into gut lumen where metabolites were formed as intestinal microflora-mediated products.  The major sites of metab. by CYP enzymes were in the morpholine and oxazolidinone rings while it was benzisoxazole redn. with the gut microflora.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAwVcjl4pZwrVg90H21EOLACvtfcHk0lioFkFwNdtsLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmvFegt7w%253D&md5=e8ae0f9a16326a3b21dffc779285ecc6</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.3109%2F00498254.2016.1156186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3109%252F00498254.2016.1156186%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DJoubran%26aufirst%3DC.%26aulast%3DLuzietti%26aufirst%3DR.%2BA.%26aulast%3DBasarab%26aufirst%3DG.%2BS.%26aulast%3DGrimm%26aufirst%3DS.%2BW.%26aulast%3DVishwanathan%26aufirst%3DK.%26atitle%3DAbsorption%252C%2520distribution%252C%2520metabolism%2520and%2520elimination%2520of%252014C-ETX0914%252C%2520a%2520novel%2520inhibitor%2520of%2520bacterial%2520type-II%2520topoisomerases%2520in%2520rodents%26jtitle%3DXenobiotica%26date%3D2017%26volume%3D47%26spage%3D31%26epage%3D49%26doi%3D10.3109%2F00498254.2016.1156186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fleming, F. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravikumar, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shook, B. C.</span></span> <span> </span><span class="NLM_article-title">Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">7902</span>– <span class="NLM_lpage">7917</span>, <span class="refDoi"> DOI: 10.1021/jm100762r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100762r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=7902-7917&author=F.+F.+Flemingauthor=L.+H.+Yaoauthor=P.+C.+Ravikumarauthor=L.+Funkauthor=B.+C.+Shook&title=Nitrile-containing+pharmaceuticals%3A+efficacious+roles+of+the+nitrile+pharmacophore&doi=10.1021%2Fjm100762r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore</span></div><div class="casAuthors">Fleming, Fraser F.; Yao, Lihua; Ravikumar, P. C.; Funk, Lee; Shook, Brian C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7902-7917</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review is structured according to the nature of the nitrile-bearing substituent.  As the no. of nitrile-contg. drug leads is vast, the review has focused on launched nitrile-contg. pharmaceuticals and currently active clin. candidates.  Most nitrile-contg. pharmaceuticals are aroms. with aliph.-, alkene-, and nitrogen-bearing nitriles being progressively less frequent.  Within each class, the bioactive nitriles are collated according to common structural elements and mode of action.  The hope is that this survey will allow greater deployment of this versatile functionality within drug leads.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR6kPPdWVuvLVg90H21EOLACvtfcHk0lj0-nRWf6M4jQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtV2kurvP&md5=040bbaebd9e8c9999d195b9a22221fea</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm100762r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100762r%26sid%3Dliteratum%253Aachs%26aulast%3DFleming%26aufirst%3DF.%2BF.%26aulast%3DYao%26aufirst%3DL.%2BH.%26aulast%3DRavikumar%26aufirst%3DP.%2BC.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DShook%26aufirst%3DB.%2BC.%26atitle%3DNitrile-containing%2520pharmaceuticals%253A%2520efficacious%2520roles%2520of%2520the%2520nitrile%2520pharmacophore%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26spage%3D7902%26epage%3D7917%26doi%3D10.1021%2Fjm100762r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkatakrishnan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaman, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Houston, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremaine, L. M.</span></span> <span> </span><span class="NLM_article-title">The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>316</i></span>,  <span class="NLM_fpage">336</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1124/jpet.105.093229</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1124%2Fjpet.105.093229" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=16192315" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD28XhslCisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=316&publication_year=2006&pages=336-348&author=R.+S.+Obachauthor=R.+L.+Walskyauthor=K.+Venkatakrishnanauthor=E.+A.+Gamanauthor=J.+B.+Houstonauthor=L.+M.+Tremaine&title=The+utility+of+in+vitro+cytochrome+P450+inhibition+data+in+the+prediction+of+drug-drug+interactions&doi=10.1124%2Fjpet.105.093229"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The utility of in vitro cytochrome P450 inhibition data in the prediction of drug-drug interactions</span></div><div class="casAuthors">Obach, R. Scott; Walsky, Robert L.; Venkatakrishnan, Karthik; Gaman, Emily A.; Houston, J. Brian; Tremaine, Larry M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">316</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">336-348</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">The accuracy of in vitro inhibition parameters in scaling to in vivo drug-drug interactions (DDI) was examd. for over 40 drugs using seven human P 450-selective marker activities in pooled human liver microsomes.  These data were combined with other parameters (systemic Cmax, estd. hepatic inlet Cmax, fraction unbound, and fraction of the probe drug cleared by the inhibited enzyme) to predict increases in exposure to probe drugs, and the predictions were compared with in vivo DDI gathered from clin. studies reported in the scientific literature.  For drugs that had been tested as precipitants of drug interactions for more than one P 450 in vivo, the order of inhibitory potencies in vitro generally aligned with the magnitude of the in vivo interactions.  With the exception of many drugs known to be mechanism-based inactivators, the use of in vitro IC50, the fraction of the affected drug metabolized by the target enzyme [fm(CYP)] and an est. of free hepatic inlet Cmax, was generally successful in identifying those drugs that cause at least a 2-fold increase in the exposure to P 450 marker substrate drugs.  For CYP3A, incorporation of inhibition of both hepatic and intestinal metab. was needed for the prediction of DDI.  Many CYP3A inhibitors showed a different inhibitory potency for three different CYP3A marker activities; however, these differences generally did not alter the conclusions regarding whether a drug would cause a CYP3A DDI in vivo.  Overall, these findings support the conclusion that P 450 in vitro inhibition data are valuable in designing clin. DDI study strategies and can be used to predict the magnitudes of DDI.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGUhOqooYvvbVg90H21EOLACvtfcHk0liGiGX8m2lvsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhslCisg%253D%253D&md5=988174eb3bb0d41655508395b1f982dd</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1124%2Fjpet.105.093229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.105.093229%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DVenkatakrishnan%26aufirst%3DK.%26aulast%3DGaman%26aufirst%3DE.%2BA.%26aulast%3DHouston%26aufirst%3DJ.%2BB.%26aulast%3DTremaine%26aufirst%3DL.%2BM.%26atitle%3DThe%2520utility%2520of%2520in%2520vitro%2520cytochrome%2520P450%2520inhibition%2520data%2520in%2520the%2520prediction%2520of%2520drug-drug%2520interactions%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2006%26volume%3D316%26spage%3D336%26epage%3D348%26doi%3D10.1124%2Fjpet.105.093229" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balani, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Humphreys, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, W. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">MacLauchlin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prakash, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Surapaneni, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upthagrove, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsky, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Z. P.</span></span> <span> </span><span class="NLM_article-title">Contribution of metabolites to P450 inhibition-based drug-drug interactions: scholarship from the IQ DMLG metabolite group</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>43</i></span>,  <span class="NLM_fpage">620</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1124/dmd.114.059345</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1124%2Fdmd.114.059345" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=43&publication_year=2015&pages=620-630&author=H.+B.+Yuauthor=S.+K.+Balaniauthor=W.+C.+Chenauthor=D.+H.+Cuiauthor=L.+Heauthor=W.+G.+Humphreysauthor=J.+L.+Maoauthor=W.+G.+Laiauthor=A.+J.+Leeauthor=H.+K.+Limauthor=C.+MacLauchlinauthor=C.+Prakashauthor=S.+Surapaneniauthor=S.+Tseauthor=A.+Upthagroveauthor=R.+L.+Walskyauthor=B.+Wenauthor=Z.+P.+Zeng&title=Contribution+of+metabolites+to+P450+inhibition-based+drug-drug+interactions%3A+scholarship+from+the+IQ+DMLG+metabolite+group&doi=10.1124%2Fdmd.114.059345"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1124%2Fdmd.114.059345&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.114.059345%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BB.%26aulast%3DBalani%26aufirst%3DS.%2BK.%26aulast%3DChen%26aufirst%3DW.%2BC.%26aulast%3DCui%26aufirst%3DD.%2BH.%26aulast%3DHe%26aufirst%3DL.%26aulast%3DHumphreys%26aufirst%3DW.%2BG.%26aulast%3DMao%26aufirst%3DJ.%2BL.%26aulast%3DLai%26aufirst%3DW.%2BG.%26aulast%3DLee%26aufirst%3DA.%2BJ.%26aulast%3DLim%26aufirst%3DH.%2BK.%26aulast%3DMacLauchlin%26aufirst%3DC.%26aulast%3DPrakash%26aufirst%3DC.%26aulast%3DSurapaneni%26aufirst%3DS.%26aulast%3DTse%26aufirst%3DS.%26aulast%3DUpthagrove%26aufirst%3DA.%26aulast%3DWalsky%26aufirst%3DR.%2BL.%26aulast%3DWen%26aufirst%3DB.%26aulast%3DZeng%26aufirst%3DZ.%2BP.%26atitle%3DContribution%2520of%2520metabolites%2520to%2520P450%2520inhibition-based%2520drug-drug%2520interactions%253A%2520scholarship%2520from%2520the%2520IQ%2520DMLG%2520metabolite%2520group%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2015%26volume%3D43%26spage%3D620%26epage%3D630%26doi%3D10.1124%2Fdmd.114.059345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smart, D. J.</span></span> <span> </span><span class="NLM_article-title">Genotoxicity of topoisomerase II inhibitors: an anti-infective perspective</span>. <i>Toxicology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>254</i></span>,  <span class="NLM_fpage">192</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1016/j.tox.2008.08.023</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1016%2Fj.tox.2008.08.023" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=18840496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVGhurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=254&publication_year=2008&pages=192-198&author=D.+J.+Smart&title=Genotoxicity+of+topoisomerase+II+inhibitors%3A+an+anti-infective+perspective&doi=10.1016%2Fj.tox.2008.08.023"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of topoisomerase II inhibitors: An anti-infective perspective</span></div><div class="casAuthors">Smart, Daniel J.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">254</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">192-198</span>CODEN:
                <span class="NLM_cas:coden">TXCYAC</span>;
        ISSN:<span class="NLM_cas:issn">0300-483X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  At present, an inevitable consequence of a chem.'s inhibitory activity on key regulators of DNA topol. in bacteria, the type II topoisomerases, is a less pronounced effect on their eukaryotic counterparts.  In the context of anti-infectives drug development, this may pose a risk to patient safety as inhibition of eukaryotic type II topoisomerases (TOPO II) can result in the generation of DNA double-strand breaks (DSBs), which have the potential to manifest as mutations, chromosome breakage or cell death.  The biol. effects of several TOPO II inhibitors in mammalian cells are described herein; their modulation of DSB damage response parameters is examd. and evidence for the existence of a threshold concept for genotoxicity and its relevance in safety assessment is discussed.  The potential utility of γH2AX, a promising and highly sensitive mol. marker for DSBs, in a novel genotoxicity pre-screen' to conventional assays is also highlighted.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqZ7tXpVQAjrbVg90H21EOLACvtfcHk0lhIhOFSQOGW6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVGhurrE&md5=b307b9975485e5cd71709c7c16cfd07a</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2008.08.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2008.08.023%26sid%3Dliteratum%253Aachs%26aulast%3DSmart%26aufirst%3DD.%2BJ.%26atitle%3DGenotoxicity%2520of%2520topoisomerase%2520II%2520inhibitors%253A%2520an%2520anti-infective%2520perspective%26jtitle%3DToxicology%26date%3D2008%26volume%3D254%26spage%3D192%26epage%3D198%26doi%3D10.1016%2Fj.tox.2008.08.023" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Azarova, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, L. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, Y. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. F.</span></span> <span> </span><span class="NLM_article-title">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">11014</span>– <span class="NLM_lpage">11019</span>, <span class="refDoi"> DOI: 10.1073/pnas.0704002104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1073%2Fpnas.0704002104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=17578914" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=11014-11019&author=A.+M.+Azarovaauthor=L.+L.+Yiauthor=C.+P.+Linauthor=Y.+C.+Tsaiauthor=Y.+N.+Lauauthor=J.+C.+Wangauthor=L.+F.+Liu&title=Roles+of+DNA+topoisomerase+II+isozymes+in+chemotherapy+and+secondary+malignancies&doi=10.1073%2Fpnas.0704002104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies</span></div><div class="casAuthors">Azarova, Anna M.; Lyu, Yi Lisa; Lin, Chao-Po; Tsai, Yuan-Chin; Lau, Johnson Yiu-Nam; Wang, James C.; Liu, Leroy F.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">11014-11019</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Drugs that target DNA topoisomerase II (Top2), including etoposide (VP-16), doxorubicin, and mitoxantrone, are among the most effective anticancer drugs in clin. use.  However, Top2-based chemotherapy has been assocd. with higher incidences of secondary malignancies, notably the development of acute myeloid leukemia in VP-16-treated patients.  This assocn. is suggestive of a link between carcinogenesis and Top2-mediated DNA damage.  We show here that VP-16-induced carcinogenesis involves mainly the β rather than the isoenzyme of Top2.  In a mouse skin carcinogenesis model, the incidence of VP-16-induced melanomas in the skin of 7,12-dimethylbenz[a]anthracene-treated mice is significantly higher in TOP2β+ than in skin-specific top2β-knockout mice.  Furthermore, VP-16-induced DNA sequence rearrangements and double-strand breaks (DSBs) are Top2β-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the importance of proteasomal degrdn. of the Top2β-DNA cleavage complexes in VP-16-induced DNA sequence rearrangements.  VP-16 cytotoxicity in transformed cells expressing both Top2 isoenzymes is, however, primarily Top2α-dependent.  These results point to the importance of developing Top2-specific anticancer drugs for effective chemotherapy without the development of treatment-related secondary malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHqEXje8wQTrVg90H21EOLACvtfcHk0lhIhOFSQOGW6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnsV2ks78%253D&md5=f10976e9b0dbb918158916036a0349a7</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0704002104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0704002104%26sid%3Dliteratum%253Aachs%26aulast%3DAzarova%26aufirst%3DA.%2BM.%26aulast%3DYi%26aufirst%3DL.%2BL.%26aulast%3DLin%26aufirst%3DC.%2BP.%26aulast%3DTsai%26aufirst%3DY.%2BC.%26aulast%3DLau%26aufirst%3DY.%2BN.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26aulast%3DLiu%26aufirst%3DL.%2BF.%26atitle%3DRoles%2520of%2520DNA%2520topoisomerase%2520II%2520isozymes%2520in%2520chemotherapy%2520and%2520secondary%2520malignancies%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2007%26volume%3D104%26spage%3D11014%26epage%3D11019%26doi%3D10.1073%2Fpnas.0704002104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moreau, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robaux, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tabary, X.</span></span> <span> </span><span class="NLM_article-title">Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1955</span>– <span class="NLM_lpage">1960</span>, <span class="refDoi"> DOI: 10.1128/AAC.34.10.1955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1128%2FAAC.34.10.1955" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=1990&pages=1955-1960&author=N.+J.+Moreauauthor=H.+Robauxauthor=L.+Baronauthor=X.+Tabary&title=Inhibitory+effects+of+quinolones+on+pro-+and+eucaryotic+DNA+topoisomerases+I+and+II&doi=10.1128%2FAAC.34.10.1955"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1128%2FAAC.34.10.1955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.34.10.1955%26sid%3Dliteratum%253Aachs%26aulast%3DMoreau%26aufirst%3DN.%2BJ.%26aulast%3DRobaux%26aufirst%3DH.%26aulast%3DBaron%26aufirst%3DL.%26aulast%3DTabary%26aufirst%3DX.%26atitle%3DInhibitory%2520effects%2520of%2520quinolones%2520on%2520pro-%2520and%2520eucaryotic%2520DNA%2520topoisomerases%2520I%2520and%2520II%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D1990%26volume%3D34%26spage%3D1955%26epage%3D1960%26doi%3D10.1128%2FAAC.34.10.1955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lynn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaever, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swanberg, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J. C.</span></span> <span> </span><span class="NLM_article-title">Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>233</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">649</span>, <span class="refDoi"> DOI: 10.1126/science.3014661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1126%2Fscience.3014661" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=3014661" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADyaL28Xlt1yltLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=233&publication_year=1986&pages=647-649&author=R.+Lynnauthor=G.+Giaeverauthor=S.+L.+Swanbergauthor=J.+C.+Wang&title=Tandem+regions+of+yeast+DNA+topoisomerase+II+share+homology+with+different+subunits+of+bacterial+gyrase&doi=10.1126%2Fscience.3014661"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Tandem regions of yeast DNA topoisomerase II share homology with different subunits of bacterial gyrase</span></div><div class="casAuthors">Lynn, Richard; Giaever, Guri; Swanberg, Stephen L.; Wang, James C.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">233</span>
        (<span class="NLM_cas:issue">4764</span>),
    <span class="NLM_cas:pages">647-9</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    </div><div class="casAbstract">The nucleotide sequence for the Saccharomyces cerevisiae gene TOP2, which encodes DNA topoisomerase  [80449-01-0] type II, was compared with the sequence for bacterial DNA gyrase.  The amino and carboxyl terminal halves of the single-subunit yeast enzyme showed homologies with the B and A subunits of bacterial gyrase, resp., at corresponding positions along the polypeptide chains.  Although the 2 enzymes differ in both quaternary structure and activity, the homol. between the 2 proteins indicates mechanistic as well as structural similarities, and a probable evolutionary relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob32rXdTBu47Vg90H21EOLACvtfcHk0ljnDdLb4cabLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28Xlt1yltLk%253D&md5=b5231a7ef2e08a09e4618af73a87631b</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1126%2Fscience.3014661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.3014661%26sid%3Dliteratum%253Aachs%26aulast%3DLynn%26aufirst%3DR.%26aulast%3DGiaever%26aufirst%3DG.%26aulast%3DSwanberg%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DJ.%2BC.%26atitle%3DTandem%2520regions%2520of%2520yeast%2520DNA%2520topoisomerase%2520II%2520share%2520homology%2520with%2520different%2520subunits%2520of%2520bacterial%2520gyrase%26jtitle%3DScience%26date%3D1986%26volume%3D233%26spage%3D647%26epage%3D649%26doi%3D10.1126%2Fscience.3014661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boos, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stopper, H.</span></span> <span> </span><span class="NLM_article-title">Genotoxicity of several clinically used topoisomerase II inhibitors</span>. <i>Toxicol. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>116</i></span>,  <span class="NLM_fpage">7</span>– <span class="NLM_lpage">16</span>, <span class="refDoi"> DOI: 10.1016/S0378-4274(00)00192-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1016%2FS0378-4274%2800%2900192-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10906417" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BD3cXkvVyqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2000&pages=7-16&author=G.+Boosauthor=H.+Stopper&title=Genotoxicity+of+several+clinically+used+topoisomerase+II+inhibitors&doi=10.1016%2FS0378-4274%2800%2900192-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Genotoxicity of several clinically used topoisomerase II inhibitors</span></div><div class="casAuthors">Boos, G.; Stopper, H.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicology Letters</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">7-16</span>CODEN:
                <span class="NLM_cas:coden">TOLED5</span>;
        ISSN:<span class="NLM_cas:issn">0378-4274</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ireland Ltd.</span>)
        </div><div class="casAbstract">DNA topoisomerase II is an essential nuclear enzyme that modulates DNA topol. during multiple cellular processes such as DNA replication and chromosome segregation.  Several important clin. antitumor drugs and antibiotics act through inhibition of topoisomerase II.  There are a no. of different steps in the action of topoisomerase II, all of which are potential targets for inhibition through drugs and also for cellular and genetic toxicity as well as for mutagenesis.  We have investigated and compared the genotoxicity and mutagenicity of the mechanistically different topoisomerase II inhibitors m-amsacrine, mitoxantrone, etoposide, genistein, ICRF 193, and berenil using the in vitro micronucleus test, single cell elelectrophoresis (comet assay) and the mutation assay (tk-locus) in L5178Y mouse lymphoma cells.  All six compds. induced micronuclei and all except berenil were mutagenic.  M-amsacrine, mitoxantrone, etoposide and genistein induced DNA migration in the comet assay, whereas ICRF 193 was only weakly pos. and berenil was neg. in this test.  Our results are in good agreement with the compds.' proposed mechanisms of interaction with topoisomerase II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr0kiIlE6JkNbVg90H21EOLACvtfcHk0libffJDg6zDrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXkvVyqtrw%253D&md5=2d4d2ab9d9deb23b535c9312c67b5611</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0378-4274%2800%2900192-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0378-4274%252800%252900192-2%26sid%3Dliteratum%253Aachs%26aulast%3DBoos%26aufirst%3DG.%26aulast%3DStopper%26aufirst%3DH.%26atitle%3DGenotoxicity%2520of%2520several%2520clinically%2520used%2520topoisomerase%2520II%2520inhibitors%26jtitle%3DToxicol.%2520Lett.%26date%3D2000%26volume%3D116%26spage%3D7%26epage%3D16%26doi%3D10.1016%2FS0378-4274%2800%2900192-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Computer-aided drug design in epigenetics</span>. <i>Front. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.3389/fchem.2018.00057</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.3389%2Ffchem.2018.00057" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=29594101" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlKns7bI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2018&pages=57&author=W.+Luauthor=R.+Zhangauthor=H.+Jiangauthor=H.+Zhangauthor=C.+Luo&title=Computer-aided+drug+design+in+epigenetics&doi=10.3389%2Ffchem.2018.00057"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Computer-aided drug design in epigenetics</span></div><div class="casAuthors">Lu, Wenchao; Zhang, Rukang; Jiang, Hao; Zhang, Huimin; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Chemistry (Lausanne, Switzerland)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">57/1-57/23</span>CODEN:
                <span class="NLM_cas:coden">FCLSAA</span>;
        ISSN:<span class="NLM_cas:issn">2296-2646</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">Epigenetic dysfunction has been widely implicated in several diseases esp. cancers thus highlights the therapeutic potential for chem. interventions in this field.  With rapid development of computational methodologies and high-performance computational resources, computer-aided drug design has emerged as a promising strategy to speed up epigenetic drug discovery.  Herein, we make a brief overview of major computational methods reported in the literature including druggability prediction, virtual screening, homol. modeling, scaffold hopping, pharmacophore modeling, mol. dynamics simulations, quantum chem. calcn., and 3D quant. structure activity relationship that have been successfully applied in the design and discovery of epi-drugs and epi-probes.  Finally, we discuss about major limitations of current virtual drug design strategies in epigenetics drug discovery and future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSWvtrXR3I5LVg90H21EOLACvtfcHk0lg22ouzCCWL_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlKns7bI&md5=5fc80a74098fb5c20c53d94b1ff1a3f2</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.3389%2Ffchem.2018.00057&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffchem.2018.00057%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DR.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DComputer-aided%2520drug%2520design%2520in%2520epigenetics%26jtitle%3DFront.%2520Chem.%26date%3D2018%26volume%3D6%26spage%3D57%26doi%3D10.3389%2Ffchem.2018.00057" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ling, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span> <span> </span><span class="NLM_article-title">Design, synthesis, and structure-activity relationship studies of novel thioether pleuromutilin derivatives as potent antibacterial agents</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4772</span>– <span class="NLM_lpage">4795</span>, <span class="refDoi"> DOI: 10.1021/jm500312x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500312x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4772-4795&author=C.+Lingauthor=L.+Fuauthor=S.+Gaoauthor=W.+Chuauthor=H.+Wangauthor=Y.+Huangauthor=X.+Chenauthor=Y.+Yang&title=Design%2C+synthesis%2C+and+structure-activity+relationship+studies+of+novel+thioether+pleuromutilin+derivatives+as+potent+antibacterial+agents&doi=10.1021%2Fjm500312x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm500312x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500312x%26sid%3Dliteratum%253Aachs%26aulast%3DLing%26aufirst%3DC.%26aulast%3DFu%26aufirst%3DL.%26aulast%3DGao%26aufirst%3DS.%26aulast%3DChu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DYang%26aufirst%3DY.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520structure-activity%2520relationship%2520studies%2520of%2520novel%2520thioether%2520pleuromutilin%2520derivatives%2520as%2520potent%2520antibacterial%2520agents%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4772%26epage%3D4795%26doi%3D10.1021%2Fjm500312x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Han, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yue, L. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, K. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, C.</span></span> <span> </span><span class="NLM_article-title">Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">5397</span>– <span class="NLM_lpage">5407</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2018.07.048</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=10.1016%2Fj.bmc.2018.07.048" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=30297119" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhvVKktbnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2018&pages=5397-5407&author=W.+C.+Luauthor=H.+Xiongauthor=Y.+Chenauthor=C.+Wangauthor=H.+Zhangauthor=P.+Xuauthor=J.+Hanauthor=S.+H.+Xiaoauthor=H.+Dingauthor=Z.+F.+Chenauthor=T.+Luauthor=J.+Wangauthor=Y.+Y.+Zhangauthor=L.+Y.+Yueauthor=Y.+C.+Liuauthor=C.+H.+Zhangauthor=Y.+X.+Yangauthor=H.+L.+Jiangauthor=K.+X.+Chenauthor=B.+Zhouauthor=C.+Luo&title=Discovery+and+biological+evaluation+of+thiobarbituric+derivatives+as+potent+p300%2FCBP+inhibitors&doi=10.1016%2Fj.bmc.2018.07.048"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and biological evaluation of thiobarbituric derivatives as potent p300/CBP inhibitors</span></div><div class="casAuthors">Lu, Wenchao; Xiong, Huan; Chen, Yu; Wang, Chen; Zhang, Hao; Xu, Pan; Han, Jie; Xiao, Senhao; Ding, Hong; Chen, Zhifeng; Lu, Tian; Wang, Jun; Zhang, Yuanyuan; Yue, Liyan; Liu, Yu-Chih; Zhang, Chenhua; Yang, Yaxi; Jiang, Hualiang; Chen, Kaixian; Zhou, Bing; Luo, Cheng</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5397-5407</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Histone acetyltransferases (HATs) relieve transcriptional repression by preferentially acetylation of ε-amino group of lysine residues on histones.  Dysregulation of HATs is strongly correlated with etiol. of several diseases esp. cancer, thus highlighting the utmost significance of the development of small mol. inhibitors against this potential therapeutic target.  In the present study, through virtual screening and iterative optimization, we identified DCH36_06 as a bona fide, potent p300/CBP inhibitor.  DCH36_06 mediated p300/CBP inhibition leading to hypoacetylation on H3K18 in leukemic cells.  The suppression of p300/CBP activity retarded cell proliferation in several leukemic cell lines.  In addn., DCH36_06 arrested cell cycle at G1 phase and induced apoptosis via activation of caspase-3, caspase-9 and PARP that elucidated the mol. mechanism of its anti-proliferation activity.  In transcriptome anal., DCH36_06 altered downstream gene expression and apoptotic pathways-related genes verified by real-time PCR.  Importantly, DCH36_06 blocked the leukemic xenograft growth in mice supporting its potential for in vivo use that underlies the therapeutic potential for p300/CBP inhibitors in clin. translation.  Taken together, our findings suggest that DCH36_06 may serve as a qualified chem. tool to decode the acetylome code and open up new opportunities for clin. intervention.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBLk30U1TP37Vg90H21EOLACvtfcHk0ljGwyo_B22vMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhvVKktbnE&md5=6ff2001a48cd5da2e46dcfd841a3fc42</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2018.07.048&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2018.07.048%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DW.%2BC.%26aulast%3DXiong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DXiao%26aufirst%3DS.%2BH.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DZ.%2BF.%26aulast%3DLu%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DY.%2BY.%26aulast%3DYue%26aufirst%3DL.%2BY.%26aulast%3DLiu%26aufirst%3DY.%2BC.%26aulast%3DZhang%26aufirst%3DC.%2BH.%26aulast%3DYang%26aufirst%3DY.%2BX.%26aulast%3DJiang%26aufirst%3DH.%2BL.%26aulast%3DChen%26aufirst%3DK.%2BX.%26aulast%3DZhou%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DC.%26atitle%3DDiscovery%2520and%2520biological%2520evaluation%2520of%2520thiobarbituric%2520derivatives%2520as%2520potent%2520p300%252FCBP%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2018%26volume%3D26%26spage%3D5397%26epage%3D5407%26doi%3D10.1016%2Fj.bmc.2018.07.048" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5CDM','PDB','5CDM'); return false;">PDB: 5CDM</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i86"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01750">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_28437"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.8b01750">10.1021/acs.jmedchem.8b01750</a>.<ul class="NLM_list-list_type-label"><li><p class="inline">Preparation of all intermediates; NMR and mass spectra of representative final compounds; MIC data for compounds (±)-<b>16a</b>–<b>d</b>, (±)-<b>20</b>, (±)-<b>24</b>, and <b>26a</b>–<b>c</b>; gel image of <i>S. aureus</i> gyrase supercoiling assay and human Topo IIα decatenation assay; and detailed data for inhibition of human topo IIα from compounds <b>33e</b> and ETX0914 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_001.pdf">jm8b01750_si_001.pdf (3.14 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.8b01750/suppl_file/jm8b01750_si_002.csv">jm8b01750_si_002.csv (4.74 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.8b01750&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-6%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.8b01750" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.8b01750" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"679a6dcfcb693da0","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
